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Summary
Muscle differentiation is a complex process finely tuned by the interplay of 
positive and negative factors. Although key positive regulators have been identified, 
there is rather little evidence of restraining molecules that can control the time and 
place of muscle differentiation. Identification of such molecules and analysis of their 
function during muscle differentiation is therefore necessary to gain new insight into 
the molecular events that regulate this process. My work centred on a gene, Dmeso 17A 
that was identified in the Taylor laboratory in a screen to isolate novel genes 
specifically expressed in muscle progenitors in Drosophila (Taylor, 2000). Its pattern of 
expression suggested it could be an inhibitor of muscle development. My aim was to 
analyse both the role and mechanism of action of Dmeso 17A.
Dmesol 7A expression rapidly declines as muscle differentiation starts, but persists 
in the adult muscle precursors that remain undifferentiated at this stage. Using the 
GAL4/UAS system (Brand and Perrimon, 1993) to both mis-express and over-express 
either full-length or modified proteins, I show that Dmeso 17A is a novel co-repressor 
that inhibits muscle progenitor differentiation. Dmef2, the key promoter of muscle 
differentiation, can suppress Dmesol7A inhibitory effect on muscle development. This 
was quantitated by a hatching and survival assay. Moreover, I show that Dmeso 17A can 
down-regulate DMe£2 activity. Dmesol7A protein contains a WRPW motif. I show that 
this motif is functionally important and is required for the interaction of Dmeso 17A 
with the co-repressor Groucho. Finally, I show that Dmesol 7A genetically interacts with 
Histone Deacetylases (HDACs), which are known to bind and down-regulate Me£2 in 
vertebrates.
My model is that Dmeso 17A down-regulates DMef2 activity through interactions 
with Groucho and HDACs, and therefore is a component of an inhibitory complex that 
holds muscle precursors in an undifferentiated state until cues trigger their 
differentiation.
x
Chapter 1: Introduction
1.1 History: how and why Drosophila entered the laboratories
1.1.1 How the Drosophila era started
The fruit fly, Drosophila melanogaster, entered laboratories about a 100 years ago. 
A major breakthrough was about to appear when, in 1907, Thomas Hunt Morgan (1866- 
1945) started breeding flies in “The Fly Room”. His intention was to generate an 
individual phenotypically different from the rest. “He hoped to find an occasional fly 
that had undergone a mutation, a sudden change in body form” (a phenomenon that had 
been previously described in plants by Hugo de Vries).
“Morgan had turned from Mendel's plants to the study of animals, but soon found 
that the rats and mice he was using reproduced too slowly and so, were impractical for 
studying heredity. His search for a more suitable organism led him to Drosophila 
melanogaster, known as the fruit fly because it feeds on decaying fruit.” He chose 
Drosophila for five reasons: (1) it is “easy to raise in the laboratory” (2) it is “fertile all 
year long and very prolific, producing a new generation every twelve days”; (3) “male 
and female offspring are easy to distinguish”; (4) “embryonic development occurs 
outside the body”, simplifying the study of the effects of mutations on development; (5) 
it “has only four pairs of chromosomes.”
In 1910, in one of his culture bottles filled with thousands of flies (simply reared on 
mashed bananas!), he observed a discrete variation. One male fly had white rather than 
the normal bright red eyes. He realised the implications of this immediately. “The birth 
of this single spontaneous mutant allowed him to begin addressing some key questions 
in heredity: How did this white eye colour originate? What determines eye colour?”
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Aroused by curiosity, he bred “The Fly” with wild-type (red-eyed) females. All of 
the offspring (Fi) were red-eyed. Morgan then crossed Fi flies together and in the second 
generation (F2), he noticed that only some flies had white eyes, all of which were males. 
To explain this curious phenomenon, he postulated that the white eye colour is linked to 
sex. From this he developed the hypothesis of sex-linked characters, which he postulated 
were on the X-chromosome of females. This finding constituted the basis of Morgan's 
most important idea: the chromosomal theory o f heredity. In 1915, together with his 
students, Sturtevant and Bridges, he summarised their work in The Mechanism o f 
Mendelian Heredity (Morgan, T. H. et al., 1915), a book of historic importance (this 
short history of Thomas Hunt Morgan and his work is summarised from 
http://www.columbia.edu/cu/alumni/Magazine/Morgan/morgan.htmlT
1.1.2 Drosophila: a super model organism
The white eye mutant discovery marked the beginning of the reign of Drosophila. 
Ever since Morgan’s discovery, the fruit fly has become one of the major model 
systems for a wide variety of biological fields: Genetics, Developmental Biology, 
Biomechanics, Evolutionary Biology, Pharmacology, Neurogenetics, Ecology and many 
more. During one hundred years of research a wealth of knowledge in the understanding 
of different biological processes has been accumulated.
Today, Drosophila represents a great tool for biologists:
Its genome has been completely sequenced (Adams et al., 2000). A large part 
of it is annotated and it is available on the Drosophila genome project web site 
(http://www. fruitflv.orgT
Genetic and molecular tools are available to the community. For example, 
mutants or particular flies can be easily obtained from the stock centres.
A whole range of experimental techniques is easily accessible.
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Its Biology is very similar to that of humans. 60% of Drosophila genes have 
human counterparts (Rubin, G.M., 2001) and 77% of human disease genes 
have orthologs in Drosophila (Reiter et al., 2001).
In recent years, Drosophila researchers have developed powerful genetic techniques 
that allow rapid identification and characterization of genes with similar functions in 
higher organisms. The high level of gene conservation, the similarity of cellular 
processes and the functional conservation of important factors between Drosophila and 
mammals, make Drosophila an exceptional model to dissect the molecular mechanisms 
regulating the formation of complex organisms. Moreover, findings in Drosophila could 
have an important impact on the treatments of human diseases.
1.2 Muscle as a model system
Over the last two decades, a thorough understanding of many aspects of 
developmental biology has been gained through investigations of the fruit fly. Much is 
now known about both the establishment of the basic body plan (antero-posterior (A/P) 
and dorso-ventral (D/V) axes) and the specification of the three germ layers of the 
Drosophila embryo (ectoderm, mesoderm and endoderm). Some of the patterning 
mechanisms that subsequently subdivide the germ layers into subpopulations of 
progenitors for different cell-types are also quite well understood. In contrast, there is a 
major gap in our knowledge of how these general patterning mechanisms are interpreted 
to produce the range of specific cell-types and then how gene expression, cell migration 
and differentiation is coordinated to form functional tissue.
Muscle differentiation is a model of choice for studying this issue as over the last 
decade it has become a paradigm for cell differentiation. Many aspects of muscle 
specification and differentiation (formation, structure, molecular mechanism) have been
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preserved throughout evolution between Drosophila and higher organisms. Like in 
vertebrate embryos, Drosophila muscle determination is influenced by signals such as 
Wnt, TGFp and Hedgehog family members (Baylies et al., 1998). Genes crucial for 
muscle differentiation, like twist (Baylies and Bate, 1996; Castanon and Baylies, 2002) 
or mef2 (Bour et al., 1995; Lilly et al., 1995; Ranganayakulu et al., 1995) have also been 
remarkably conserved. Nevertheless, a lot remain to be uncovered about the 
mechanisms underlying muscle differentiation. Although key positive regulators such as 
DMef2 have been characterised, little is known about how their expression and activity 
are modulated. Dmef2 is expressed very early in the mesoderm (Taylor et al., 1995). 
Yet, characterised target genes are activated later during muscle differentiation (Lin et 
al., 1996; Damm et al., 1998). This suggests that there are inhibitory mechanisms 
regulating DMef2 activity before the onset of muscle differentiation.
During normal development, it is apparent that restraining mechanisms control cell 
differentiation, both spatially and temporally. For example, during muscle development 
in Drosophila, the precursors of the adult muscles appear early in embryogenesis and 
are committed to the muscle fate, but they remain undifferentiated while other 
myoblasts around them differentiate (Bate, 1991; Bate, 1993). Another example, from 
vertebrate muscle development, are the satellites cells, which also are quiescent, 
undifferentiated cells that are able to proliferate and differentiate to mediate post-natal 
growth or regeneration of muscles (Seale and Rudnicki, 2000; Morgan and Partridge, 
2003). Vertebrate limb bud muscle development also provides an example of delayed 
differentiation of committed cells. While differentiation starts in the somite, some 
myoblasts migrate towards the limb bud and remain undifferentiated until they reach 
their final destination (Christ et al., 1995; Buckingham et al., 2003).
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Restraining mechanisms are therefore required during normal development and 
muscle differentiation should be considered as a balance of promoting and restraining 
influences. A better understanding of the regulation of muscle differentiation requires 
the identification and characterisation of negative regulators.
In mammalian cell culture, some candidate negative regulators have been 
identified, but in general rather little is known of their in vivo roles in development (for 
review see Olson, 1992; Taylor, 2005). Examples include:
- Mouse Twist, which in cell culture can inhibit the function of two key regulators of 
myogenesis, MyoD and Mef2 (Molkentin et al., 1995; Weintraub et al., 1991; 
reviewed in Black and Olson, 1998; Taylor, 2005), and therefore inhibits muscle 
differentiation (Hebrok et al., 1994; Spicer et al., 1996). However, although mice 
lacking twist function have somite defects (Chen et al., 1995), its in vivo role in 
muscle development is not understood.
- The histone deacetylases (HDACs), which can bind to Mef2 and down-regulate its 
activity in cell culture, but have not been directly implicated in muscle differentiation 
in vivo (see Chapter 6, section 6.4).
- Id proteins, which are helix-loop-helix (HLH) proteins that lack a DNA binding 
domain. In vitro and cell culture experiments have shown that Id binds to E proteins, 
the MyoD heterodimerisation partner, and so inhibits MyoD function (Benezra et al., 
1990; Jen et al., 1992). However, the role of Id during vertebrate skeletal muscle 
development is not established.
- HES1, a member of the HES (mammalian homologs of Drosophila Hairy and E(spl)) 
family, which in cell culture inhibits the activity of MyoD, and therefore might 
inhibit muscle differentiation (Sasai et al., 1992). However, over-expression of HES 1 
does not prevent myoblast differentiation (Shawber et al., 1996). Mice lacking HES1
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display severe defects in neurogenesis, but there no report of defects in muscle 
differentiation (Ishibashi et al., 1995).
- MSX1, a member of the Msx homoprotein family, which with histone H lb binds to 
MyoD and inhibits its activity in cell culture (Lee et al., 2004). No in vivo role in 
muscle development has been described for MSX1.
Some examples of inhibitors of muscle development have also been described in 
Drosophila and include:
- twist, which can inhibit the development of adult indirect flight muscles (IFMs) 
(Anant et al., 1998; This Chapter, see section 1.5.1). This role as an inhibitor contrasts 
with its function in the embryo as a promoter of muscle development and as activator of 
Dmef2 expression (Taylor et al., 1995, Baylies and Bate, 1996; Cripps and Olson, 1998, 
This Chapter, see section 1.5.1).
- Zfh-1, a zinc finger homeodomain transcriptional repressor, which may down- 
regulate Dmef2 expression and therefore inhibit myogenesis (Fortini et al., 1991; 
Postigo et al, 1997; Postigo et al., 1999).
- Notch, which in the adult can inhibit IFM development, possibly through Twist, 
which inhibits muscle development at this stage (Anant et al., 1998). Notch also inhibits 
muscle differentiation during embryogenesis by down regulating twist, which at this 
stage promotes muscle development (Baylies and Bate, 1996; Tapanes-Castillo and 
Baylies, 2004; This Chapter, see section 1.5.2; Chapter 3, see section 3.4.2).
- Extra macrochaete (Emc), an HLH protein related to vertebrate Id proteins. Mutants 
for emc display extreme disruption of the somatic musculature, although the mechanism 
of this effect is not known (Cubas et al., 1994).
In summary, it is evident that negative regulation is a crucial aspect of muscle 
development and much is to be learned from the analysis of inhibitors of differentiation.
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Some negative regulators have been identified, but their mechanisms of action are still 
to be defined in vivo. Finally, identification and analysis of new regulators is required to 
have a clearer picture of how muscle differentiation is regulated in vivo. For all the 
reasons mentioned in the previous section, Drosophila represents an excellent model to 
address these issues.
1.3 Muscle development in Drosophila
During early Drosophila development, like in vertebrate embryos, muscles form 
from the mesoderm. This process can be divided into three stages: the specification of 
the mesoderm, its subsequent subdivision with the formation of muscle progenitors and 
the expression of muscle specific genes, and lastly the differentiation of these 
progenitors into individual muscles. This section will present briefly the specification of 
the mesodermal germ layer and its subdivision leading to muscle formation.
1.3.1 Mesoderm specification and subdivision
13.1.1 Mesoderm specification
In Drosophila, the mesoderm is formed by the most ventral cells of the blastoderm- 
stage embryo. During the establishment of the D/V axis, a high concentration of the 
maternal transcription factor Dorsal, in the ventral part of the embryo, activates the 
expression of two zygotic genes, snail (sna) and twist (twi) (Ip et al., 1992; Jiang et al., 
1991; Pan et al., 1991; Thisse et al, 1991), which are both required for mesoderm 
specification. Embryos mutant for either gene fail to gastrulate normally and form no 
mesoderm derivatives (Leptin, 1991). During gastrulation, twi- and s«a-expressing 
mesodermal cells invaginate along the ventral furrow, divide twice and spread dorsally
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to form a monolayer in close contact with the overlying ectoderm (Leptin and 
Granewald, 1990).
sna encodes a zinc-finger transcription factor (Boulay et al., 1987), and is required 
for the repression of mesectodermal and neurectodermal genes (reviewed in Ip and 
Gridley, 2002). During gastrulation, it is also required for the initial phase of mesoderm 
invagination (Ip et al., 1994; reviewed in Ip and Gridley, 2002). After gastrulation, 
during the first stages of germ band elongation, sna expression disappears from the 
mesoderm and its transcript now accumulates in the developing central and peripheral 
nervous systems (Alberga et al., 1991).
twi encodes a bHLH transcription factor. It is expressed in all mesodermal cells 
(Thisse et al., 1988), and is required for the activation of muscle-specific differentiation 
genes. These genes include the homeobox gene tinman (tin) and the MADS domain 
transcription factor Dmef2 (Drosophila myocyte enhancer factor 2) (Taylor et al., 1995; 
Yin et al., 1997; Cripps and Olson, 1998). After gastrulation, twist remains expressed in 
all mesodermal cells (Thisse et al., 1988), but at the end of germ band elongation its 
expression is modulated into domains of high and low levels of expression. During and 
after germ band retraction, its expression declines, only persisting in the adult muscle 
precursors (AMPs) (Bate et al., 1991).
Thus, after gastrulation, as the germ band begins to extend, the early-specified 
mesoderm is rather uniform with all cells expressing uniform levels of twi, and of its 
targets tin and Dmef2. Differences between mesodermal cells become evident slightly 
later, by the end of germ band extension. At this stage, the mesoderm enters a period of 
substantial reorganisation.
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1.3.1.2 Mesoderm subdivision
Towards the end of germ band elongation, the mesoderm is segmented, along the 
antero-posterior (A/P) axis, into a series of units from which the progenitors of different 
mesodermal tissues will be formed (Dunin Borkowski et al., 1995; Azpiazu et al., 1996; 
Riechmann et al., 1997). The mesoderm then segregates into two layers. The external 
layer remains in contact with the ectoderm and will give rise to most of the somatic 
muscles and the heart. The internal one loses its contact with the ectoderm and will give 
rise to the visceral mesoderm, fat body, gonadal mesoderm, mesodermal glial cells and 
some dorsal somatic muscles (Dunin Borkowski et al., 1995; Riechmann et al., 1997).
This subdivision of the mesoderm is revealed by the expression pattern of Twist. At 
the end of germ band elongation, Twist expression is modulated in each mesodermal 
segment into domains of high and low levels of expression. High levels of Twist are 
found in the cells that form the external mesodermal layer in contact with the ectoderm. 
Cells in the domain of low Twist expression lose contact with the ectoderm and form 
the inner mesodermal layer (Bate and Rushton, 1993; Dunin Borkowski et al., 1995). 
This segmentally repeated modulation of Twist expression is a crucial element to the 
subdivision of the mesoderm. High levels of Twist are necessary for switching cells into 
somatic myogenesis, whereas low levels allow the development of other mesodermal 
derivatives (Baylies and Bate, 1996; Castanon et al., 2001; see section 1.5.1).
This subdivision of the mesoderm along the A/P, but also the D/V axis, is induced 
by intrinsic transcription factors together with signals coming from surrounding tissues. 
Most of these factors and signals, coming from different regions of the overlying 
ectoderm, are used in many developmental processes and include the signals wingless 
(wg), hedgehog (hh) and decapentaplegic (dpp), a member of the BMP superfamily (for 
review see Baylies et al., 1998).
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Along the A/P axis, the mesoderm is partitioned by the pair-rule genes even-skipped 
(eve) and sloppy-paired (sip). Eve domains will give rise to visceral muscles and the fat 
body, whereas somatic muscle and the heart will form from Sip domains (Azpiazu et al., 
1996; Riechmann et al., 1997). In eve mutants the primordia of the fat body and of the 
visceral mesoderm fail to develop (Azpiazu et al., 1996; Riechmann et al., 1997), and 
no heart or somatic muscle is formed in the absence of sip (Riechmann et al., 1997).
Eve and Sip are expressed in the mesoderm as well as in the ectoderm and their 
effects on mesodermal patterning are both direct and indirect. They act directly, within 
the mesoderm, inducing or repressing genes. For example, Eve induces bagpipe (bap), 
which is important for visceral muscle differentiation (Azpiazu and Frasch, 1993). 
Their indirect action is through the activation of downstream targets within the 
ectoderm, like wg (for Sip) or hedgehog (for Eve) (Riechmann et al., 1997). Wg, by 
maintaining twi expression (Bate and Rushton, 1993), allocates cells of the Sip domain 
to the somatic differentiation pathway.
Along the dorso-ventral (DAO axis* the mesoderm is divided by dpp. Dpp is 
expressed dorsally in the ectoderm and, as the mesodermal cells migrate dorsally, they 
come under its influence. Dpp acts on the mesoderm by maintaining tin expression, 
which is required for the differentiation of dorsal mesodermal derivatives (Azpiazu and 
Frasch, 1993; Frasch, 1995). At the same time, Dpp represses ventrally expressed genes 
(Staehling-Hampton et al., 1994).
Thus, at the end of germ band extension, each mesodermal segment is subdivided 
along both the A/P and the D/V axes. In the posterior part of each segment, in the Sip 
domain, dorsal cells under the influence of Dpp and Wg give rise to the heart and some 
dorsal somatic muscles. Ventral cells that receive only Wg from the ectoderm, give rise 
to most of the somatic muscles. In the anterior part of the segments, within the Eve
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domain, dorsal cells that are under the influence of Dpp and Hh give rise to the visceral 
musculature, whereas ventral cells are committed to generate the fat body and other 
derivatives (for review see Baylies et al., 1998).
1.4 Differentiation of mesodermal derivatives
1.4.1 The larval body wall musculature
At the end of embryogenesis, the larval somatic muscles of Drosophila form an 
intricate pattern of syncytial and striated muscles on the inner surface of the ectoderm 
(Bate, 1990; Bate, 1993). Each muscle is formed by the fusion of myoblasts and inserts 
into the epidermis. They are individual units distinguishable from their neighbours by 
size, shape, orientation, epidermal attachment, innervation and position (Bate, 1990). 
Each of the abdominal segments A2-A7 has a very stereotyped set of thirty muscles 
(Figure 1.1) with a modified pattern in Al (where only 29 muscles are present). There 
also are unique patterns in A8, the thorax and the more terminal segments. This 
intersegmental diversity is determined by autonomous function of homeotic genes in 
mesodermal cells (Michelson, 1994). In all my experiments, I have only considered 
abdominal segments A2-A7.
The morphogenesis of the larval somatic muscle has been well characterised (Bate 
1990). The first sign of muscle development occurs at the onset of germ band 
shortening with the appearance of fused doublets or triplets of cells in the most ventral 
part of the mesoderm. These small syncytia are the precursors of some of the ventral 
somatic muscles. During germ band shortening, new syncytia form ventrally, but also 
dorsally and laterally. By the end of germ band shortening, the location of these 
precursors containing two to three nuclei prefigures the future muscle pattern. Each 
precursor then enlarges by fusion with neighbouring myoblasts, expresses structural
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Figure 1.1: Wild-type somatic muscle pattern in Drosophila.
A flattened view o f an A2-7 abdominal hemisegment. (A) Internal view. 
(B) External view. Abbreviations: DA: dorsal acute; DO; dorsal oblique; 
DT; dorsal transverse; LL: lateral longitudinal; LO: lateral oblique; LT: 
lateral transverse; VA: ventral acute; VL: ventral longitudinal; VO: ventral 
oblique; VT: ventral transverse; ISN: intersegmental nerve; SN: segmental 
nerve; TN: transverse nerve. This figure is from Bate (1993).
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genes and projects processes towards their final attachment sites on the ectoderm. By 13 
hours after egg laying (end of stage 15 (all stages according to Campos-Ortega, 1997)), 
characteristic insertion points on the ectoderm have been established and the muscle 
pattern is complete (Bate, 1990).
The syncytial muscle precursors result from early fusion events within the somatic 
muscle-forming domains of the mesoderm, between two specific classes of myoblasts: 
the founder cells and the fusion competent myoblasts (FCMs). Founders are central to 
somatic muscle development as each one of them give rise to a particular muscle. They 
act as attractants and seed the muscles by fusion with the FCMs (reviewed in Baylies et 
al., 1998; Ruiz-Gomez, 1998; Taylor, 2002; Chen and Olson, 2004).
Muscle founders and FCMs are specified, at the end of germ band elongation, 
within domains of high Twist expression. In these domains, clusters of cells express the 
proneural gene lethal of scute ( l ’s c )  and have the potential to become muscle 
progenitors. However, only one cell within each cluster is singled out to become a 
muscle progenitor. This is by a Notch-mediated lateral inhibition process (Carmena et 
al., 1995). Each muscle progenitor then undergoes an asymmetric division to generate 
either two muscle founders or one founder and an AMP. The remaining cells of the 
myogenic clusters differentiate as FCMs (Carmena et al., 1998; Ruiz-Gomez and Bate, 
1997; reviewed in Baylies et al., 1998; Ruiz-Gomez, 1998; Taylor, 2002; Chen and 
Olson, 2004).
Each muscle progenitor expresses a particular combination of genes that determine 
its identity. These so-called “identity genes” include S59 (Dohrman et al., 1990), 
Kruppel (Kr) (Gaul et al., 1987), vestigial (vg) (Williams et al., 1991), connectin (con) 
(Nose et al., 1992), apterous (ap) (Bourgouin et al., 1992) and even-skipped (eve) 
(Frasch et al., 1987). When the progenitors divide, the pattern of identity genes is not
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necessarily conserved in the two sibling founders. In some cases, the pattern of gene 
expression initiated in the progenitor is maintained in both founders. This is the case for 
progenitors expressing connectin (Nose et al, 1992). In some other cases, expression of 
one or more identity genes changes in at least one of the founders. One such example is 
the progenitor of the VA1 and VA2 muscles, which expresses the identity genes S59 
and Kr. As it divides, S59 expression is maintained in both founders, whereas Kr is lost 
from the founder of the VA1 muscle (Ruiz-Gomez et al., 1997).
Thus, shortly before the onset of germ band shortening, founders arise from the 
division of muscle progenitors and each one of them expresses a combination of identity 
genes. These genes are characteristic of individual muscles and determine specific 
muscle differentiation (Ruiz-Gomez et al., 1997; Baylies et al., 1998; Taylor, 2002; 
Chen and Olson, 2004). During the fusion process, FCMs are recruited to the 
characteristic pattern of identity genes of the founder they fuse with. Therefore, the 
syncytial muscle precursors and, later, the muscles themselves can be identified by their 
pattern of identity gene expression.
Although differential expression of identity genes specifies each founder, the 
general process of fusion with FCMs is common. This process can be divided into cell 
attraction, adhesion, alignment and finally the fusion itself (Doberstein et al., 1997). 
Several genes encoding products involved in fusion have been identified (reviewed in 
Taylor, 2002; Taylor, 2003; Chen and Olson, 2004).
Some of these genes are expressed in both founders and FCMs. These include 
myoblast city (mbc) (Rushton et al., 1995; Erikson et al., 1997), Dmef2 (Bour et al., 
1995; Lilly et al., 1995), blown fuse (blow) (Doberstein et al., 1997), and Dtitin (Zhang 
et al., 2000). Mutations in any of these result in disruption of myoblast fusion. Another 
gene, roughest (rst), encodes an immunoglobulin (Ig)-domain containing cell adhesion
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molecule (Strunkelnberg et al., 2001) and is expressed at the surface of both types of 
myoblast. The lack of rst however has very little effect on muscle development 
(Strunkelnberg et al., 2001). Other genes are specific to either founders or FCMs.
In muscle founders, three have been described. (1) dumbfounded (duf), which, like 
rst, encodes an Ig-domain cell adhesion molecule (Ruiz-Gomez et al. 2000). Duf and 
Rst act redundantly, at the surface of founders, as attractants of FCMs. Deletion of both 
genes causes a complete block of fusion (Ruiz-Gomez et al., 2000; Strunkelnberg et al., 
2001); (2) antisocial [(ants), also called rolling pebbles (rols)]. Ants is an adaptor 
protein that binds Duf on the inner surface of the membrane, and Mbc, which is a 
cytoplasmic protein implicated in mediating changes in the cytoskeleton (Chen and 
Olson, 2001; Erikson et al., 1997). (3) loner, which encodes a regulator of the ADP- 
ribosylation factor (ARF)6 small GTPase (Chen et al., 2003).
In FCMs, two genes encoding transmembrane molecules have been described. 
Sticks and stones (Sns) and Hibris (Hbs), which are both Ig-domain cell adhesion 
molecules (Bour et al., 2000; Dworak et al., 2001). The loss of sns results in lack of 
fusion (Bour et al., 2000). Hbs on the other hand, is not essential for myoblast fusion, 
but it could inhibit Sns function. The over-expression of hbs blocks myoblast fusion, 
whereas the absence of hbs causes only minor defects (Dworak et al., 2001; Artero et 
al., 2001).
The description of all these molecules has allowed a model for myoblast fusion to 
emerge (see Taylor, 2002; Taylor, 2003; Chen and Olson, 2004). First, founders attract 
FCMs. Then after the initial recognition, the cells adhere maybe thanks to the binding of 
Duf to Sns. In the founder cell cytoplasm, Duf binds Rols/Ants, which in turn binds 
Mbc. Mbc then activates the small GTPase Drac, which regulates actin-cytoskeleton 
rearrangements. Duf can also recruit Loner, which activates ARF6. ARF6 is required
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for the proper subcellular localisation of Drac. Downstream effectors of Drac might 
include the structural protein Dtitin. Relatively little is known about the signalling 
components in the fusion competent cells. Moreover, although cytoskeleton 
rearrangement is a prerequisite for fusion, little is known about the actual fusion of the 
membranes (for review, see Taylor, 2002; Chen and Olson, 2004).
By the end of germ band retraction, each muscle precursor is specified expressing a 
particular combination of identity genes. They then start differentiating into functional 
multinucleated muscles by further fusion, activation of structural genes and by finding 
their final attachment sites on the ectoderm.
A key gene involved in the differentiation process is Dmef2. As mentioned earlier, 
Dmef2 is a direct target of Twist in the somatic mesoderm (Taylor et al., 1995; Cripps 
and Olson, 1998). In Dmef2 mutants, genes such as eve, S59 or ap are expressed in the 
somatic mesoderm indicating that founders form and are specified (Lilly et al., 1995; 
Bour et al., 1995, Ranganayakulu et al., 1995). However, later stages of muscle 
differentiation are impaired. There is an almost complete lack of myosin expressing 
cells within the somatic mesoderm and multinucleated fibres fail to form (Bour et al., 
1995; Lilly et al., 1995; Ranganayakulu et al., 1995; Gunthorpe et al., 1999). Moreover, 
it has been shown that different levels of DMef2 can affect different aspects of muscle 
differentiation (Gunthorpe et al., 1999). Dmef2 is therefore required both for fusion and 
for the activation of genes necessary for the general process of differentiation.
Only few direct targets for DMef2 have been identified. These include Tropomyosin 
and p3-tubulin, which are both characteristic components of differentiated muscles (Lin 
et al., 1996; Damm et al., 1998), and Actin57B, which is the major myofibrillar actin 
expressed in muscle during embryogenesis (Kelly et al. 2002). However, there is 
evidence suggesting that Dmef2 regulates other genes that play a role in somatic muscle
- 15-
Chapter 1: Introduction
differentiation. These include, the muscle LIM proteins Mlp60A and Mlp84B, which 
are components of the muscle contractile apparatus (Stronach et al., 1999), muscle 
Myosin and Paramyosin (Lilly et al., 1995, Bour et al, 1995; Gunthorpe et al, 1999; 
Arredondo et al., 2001), and Muscleblind, whose function is required for the formation 
of Z-bands and tendon cells at muscle attachment sites (Artero et al., 1998).
As they are differentiating, myotubes begin to search for their future attachment 
sites. During this phase, myotubes form filopodia that presumably sense the 
environment for guidance cues. They finally attach to specific tendon-like cells on the 
inner surface of the ectoderm (Bate, 1990). The earliest known marker for tendon cell 
precursors is the zinc-finger transcription factor Stripe (Volk and VijayRaghavan,
1994). The crucial influence of tendon cell precursors on muscle migration and 
attachment has come from the analysis of stripe mutants (Frommer et al., 1996). In 
these mutants, myotubes migrate to aberrant positions and fail to attach to the 
epidermis. This demonstrates an instructive role of the tendon cell precursors for 
myotube pathfinding. Moreover, the analysis of these mutants also suggests a role of the 
tendon cells in sending signals to the myotubes that have reached their destination to 
stop their search for attachment sites. Indeed, in stripe mutants, some myotubes 
continue to migrate at a time when they would have normally stopped and attached 
(Frommer et al., 1996; Schnorrer and Dickinson, 2004).
1.4.2 The visceral musculature
Two types of visceral muscle surround the larval midgut and provide the force for 
the peristaltic movements of digestion: inner circular and outer longitudinal muscles 
(Bate, 1993; Campos-Ortega, 1997). In contrast, only one type envelops the foregut and 
the hindgut.
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Progenitors of the midgut circular visceral muscles arise from segmentally repeated 
subsets of cells, within the Eve domains, expressing a low level of Twist. These cells 
express the homeodomain transcription factor Bap (Azpiazu et al., 1996). The 
expression of bap in these cells is induced by Tin, whose expression is restricted to the 
dorsal mesoderm. Mutations in both tin and bap disrupt the formation of the visceral 
mesoderm (Azpiazu and Frasch, 1993; Bodmer, 1993). During midgut development, the 
6ap-expressing cells move internally and spread along the A/P axis to give rise to the 
circular midgut visceral mesoderm (Azpiazu and Frasch, 1993). As the midgut forms, it 
goes through a series of morphogenetic movements leading to the formation of three 
constrictions. The correct differentiation of the visceral musculature is essential for the 
proper formation of these constrictions (Reuter and Scott, 1990).
Although bap is required for correct visceral mesoderm development, it is not 
maintained during visceral muscle development (Azpiazu and Frasch, 1993). 
Differentiation of these muscles therefore occurs through downstream genes. These 
include vimar (Lo et al., 1998), p3-tubulin (Zaffran and Frasch, 2002) and biniou (bin) 
(Zaffran et al., 2001). bin is a particularly important downstream target for Bap as in its 
absence differentiation of visceral muscle fails (Zaffran et al., 2001).
Tin also induces the expression of Dmef2 and /33-tubulin in the developing visceral 
mesoderm (Cripps et al., 1999; Kremser et al., 1999). As in the somatic musculature, 
Dmef2 is a central component of visceral muscle differentiation. In Dmef2 mutants, the 
visceral midgut mesoderm forms, as tin and bap are normally expressed (Lilly et al.,
1995), but fails to constrict and there is almost no myosin expression in the visceral 
midgut musculature (Bour et al., 1995). Interestingly, unlike in the somatic musculature, 
/33-tubulin is not a target of DMef2 in the visceral musculature (Damm et al., 1998). 
Evidence suggests that in the visceral mesoderm DMef2 can regulate the expression of
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aPS2 integrin (Ranganayakulu et al., 1995; Lin et al, 1997) and myosin (Lilly et al., 
1995, Bour et al, 1995; Gunthorpe et al, 1999).
Visceral muscles, like the somatic muscles, are syncytial units resulting from the 
fusion of founders and FCMs (San Martin et al., 2001; Klapper et al., 2001). Two 
different classes of founder myoblasts have been described for the circular and the 
longitudinal muscles, but there appears to be one common pool of FCMs (Martin et al., 
2001; Klapper et al., 2002). The specification of visceral muscle founders requires the 
function of jelly-belly (jeb) which encodes an LDL receptor repeat-containing protein. 
In jeb  mutants, founder cells do not develop and all the visceral muscle progenitors 
become FCMs and are incorporated into the somatic musculature (Weiss et al., 2001; 
Lee et al., 2003; Englund et al., 2003; Stute et al., 2004).
There are other similarities with somatic muscles. For example, like in the somatic 
mesoderm, Duf and Sns are expressed in founders and FCMs respectively (San Martin 
et al., 2001; Klapper, 2002). Moreover, identity genes such as connectin are also found 
in the developing visceral musculature (San Martin et al., 2001).
All these similarities provide evidence that the same general process of myoblast 
fusion applies to both somatic and visceral muscles. Founder cells are specified by 
distinct patterns of gene expression and then fuse with FCMs to form muscle 
progenitors that enlarge by further fusion (San Martin et al., 2001; Klapper et al., 2002).
1.4.3 The heart
The Drosophila heart is a dorsomedial muscular tube also termed the dorsal vessel 
that pumps haemolymph throughout the body cavity. It is composed of two cell types: 
the cardioblasts and the pericardial cells (for reviews see Cripps and Olson, 2002; 
Zaffran and Frasch, 2002). Cardioblasts are arranged in two rows at the dorsal midline
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of the embryo and are surrounded by four rows of pericardial cells (Ward and Skeath, 
2000). Whereas the cardioblasts express muscle proteins and form the contractile heart 
tube, the role of the pericardial cells is poorly understood. They do not express muscle 
proteins and have been called the pericardial nephrocytes and described as excretory 
cells (Han and Olson, 2005).
The different cell types of the heart derive from segmentally repeated clusters of 
dorsal mesodermal cells within the domain of high Twist expression. As cells from low 
ftmt-expressing domains move interiorly to form visceral muscles, the heart progenitors 
rearrange and, as the germ band retracts, form a continuous line on both sides of the 
embryos. During embryogenesis, heart precursors migrate from each side of the embryo 
to the dorsal midline where they converge to form the dorsal vessel.
The early activation of tin by Dpp in the dorsal part of the embryo is central in the 
control of heart development. Tin is required for the specification of all heart cells 
(Bodmer, 1993; Azpiazu and Frasch, 1993). For example, together with Twist, Tin 
maintains the expression of eve which is required for the determination of some 
pericardial cells (Su et al., 1999; Halfon et al., 2000; Knirr and Frasch, 2001). Tin also 
directly activates Dmef2, which is required for the differentiation of the cardioblasts, 
and /33-tubulin, which is characteristic of differentiated cardioblasts (Cripps et al., 1999; 
Kremser et al., 1999). It is interesting to note that like in the visceral musculature and 
unlike in the somatic musculature, DMef2 does not regulate expression p3-tubulin in 
the cardioblasts (Damm et al., 1998). Although Tin is required for heart development, it 
is not sufficient to promote cardiogenesis. Another factor is required, pannier, which 
encodes a GAT A family transcription factor. Pannier and Tin function synergistically to 
promote cardiogenesis (Klinedinst et al., 2003; Gajewski et al., 1999).
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During the migration of heart precursors to the dorsal midline, the different 
populations of cells are specified by the activation of a complex network of genes 
(reviewed in Cripps and Olson, 2002; Zaffran and Frasch, 2002). As they arrive at the 
dorsal midline, differential gene expression allows the identification of the cardioblasts 
and different subsets of the pericardial cells. For example, cardioblasts express DMef2 
(Lilly et al., 1994; Taylor et al., 1995), Myosin, p3-tubulin (Damm et al. 1998) and Tin 
(Bodmer, 1993; Azpiazu and Frasch, 1993). Pericardial cells express, amongst others, 
Zfhl (Lai et al., 1991), Eve (Frasch et al., 1987) and Odd (Ward and Coulter, 2000; 
Ward and Skeath, 2000).
1.4.4 The adult musculature
In Drosophila, adult muscles form during pupal metamorphosis and replace the 
larval somatic muscles. During this period almost all larval somatic muscles degenerate 
by histolysis (Bate, 1993). The adult muscles develop in characteristic positions and 
differ from the larval muscle by their size and the fact that they can be constituted of 
multiple fibers (Miller, 1950). This latter characteristic makes Drosophila adult muscles 
more like vertebrate skeletal muscle than the larval somatic muscles. In this section I 
will describe the development of the adult thoracic and abdominal muscles.
Although they only develop during metamorphosis, adult muscles originate in the 
embryonic mesoderm (Lawrence, 1982, Bate et al., 1991, Bate, 1993). All through 
embryogenesis and part of the larval life, these Twist-expressing muscle precursors 
remain in an undifferentiated state. They are only triggered to proliferate and 
differentiate later in larval life and during the early pupal stages (Bate et al., 1991; Bate, 
1993). In this respect, Drosophila AMPs resemble vertebrate satellite cells, which, as 
mentioned earlier, are also quiescent, undifferentiated cells that proliferate and
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differentiate to mediate muscle growth and regeneration (reviewed in Seale and 
Rudnicki, 2000; Morgan and Partridge, 2003).
The adult thoracic muscles develop from the adepithelial cells associated with the 
wing imaginal disc (Bate, 1993). These muscles are subdivided in two groups: the direct 
flight muscles (DFMs) and the indirect flight muscles (IFMs). The latter comprises two 
subclasses of muscles: the Dorso-Ventral Muscles (DVMs) and the Dorso-Lateral 
Muscles (DLMs) (Bate, 1993; Roy and VijayRaghavan; 1999; Taylor, 2005). At the 
onset of metamorphosis, larval muscles begin to hystolyse. An exception is three 
oblique muscles, which will serve as templates for the formation of the DLMs. By 
twelve hours after pupae formation (APF), the histolysis is complete and the precursors 
associated with the wing discs migrate to the muscle-forming regions near the epidermis 
(Fernandes et al., 1991; reviewed in Roy and VijayRaghavan; 1999; Taylor, 2005). 
This migration of precursors can be compared to that of vertebrate progenitors, which 
migrate to form the limb muscle for example. Thirteen hours APF, the larval template 
muscles split and the DLMs start assembling. DLMs are formed by 16-17 hours APF. 
At the same time, the DVMs form by de novo fusion of muscle precursors. By 24 hours 
APF, DLMs and DVMs are complete (Fernandes et al., 1991; Bate, 1993; Farrell et al., 
1996; reviewed in Roy and VijayRaghavan; 1999; Taylor, 2005).
In the abdomen, muscle formation occurs later than in the thorax and gives rise to a 
well-defined set of fibres, which form dorsally, laterally and ventrally in each segment 
(Currie and Bate, 1991). During the early pupal stages (0-24 hours APF), the AMPs 
proliferate and migrate along the nerves to the muscle forming-regions. By 28-30 hours 
APF, these precursors begin to fuse. By 50 hours APF, the pattern of the abdominal 
muscles is complete (Bate, 1993, Roy and VijayRaghavan; 1999; Taylor, 2005).
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As in the embryo, the formation of adult muscles could be initiated by founder cells. 
A recent study (Dutta et al., 2004) has shown that the pattern of adult muscles is 
prefigured by a pattern of precursors expressing Duf, which is a founder specific gene in 
the embryo (Ruiz-Gomez et al. 2000). Analysis of the DVMs showed that the number 
of Duf-expressing cells corresponds to the number of fibers in an adult muscle. 
Moreover, they showed that, when fusion is compromised, these cells develop as 
myosin-expressing cells (Dutta et al., 2004). In the embryo, this a key feature of founder 
myoblasts (Rushton et al., 1995). Nevertheless, unlike in the embryo, the adult founders 
do not seem to be segregated by Notch-mediated lateral inhibition (Dutta et al., 2004). 
A recent study suggests a key role for FGF signaling in this process (Dutta et al., 2005).
1.5 Genes important for somatic muscle differentiation
In Drosophila, the main pathway of somatic muscle differentiation is centered on 
two key regulators: Twist and its direct target, DMef2 (Taylor et al., 1995; Baylies and 
Bate, 1996; Cripps and Olson, 1998; reviewed in Black and Olson, 1998; Taylor, 2005). 
Earlier in this Chapter, I presented an overview of their roles during the development of 
the different muscle types. I will now focus on what is known about their function 
during somatic muscle differentiation.
1.5.1 Twist
Drosophila Twist is the founding member of a conserved family of bHLH 
transcriptional regulators found in human, mouse, nematodes, zebrafish and chicken 
(for review see Castanon and Baylies, 2002). Genetic analysis of twist function in 
Drosophila showed that it can promote somatic muscle differentiation (Baylies and Bate,
1996). In this study, Baylies and Bate investigated twist function using gain-of and loss-
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of-function approaches. Gain-of-function was achieved using the GAL4/UAS system 
(Brand and Perrimon, 1993) and loss-of-function was obtained with a temperature- 
sensitive combination of two twist alleles [twistv50/twistry50; Simpson, 1983; Thisse et al, 
1987]. Because in the absence of twist no mesoderm is formed (Simpson, 1983; Leptin, 
1991), the use of this heteroallelic combination was necessary to knock-out twist 
function after the formation of the mesoderm. They showed that high levels of twist are 
necessary for switching cells into somatic myogenesis, whereas low levels allow the 
development of other mesodermal derivatives (Baylies and Bate, 1996).
This function of promoter of muscle differentiation for Twist in Drosophila 
contrasts with that of mouse Twist (MTwist). In cell culture, MTwist can inhibit the 
function of MyoD and Me£2 proteins and therefore can inhibit myogenesis (Hebrok et 
al., 1994; Spicer et al., 1996). However, further analysis of twist function in Drosophila 
showed that, even though it promotes somatic myogenesis in the embryo, it can also 
play a role as an inhibitor of IFM differentiation (Anant et al., 1998). As mentioned 
earlier, twist expression persists in the precursors of the adult muscles during 
embryogenesis (Bate et al. 1991). As these precursors start their differentiation, twist 
declines (Currie and Bate, 1991; Fernandes et al., 1991). Anant et al. have shown that 
this decrease of twist expression is required for IFM differentiation. Persistent twist 
expression in the precursors of the adult muscles results in a reduction of myosin 
expression and degeneration of the IFMs (Anant et al., 1998).
Although this inhibitory function is consistent with the role of MTwist, it contrasts 
with twist function in the embryo. An explanation for this duality of twist function is 
provided by Castanon et al. who have further defined the role of twist and the 
importance of Twist levels in the differentiation of mesodermal derivatives in 
Drosophila. They showed that the activity of Twist as a promoter or an inhibitor of
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somatic muscle differentiation depends on its dimerisation partner. In domains of high 
Twist expression, Twist homodimerises and promotes somatic myogenesis. In domains 
of low Twist expression, Twist predominantly dimerises with Daughterless (Da), which 
is the homologue of vertebrate E protein and is required for mesoderm development 
(Castanon et al., 2001). Twist/Da heterodimers can repress somatic myogenesis 
(Castanon et al., 2001).
1.5.2 Dmef2
The Myocyte enhancer factor 2 (Mef2) was first identified in mammalian cell 
culture as a protein binding an A/T rich sequence in an enhancer of the muscle creatine 
kinase (mck) gene (Gosset et al., 1989). The Mef2-binding site was subsequently 
identified in nearly all known skeletal muscle genes (reviewed in Black and Olson,
1998). Mef2 proteins belong to the MADS box family of transcription factors and are 
essential for the activation of muscle gene expression (for review see Black and Olson, 
1998; Taylor, 2005). However, although numerous mammalian cell culture studies 
indicate that Mef2 proteins are essential for skeletal muscle differentiation, their role in 
the process in vivo is still unclear.
Four vertebrate mef2 genes [mef2a, -b, -c and -d; (Pollock and Treisman, 1991; 
Chambers et al., 1992; Yu et al., 1992; Breitbart et al., 1993; Leifer et al., 1993; Martin 
et al., 1993; McDermott et al., 1993; Ticho et al.1996; Morisaki et al., 1997)] have been 
identified. These genes regulate myogenesis, at least in part, through interaction with 
other transcription factors. The best studied examples of such interactions involve the 
Myogenic Regulatory Factor (MRF) family (reviewed in Black and Olson, 1998; Taylor, 
2005). Members of this family are bHLH transcription factors and include MyoD, 
Myf5, Myogenin and MRF4 (Weintraub et al., 1991). MyoD, the founding member of
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this family, can convert any cell type into myoblasts. These myoblasts can then 
differentiate into muscles (Weintraub et al., 1991). In cultured cells, Mef2 proteins can 
interact with members of the MRF family to synergistically activate muscle gene 
expression (Kaushal et al., 1994; Molkentin et al., 1995). In addition to the bHLH 
factors, other transcription factors interact with Mef2 to promote myogenesis. For 
example, the Ets domain transcription factor, polyoma virus enhancer activator 3 
(PEA3), can promote the differentiation of satellite cells following degeneration and 
this action is potentiated by interaction with Mef2 (Taylor et al., 1997).
Interactions of Mef2 with other transcription factors can also inhibit its activity. As 
mentioned in the previous section, MTwist can interact with Mef2 and inhibit its 
activity (Spicer et al., 1996). This inhibition of Mef2 activity by MTwist is dependent 
on binding of MTwist to the C-terminal transcriptional activation domain of Mef2 
(Spicer et al., 1996). This activity of MTwist contrasts with that of Drosophila twist, 
which has been shown to positively regulate Dmef2 expression (Taylor et al., 1995; 
Cripps and Olson, 1998). Other transcriptional regulators such as HDACs have also 
been shown to bind to Mef2 and repress its activity in cell culture (see Chapter 6, 
section 6.4).
Because of the overlapping pattern of expression and possibly function of the four 
Mef2 genes (reviewed in Black and Olson, 1998), analysis of Knock-out mice is rather 
complicated. Analysis of mice lacking mef2-cy which is the earliest of the four genes to 
be expressed in developing skeletal muscles (Edmondson et al., 1994), indicates that 
Mef2-C could be required for the activation of the skeletal muscle differentiation 
program (Lin et al., 1998). This analysis is limited to the observation of some muscle 
defects through the expression of a muscle specific reporter transgene.
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In contrast to vertebrates, Drosophila possesses a single mef2 gene (Dmef2) (Lilly 
et al., 1994) and its in vivo role during somatic muscle differentiation is clearly 
established. In Dmef2 mutant embryos, there is an almost complete loss of Myosin- 
expressing cells within the somatic mesoderm and multinucleated fibres fail to form 
(Bour et al., 1995; Lilly et al., 1995; Ranganayakulu et al., 1995; Gunthorpe et al., 
1999). These effects occur quite late in the muscle differentiation process. Muscle 
founders are specified normally, as revealed by the expression of markers such as eve or 
S59y but they fail to fuse (Lilly et al., 1995; Bour et al., 1995, Ranganayakulu et al., 
1995). These unfused founders do not differentiate into mononucleated fibres (Prokop 
et al., 1996). Dmef2 is therefore required for the fusion of founder cells with FCMs and 
for the subsequent differentiation of the somatic muscle precursors. Loss of Dmef2 also 
affects the differentiation of visceral and cardiac muscle (see sections 1.4.2 and 1.4.3). 
This mutant phenotype demonstrates that, in Drosophila, Dmef2 is central to the 
differentiation of all muscle types.
However, as mentioned in section 1.4.1, only a few targets have been identified for 
DMef2. These include Tropomyosin and p3-tubulin, which are both characteristic 
components of differentiated muscles (Lin et al., 1996; Damm et al., 1998), and 
Actin57B, which is the major myofibrillar actin expressed in muscle during 
embryogenesis (Kelly et al. 2002). Moreover, the analysis of Dmef2 has mainly focused 
on its function during differentiation. Yet, Dmef2 is expressed in the mesoderm long 
before the onset of muscle differentiation (Taylor et al., 1995), and therefore could 
affect gene expression earlier than generally supposed. Two examples of early Dmef2 
targets have been described supporting this idea: Dmesol8E, whose expression is 
dependent upon Dmef2 function at stage 11-12 (Taylor, 2000) and Actin57B, whose
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expression is reduced from stage 10 in Dmef2 mutant embryos (Kelly et al., 2002). This 
facet of Dmef2 function remains to be fully explored.
Like vertebrate Mef2 proteins, Dmef2 has been shown to directly interact with other 
transcription factors to regulate muscle differentiation. For example, its interaction with 
the Drosophila PAR domain-bZIP transcription factor PDP1 is necessary for regulating 
somatic muscle differentiation and the activation of the tropomyosinl gene (Lin et al.,
1997). Moreover, the regulation of Actin57B by DMef2 might require a co-factor 
(Kelly et al., 2002).
In conclusion, although Mef2 proteins play key roles in muscle differentiation in 
both vertebrates and Drosophila, a lot remains to be uncovered about their mechanism 
of action and the regulation of their activity in vivo.
1.6 Novel genes in muscle development
Progress in a molecular understanding of muscle development requires both the 
identification and analysis of genes that operate downstream of the molecules that 
pattern the mesoderm and also an understanding of the events that subsequently occur in 
muscle differentiation.
In order to investigate this issue, Dr Taylor undertook a screen to identify genes that 
are specifically expressed in the progenitors of the developing muscle. The analysis of 
these genes has two aims. The first is to analyse the control of their expression to 
determine how the general signals and transcription factors that pattern the mesoderm 
initiate cell-type specific gene expression. This forges an initial link from the early 
patterning events to the production of functional tissue. The second is to analyse what 
these genes do and how do they do it. The aim here is to understand the molecular
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events of muscle differentiation. It is this second aspect that is the focus of my PhD 
project.
Dr Taylor's screen used the technique of subtractive hybridisation linked to cDNA 
library construction (Taylor, 2000). He made a subtracted cDNA library enriched more 
than 100-fold for mesodermal cDNAs. Essentially, the approach was to take cDNA 
from wild type embryos and to subtract that from twist mutant embryos, which develop 
with no mesoderm. cDNAs from the subtracted library were then screened by in situ 
hybridisation to identify genes with specific expression patterns early in muscle 
differentiation. DNA sequencing determined whether clones with temporally and 
spatially significant expression patterns were previously undescribed. These novel 
genes are a rich source for current and future research. This innovative screen was the 
first to use zygotic mutations coupled to subtractive hybridisation to isolate genes 
specifically associated with a particular developmental event. The philosophy of this 
approach is to first identify differentially expressed genes, and then use reverse genetics 
to determine functions of the gene. This is greatly facilitated by resources provided by 
The Drosophila Genome Project.
The screen led to the isolation of novel genes specifically expressed in precursor 
cells of the different muscle types. My project centres on one of these genes: Dmesol7A.
Preliminary work in the laboratory has centred on a basic description of the gene, 
making/isolating essential gene-specific reagents, and initiating studies of what the gene 
does. The general approach was:
- Isolation of full-length cDNA and genomic DNA
- Analysis of the expression pattern of the gene to obtain clues on its function
- Making antibodies to detect protein expression and to compare with RNA expression
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- Computer-based analysis of the gene sequence to look for protein motifs and similar 
genes in other species
- Making transgenic lines to manipulate gene expression
My work on this gene is divided into two parts: the first aim is to analyse the role of 
the gene in the development of the different muscle types. The second aim, after 
investigating what the gene does, is to determine how does it do it. What is the gene 
function? Is it a transcription factor? Does it modulate signalling? Which proteins does 
it interact with?
My general approach was to manipulate the gene’s expression in order to determine 
what its role is and what is the mechanism by which it acts. Using the GAL4/UAS 
system to both miss-express and over-express full length or modified proteins, I have 
been able to test genetic interactions between Dmesol 7A and putative interactor(s) or 
target(s).
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2.1 Molecular Biology
2.1.1 Agarose gel electrophoresis
Electrophoresis was used to separate DNA fragments. 1% agarose (w/v) / IX TBE 
(90mM Tris-Borate, 2mM EDTA, pH 8.3) gels were used. 5-10 pi of a lOmg/ml 
ethidium bromide solution was added to the gels and the fragments were visualised 
using an UV transluminator to detect the fluorescence of the ethidium bromide that had 
intercalated within the DNA. A 1Kb ladder (Fermentas) or Lambda HindHI were used 
as molecular weight markers.
2.1.2 DNA extraction from agarose gels
DNA fragments were extracted from agarose gels using the QIAquick gel 
extraction kit (Qiagen) following the manufacturer’s instructions
2.1.3 Bacterial cultures and plates
Bacteria were grown either in liquid culture in Luria-Bertani (LB) medium (per 
Litre: lOg Bacto-tryptone, 5g yeast extract, 5g NaCl, pH 7.0) at 37°C with continuous 
shaking at 300rpm, or on LB-agar (LB plus 15g/L Bacto-Agar) plates at 37°C. 
Ampicillin, at a final concentration of lOOpg/ml, or Kanamycin, at a final concentration 
of 50pg/ml, were used as selectors.
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2.1.4 Transformation of competent cells
The E.coli DH5a bacterial strain was used for transformation. 50jil of competent 
cells were incubated with 1-5 pi (20 to lOOng) of DNA for 20 minutes on ice, heat- 
shocked at 42°C for 45 seconds and replaced on ice for at least 1 minute. 450pl of SOC 
medium (2% Tryptone, 0.5% Yeast Extract, lOmM NaCl, lOmM KC1, lOmM MgCb, 
lOmM MgSC>4, 20mM Glucose) was added and the transformed cells incubated at 37°C 
for 30 minutes to allow them to recover and to express the antibiotic resistance gene. 
50pi and 250pl of sample were plated onto LB-agar/ antibiotic plates and incubated 
overnight at 37°C.
2.1.5 Plasmid DNA preparation
Small scale DNA preparations (minipreparations) were undertaken either by a 
rapid boiling lysis method (boiling miniprep), or by using the QIAprep Spin Miniprep 
Kit (Qiagen). In both methods, 1.5ml of a 3ml overnight E.coli DH5a culture was 
collected by centrifugation at 13 OOOrpm in a microfuge for 5 minutes.
When the QIAprep Spin Minirep Kit was used, the manufacturer’s instructions 
were followed.
For the boiling miniprep method, the bacterial pellets were resuspended in 150pl 
STET buffer (0.1M NaCl, lOmM Tris-HCl pH 8.0, ImM EDTA pH 8.0, 5% Triton X- 
100) supplemented with 15 pi fresh lysozyme (Sigma, lOmg/ml). Cells were then lysed 
in a boiling water bath for 45 seconds. After centrifugation (13 OOOrpm in a microfuge 
for 10 minutes), the supernatant was transferred into a fresh 1.5ml microcentrifuge tube 
and the DNA was precipitated with an equal volume of isopropanol. The DNA was 
pelleted by centrifugation (13 OOOrpm in a microfuge for 10 minutes), washed with 70% 
ethanol and resuspended in 30pl TE containing RNase A (Sigma, 5pg/ml).
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Larger scale DNA preparations (midipreparations) were undertaken using the 
QIAfilter Plasmid Midi Kit (Qiagen) according to the manufacturer’s instructions.
2.1.6 DNA precipitation with ethanol
DNA was precipitated by the addition of 2 volumes of ice cold ethanol after the 
salt concentration was adjusted with 1/10 volume of 3M sodium acetate. The mixture 
was incubated for 20-30 minutes at -80°C and the DNA was recovered by centrifugation 
at 13.000 rpm in a microfuge for 15 minutes. The pellet was washed with 70% ethanol, 
air dried and resuspended in a suitable volume of double distilled H2O.
2.1.7 Restriction enzyme digest
Reactions were carried out in 50 pi containing the DNA to be digested, the 
restriction endonuclease(s) (NEB or Promega) and the appropriate reaction buffer (NEB 
or Promega). An excess of enzyme (typically 3-fold) per pg of DNA was used (without 
exceeding 10% of the reaction volume). Reactions were incubated at 37°C for 2 hours 
and stopped by heat killing the enzyme for 20 minutes at the temperature indicated by 
the manufacturer. For double digests, reactions were performed either simultaneously or 
sequentially. In the first case, the buffer providing optimum reaction conditions for both 
restriction endonucleases was selected. If no single buffer was found, the reaction was 
carried out with the first enzyme alone, then the DNA was precipitated with ethanol and 
finally digested with the second enzyme.
When 5’ overhang filling was required to generate blunt ends, the DNA was 
digested with the first enzyme and the reaction was stopped by heat killing the enzyme, 
lpl of T4 DNA polymerase (3U/pl; NEB) and 0.5pl of lOmM dNTPs (Promega) were
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then added. The reaction was incubated for 30 minutes at 37°C. After completion, the 
DNA was precipitated with ethanol and digested with the second enzyme.
For the preparation of plasmid DNA for ligations, 5 pi of lpg/pl vectors were 
digested as described above, precipitated with ethanol and the DNA pellet was 
resuspended in 26pl H2O. Linearised vectors were then dephosphorylated by the 
addition of 3 pi of lOx buffer 3 (NEB) and lpl of alkaline phosphatase calf intestinal 
(CIP) (NEB). Reaction were incubated at 37°C for 30 minutes and stopped by the 
addition of 0.5pl of 0.5M EDTA and then by heat killing the CIP for 5 minutes at 65°C.
In all cases, restriction fragments and linearised vectors were purified by gel 
extraction prior to ligation.
2.1.8 Ligation of DNA fragments into plasmids
Ligation of cohesive or blunt end DNA fragment was carried out in a lOpl volume 
containing lpl of 10X ligation buffer (NEB), lpl of T4 DNA ligase (NEB), lpl of 
linearised plasmid DNA (50ng/pl) and a 3x molar excess of DNA fragment to be ligated. 
Reactions were incubated overnight at 16°C or at 12°C if EcoRI was used for the 
digests. 3-5pl of ligation reactions were used for transformation.
- 33-
Chapter 2: Materials and Methods
2.1.9 Polymerase Chain Reaction (PCR)
Standard PCR reactions were carried out for the generation of the various 
constructs (see sections 2.1.11; 2.1.14; 2.1.15). Unless otherwise stated, the DyNAzyme 
EXT high fidelity DNA Polymerase (Finnzymes) was used. Typically, reactions were 
carried out in a 50pl volume, containing 5pi of optimised DyNAzyme EXT buffer 
(containing 1.5mM MgCk), lpl of lOmM dNTPs (Promega), lpl of lOpM forward 
oligonucleotide primer (MWG), lpl of lOpM reverse oligonucleotide primer (MWG), 
lpl of lOOng/pl template DNA (plasmid or genomic) and lp l of DNA polymerase. The 
volume was then adjusted with double distilled H2O. The DNA templates were 
amplified using 20-25 cycles in a Peltier thermal cycler (MJ Research) equipped with a 
heated lid.
The following program was used:
- Initial denaturation: 95°C, 5 minutes
- Denaturation: 95°C, 1 minute
- Annealing: 55-65°C, 1 minute
- Extension: 72°C, 1 minute/Kb of template sequence
- Final extension: 72°C, 5-10 minutes
At the end of the program, 5 pi of the PCR reaction was used to analyse the 
products on a 1% agarose gel and 2pl were used to measure the concentration of the 
products using a spectrophotometer. The PCR products were then ligated by TA cloning 
into the PGEM-T cloning vector (Promega) according to the manufacturer’s instructions. 
The TA cloning was possible because the DyNAzyme EXT DNA Polymerase adds a 
non-templated adenine residue at the 3’ end of a DNA fragments.
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2.1.10 Preparation of Digoxigenin-labelled RNA probe
The DNA template for the Dmesol7A RNA probe was a 579bp cDNA fragment 
in pBluescript II KS (-) isolated from a subtracted library (Taylor, 2000). The 2.6kb P3 
tubulin cDNA fragment (from construct PC60-1L, a gift from Detlev Buttgereit) was 
subcloned into pBluescript II KS (+). The Dmef2 cDNA (an approximately 3kb 
fragment) was in pBluescript II KS (-) (Taylor et al., 1995).
Prior to transcription, DNA templates were linearised as described in section 2.1.7. 
The Dmesol7A cDNA was digested with Hindlll (NEB), the P3 tubulin cDNA with 
Xhol (NEB) and the Dmef2 cDNA with Hindm (NEB). Linearised DNAs were then 
purified by gel extraction.
Transcription reactions were carried out in 50pl containing approximately 500ng 
of linearised template DNA, lpl of 10X transcription buffer (Roche), lp l of DIGNTP 
mix (Roche), 0.5pl of RNAse inhibitor (Roche) and lpl of T7 RNA polymerase 
(Roche). The volume was then adjusted to lOpl with double distilled H2O. Reactions 
were incubated at 37°C for 2 hours. After transcription, the DNA template was removed 
by the addition of lpl of DNAsel buffer, 6pl of H20 and 3pi of DNAsel RNase free 
(lOU/pl; Roche). This was incubated at 37°C for 15 minutes. The RNA probes were 
then fragmented with 80pl of 125mM sodium carbonate (pH 10.2) at 60°C for 
15minutes. The alkaline hydrolysis of the probes was stopped by adding of 50pl 7.5M 
ammonium acetate. RNA was precipitated with isopropanol, washed with 70% ethanol, 
air dried and resuspended in TEiformamide (1:1).
The yield of DIG-labelled RNA was estimated in a spot test using a DIG-labelled 
control (Roche). The test was performed following the manufacturer’s instructions. 
Briefly, dilutions of both the control and the probes (all in RNase free double distilled 
H2O) to be tested were spotted and cross-linked to a positively-charged nylon
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membrane (Roche). The spots were then colorimetrically detected and the comparison 
of the intensities of the spot allowed an estimation of labelling yield. Probes were 
diluted with TEiformamide (1:1) to 25ng/pl and 5pi was used for in situ hybridisation.
2.1.11 Generation of the UAS-Dmesol7A-RNAi construct
Knock-down of Dmesol 7A was achieved via dsRNA interference (RNAi) using a 
splice-activated UAS hairpin vector (pJM1084; Reichhart et al, 2002). The entire 
coding region of Dmesol 7A was used and convenient restriction sites were inserted by 
PCR at the 5’ and 3’ ends of Dmesol 7A cDNA. The following primers were used:
- 5’ GGAGCTAGCATGGGCGTCATCTACAAG 3’ (Tm 68.0°C; bold: Nhel site)
- 5’ GGAGGATCCCTACCAAGGTCGCCACAC 3’ (Tm 71.0°C; bold: BamHI
site)
The Tms indicated in brackets were calculated according to the formula given on 
the MWG web site for primers longer than 15bp (http://www.mwg-biotech.com).
The PCR fragment was ligated into pGEM-T (Promega), grown and sequenced. It 
was then digested, using the BamHI and Nhel restriction endonucleases, and gel 
purified. The purified product was ligated into pJM1084 on both sides of the intronic 
spacer, in between the BamHI and Nhel sites (Antisense, 5’ of the intron) or the 
compatible Bglll and Xbal sites (Sense, 3’ of the intron) (Figure 2.1).
The construct was then prepared and injected as described in section 2.3.5 and the 
GAL4/UAS system (Brand and Perrimon, 1993) was used to express the dsRNA 
construct.
- 36-
Chapter 2: Materials and Methods
Ntlei Bar
* '
iHI Bg
r y
III Xbal
I
UAS Hsp70 
TATA A
S '  Dmesol7A 
anti sense
Intron Dmesol7A 
sense
Figure 2.1
2.1.12 Total RNA extraction from Dmesol 7A~RNAi~expressing 
embryos
To test whether Dmesol 7A-RNAi is inducing a knock-down of Dmesol 7A, RNA 
was extracted from embryos expressing Dmesol 7A-RNAi in order to perform semi- 
quantitative RT-PCR. Females homozygous for a UAS-Dmesol7A-RNAi construct were 
crossed with males homozygous for Dmesol 7A-GAL4. Wild-Type flies were used as a 
control. Crosses were set up in cages where flies were allowed to lay eggs on apple 
juice-agar plates supplemented with fresh yeast at 25°C for 40 minutes. The plates were 
then further incubated at 25°C until the embryos reached stage 12 (7 hours).
30 minutes before they reached the desired stage, the embryos were transferred 
into a mesh basket and rinsed thoroughly with water to eliminate the yeast. They were 
then arranged in one layer on a new plate to facilitate sorting. The stage of development 
of the embryos was checked by looking at the yolk autofluorescence using a green filter. 
The yolk shape changes during development allowing precise staging of the embryos. A 
minimum of 150 embryos were selected for RNA extractions. Unfertilized embryos 
were discarded.
Selected embryos were transferred to a 1.5ml microcentrifuge tube and rinsed 3 
times with double distilled H2O. After the last rinse, the embryos were spun down for a
- 37-
Chapter 2: Materials and Methods
few seconds at maximum speed and all the water carefully removed. Embryos were 
frozen in liquid nitrogen and stored at -70°C prior to RNA extraction
RNA was extracted using the RNeasy Protect Mini Kit (Qiagen) according to 
manufacturer’s instructions. The concentration of RNA was determined by 
spectrophotometry.
2.1.13 Semi-quantitative Reverse Transcription-PCR (RT-PCR)
Reverse transcription was performed using the Superscript III First-Strand 
Synthesis System for RT-PCR (Invitrogen) following the manufacturer’s instructions. 
500ng of total RNA from Dmesol 7A-RNAi over-expressing or wild type embryos was 
used for first strand cDNA synthesis. The following gene-specific primers were used to 
reverse transcribe both Dmesol 7A and a control, rp49 (Tamate et al., 1990; Borie et al.,
1999):
- For Dmesol 7A: 5’ TACCAAGGTCGCCACACCAC 3’ (Tm 61.4°C)
- For rp49: 5’ TGTGTATTCCGACCACGTTACAAG 3’ (Tm 61.0°C)
2.5(il of cDNA products were used for amplification with lpl of BIOTAQ DNA 
polymerase (5U/pl; Bioline), in the buffer provided by the manufacturer and in the 
presence of the specific primers for both Dmesol 7A and rp49, which was used as an 
internal control. Reactions were carried out in a Peltier thermal cycler (Mj Research) 
using the following program:
- Initial denaturation: 95°C, 3 minutes
- Denaturation: 95°C, 1 minute
- Annealing: 60°C, 1 minute
- Extension: 72°C, 1 minute
- Final extension: 72°C, 5 minutes
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A total of 25 cycles was used. This number was chosen so that the amplification 
products were clearly visible on an agarose gel and can be quantified, but also that the 
reaction was in the exponential phase and had not reached a plateau of amplification. 
The two sets of primers were also tested to make sure that they did not compete when 
used in the same PCR reaction.
Images of the RT-PCR agarose gels were acquired with a led camera and 
quantification of the bands was performed using the Gene tool software (Syngene).
2.1.14 Generation of the Dmesol 7A-GAL4
Dmesol 7A-GAL4 was generated using a 2.8Kb restriction fragment (EcoRI/ Xhol) 
from the Dmesol 7A enhancer region. This fragment has previously been tested in the 
laboratory in a reporter construct. LacZ expression driven by this enhancer is very 
similar to that of Dmesol 7A.
The 2.8Kb were cloned into the pPTGAL vector (Sharma et al., 2002) which 
contains the GAL4 coding sequence and allows insertion of enhancer fragments and 
immediate injection for the generation of transgenic lines.
Because there is no Xhol restriction site in the pPTGAL polylinker, the 2.8Kb 
fragment and the vector were first digested with Xhol and BamHI respectively and 
blunt ends were generated by 5’ overhang filling. DNAs were then digested with EcoRI, 
gel purified and ligated.
The construct was then prepared and injected as described in section 2.3.5.
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2.1.15 Generation of GST-Dmesol7A and GST-Dmesol7A-AWRPW 
fusion proteins
To allow expression in either rabbit reticulocyte lysate or prokaryotic system, the 
constructs were generated using the pET-3a vector (Novagen) in which the T7-Tag was 
removed and replaced by GST (GST-pET-3a,). The following primers, containing Ndel 
or BamHI restriction sites, were used to amplify the GST DNA from the pGEX-2TK 
vector (Amersham Bioscience):
- 5’ GC AT ATGTCCCCT AT ACT AGGTT ATTGG 3’ (Tm 63.6°C; bold: Ndel
restriction site)
- 5’ GGATCCATCCGATTTTGGAGGATGGTCG 3’ (Tm 68°C; bold: BamHI
restriction site)
The PCR fragment was ligated into pGEM-T (Promega), grown and its sequence 
verified. It was then digested, using Ndel and BamHI, and gel purified. The pET-3a 
vector was also digested with Ndel and BamHI, to remove the T7-Tag, 
dephosphorylated and gel purified.
Fragment and vector were ligated as described in section 2.1.8 (Figure 2.2). The 
new GST-pET-3a vector was then prepared by digestion with BamHI, 
dephosphorylation and gel purification.
Dmesol7A and Dmesol7A-AWRPW DNA fragments, containing BamHI 
restriction sites at both ends, were generated by PCR from Dmesol 7A cDNA in 
pBluescript II KS (-) (Taylor, 2000). The following primers were used:
■ For Dmesol 7A full length:
- 5’ GGAGGATCCATGGGCGTCATCTACAAG 3’ (Tm 68°C; bold: BamHI
restriction site)
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- 5’ CTCGGATCCCTACCAAGGTCGCCAC 3’ (Tm 69.5°C; bold: BamHI
restriction site)
■ For Dmesol 7A-AWRPW:
- 5’ GGAGGATCCATGGGCGTCATCTACAAG 3’ (Tm 68°C; bold: BamHI
restriction site)
- 5’ CTCGGATCCCTACACCACCATTCGCTG 3’ (Tm 69.5°C; bold: BamHI
restriction site)
The PCR fragments were ligated into pGEM-T (Promega), grown and sequenced. 
They were then digested, using BamHI, and gel purified. Full length and truncated 
Dmesol 7A were ligated into GST-pET-3a (Figure 2.2).
Constructs were then prepared and injected as described in section 2.3.5.
N<el BarnHI BamHI
1
T7
promoter GST Dmesol7A or Dmesol7A-AWRPW
Figure 2.2
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2.2 Protein work
2.2.1 Acrylamide gel electrophoresis
Acrylamide gel electrophoresis was used to separate protein samples. Gels and 
samples were prepared following the method described in Sambrook and Russell 
(Molecular Cloning, third edition, 2001) A 12% acrylamide/SDS resolving gel (12% 
acrylamide/bis-acrylamide, 375mM Tris-HCl pH 8.8, 0.1% SDS) and a 4% 
acrylamide/SDS stacking gel (4% acrylamide/bis-acrylamide, 125mM Tris-HCl pH 6.8, 
0.1% SDS) were used. Samples were run, in a mini proteanlll electrophoresis cell 
(Biorad), at 70 volts through the stacking gel and at 100 volts through the resolving gel 
in Tris-glycine running buffer (25mM Tris, 250mM glycine, 0.1% SDS, pH8.3). The 
SeeBlue Plus2 protein standard (Invitrogen) was used as a molecular weight marker. 
Gels were either fixed in 50% methanol/10% glacial acetic acid and dried before 
exposure to X-ray film for autoradiography, or stained for 30 minutes in a Coomassie 
Brilliant Blue solution (lg/L Coomassie Brilliant Blue (Sigma), 10% methanol; 10% 
glacial acetic acid). Stained gels were submerged overnight in destain solution (10% 
methanol; 10% glacial acetic acid) to remove excess Coomassie Brilliant Blue.
2.2.2 Expression of proteins in bacteria
GST-fusion protein constructs were expressed using the E.coli BL21 strain 
(Stratagene). Prior to purification, miniprotein preparations were performed to assess 
the expression of each construct. To do so, 500pl of an overnight culture of a selected 
colony grown in LB ampicillin was used to inoculate 4.5ml of LB ampicillin (1:10 
dilution). The culture was grown for 1.5 hours at 30°C with shaking at 250rpm. Before 
induction with freshly made IPTG (isopropyl-p-D-thiogalactopyranoside, 0.6mg/ml, 
Sigma), a 2ml sample was removed for SDS PAGE analysis. The induced culture was
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grown for a further 3 hours at 30°C and bacteria were harvested by centrifugation for 1 
minute at 13 OOOrpm in a microfuge in a 2ml tube. The cells were resuspended in lOOpl 
SDS sample buffer and boiled for 3 minutes. 20pl were loaded onto an SDS 
polyacrylamide gel.
In order to purify the GST-fusion proteins, selected clones expressing the 
constructs were grown in larger cultures. A 10ml culture was grown at 30°C with 
shaking at 250rpm until the OD550 reached 2.0-2.5 (usually about 14-16 hours growth). 
About 5ml of this culture was then diluted into 100ml of LB amp and incubated at 30°C 
with shaking at 250rpm until the OD550 reached 0.5 (usually 1-1.5 hours growth). 
Expression of the fusion protein was induced with 60mg/100ml IPTG and the cultures 
were further incubated for 3 hours at 30°C. Cells were then harvested by centrifugation 
at 4000rpm at 4°C in a Sorvall SS-34 rotor for 10 minutes. Bacterial pellets were 
resuspended in 10ml MTPBS (150mM NaCl, 16mM Na2HP04, 4mM NaH2P04, pH 7.3) 
supplemented with protease inhibitors (Roche mini-complete EDTA free tablets) and 
0.1% P-mercaptoethanol (Sigma). A 1ml sample was removed at this point to check the 
level of induction prior to purification. The resuspended bacteria were transferred into a 
50ml tube on ice and sonicated using a Soniprepl50 sonicator for 1 minute at 12-14 
microns amplitude. The samples were cooled and then sonicated for a further 30 
seconds. The probe was also allowed to cool during the interval. 1ml of 10% Triton was 
added and insoluble material was removed by centrifugation at 13 OOOrpm in a Sorvall 
SS-34 rotor at 4°C for 10 minutes. The supernatant (SN) was transferred to a 15ml 
Falcon tube and a 1ml sample was removed for SDS PAGE analysis. The rest of the SN 
was mixed with 2ml of glutathione-sepharose beads (Qiagen)/MTPBS (1:1 slurry). The 
beads were prepared by pre-swelling and washing in MTPBS with 0.1% p- 
mercaptoethanol at 4°C 3hours before use. The SN and beads were rolled at 4°C for 30
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minutes before pouring into a plastic column (Pierce). The columns were washed with 3 
times 10ml MTPBS supplemented with protease inhibitors. 0.1% Triton was added for 
the first 2 washes. The beads were recovered from the column and stored at 4°C as a 
50:50 slurry with MTPBS supplemented with protease inhibitors. A sample was taken 
to check the purification and estimate the amount of fusion protein recovered on SDS 
PAGE.
2.2.3 Expression of radiolabelled Groucho protein in-vitro
In-vitro translated Groucho (Gro) was produced using the TNT rabbit reticulocyte 
lysate system (Promega) which couples transcription and translation. Manufacturer’s 
instructions were followed and T7 RNA polymerase (Promega) was used. Template was 
full length groucho, cloned in pET-3A (pET-gro, a gift from M.Wainwright). Reactions 
were performed with lpg of DNA template and Redivue [35S]-Methionine (Amersham 
Biosciences) was used to radiolabel the translation products. [35S]-Gro was analysed 
and visualised by SDS PAGE and autoradiography (see section 2.2.1).
2.2.4 Pull-down assay
In each protein-protein interaction assay, the amounts of fusion protein used, 
estimated by Coomassie staining of SDS PAGE gels, were normalised to 30pl of beads 
of the least concentrated one. Blank glutathione beads, blocked with normal goat serum, 
were used to bring the volume in all tubes to 30fil. Then, 180pl of binding buffer 
(20mM Hepes-KOH pH 7.9, 50mM KC1, 2.5mM MgCl2, 10% glycerol, ImM DTT, 
0.2% NP40, 3pl/180pl normal goat serum, 3pl/180pl lOOmM PMSF (17.42 mg/ml in 
isopropanol)) was added to each tube and the slurry was rolled at 4°C for one hour. 
Approximately 25pl of programmed reticulocyte lysate containing radiolabelled Gro
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was then added and the tubes rolled overnight at 4°C. The beads were then washed four 
times with 1ml RIPA buffer (lOmM Tris-HCl pH 7.5, 150mM NaCl, lmM EDTA, 
0.2% NP40). After each wash, tubes were briefly spun at 1 OOOrpm in a microfuge and 
the supernatant carefully removed. lOOpl of SDS loading buffer (0.1M Tris-HCl, pH 6.8, 
20% glycerol, 10% p-mercaptoethanol, 4% SDS, 0.2% bromophenol blue) was then 
added to the beads. Before loading on the gel, samples were boiled to release bound 
proteins, centrifuged for 2 minutes at 13000rpm in a microfuge to pellet the beads and 
the supernatant containing the released proteins was transferred to a fresh 1.5ml 
microcentrifuge tube. Equal amounts of each sample were loaded onto an SDS PAGE 
and radiolabelled Gro was visualised by autoradiography (see section 2.2.1).
2.2.5 Western blotting and detection of the Dmesol7A protein
2.2.5.1 Protein extraction from Drosophila embryos
Flies were allowed to lay eggs on an apple juice-agar plate for 20 minutes at 25°C. 
Embryos were further incubated at 25°C until the desired stage of development was 
reached and they were then staged and selected under a dissecting microscope. Protein 
samples were prepared from 50 stage 12 embryos.
Embryos were dechorionated and then homogenised in 12.5pl of lysis buffer 
(lOmM Hepes pH 7.4, 5mM EGTA, 5mM EDTA, 0.44% benzamide, 5% SDS, protease 
inhibitors (Roche mini complete EDTA free tablets)). They were then boiled for 4 
minutes before addition of 12.5pl of 2X SDS loading buffer. Samples were boiled for a 
further 4 minutes and stored at -70°C until required.
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2.2.5.2 Western blot
Western blot was performed using a Mini-Trans Blot electrophoretic transfer cell 
(Biorad). The gel was blotted onto Immobilon P PVDF membrane (Amersham 
Biosciences) in transfer buffer (192mM glycine, 25mM Tris). After the transfer, the 
membrane was blocked overnight at 4°C in TBST (lOmM Tris-HCl pH 7.5, 150mM 
NaCl, 0.05% Tween) containing 5% non-fat dried milk (Marvel). The blot was then cut 
in half at the level of the 36Kd marker. The upper half was incubated with a 1:1000 
dilution of the anti-p-tubulin antibody (E7 Ab; Developmental Studies Hybridoma Bank, 
Iowa). The lower half was incubated with the anti-Dmesol7A antibody diluted 1:1000. 
Both antibodies were diluted in TBST+5% milk and incubations were for 1 hour at 
room temperature. Both halves were then washed 2x 15 minutes with TBST and 
blocked for 1 hour at room temperature with TBST+5% milk. The lower half was 
incubated with a 1:10000 dilution of peroxidase-tagged anti-guinea pig secondary 
antibody (Jackson) and the upper half with a 1:10000 dilution of peroxidase-tagged 
anti-mouse secondary antibody (Vector laboratories). Dilutions and incubations were 
performed as described above. Membranes were then washed 2x 15 minutes with TBST. 
Proteins were detected using the Super Signal Chemiluminescence kit (Pierce) 
following the manufacturer’s instructions.
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2.3 Drosophila stocks and crosses
2.3.1 Maintenance of fly stocks
Fly stocks were maintained on a medium containing 6.77% commeal, 7.26% 
dextrose, 1.45% yeast, 0.68% agar and 2.26% nipagin. The majority of the stocks were 
kept at 18°C and changed every four weeks. When making stocks, crosses were kept at 
25°C.
When collecting flies for UAS/GAL4 experiments, the stocks were amplified and 
kept at 25°C during the day and 18°C during the night to optimise virgin females 
collection. The laying cages were kept at either 18°C or 25°C according to the severity 
of the phenotype desired.
New stocks received from the Drosophila stock centre (Bloomington) or other 
groups were kept in quarantine for at least three generations and inspected for mite 
infection before being brought into the laboratory’s fly room.
In all my experiments, Oregon R flies (OR) were used as wild-type.
2.3.2 Mutant stocks used
Table 1 lists the mutant stocks used.
In order to identify homozygous mutant embryos, Dme/265 and gro mutant alleles 
were placed over a blue or a green balancer chromosome (Figure 2.3). The balancer 
chromosomes carry a P-element insertion driving the expression of either {L 
galactosidase, for the so-called blue balancer, or Green Fluorescent Protein (GFP) for 
the green balancer. Both j.3-galactosidase and GFP are under the control of specific 
promoters/ enhancers. Antibody staining was used to assess p-galactosidase or GFP 
expression.
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Table 1: List of mutant stocks used
Stock Comments Origin References
Dmef2"3/SM6b
EMS induced 
strong hypomorphic 
allele
Robert Schulz
Ranganayakulu et 
al.
(1995)
Dmeft424/SM6b
EMS induced 
moderate 
hypomorphic allele
Robert Schulz
Ranganayakulu et 
al.
(1995)
Dmef265/SM6b EMS induced weak hypomorphic allele Robert Schulz
Ranganayakulu et 
al.
(1995)
groE4S/TM3,Sb EMS induced point mutation Amy Bejsovec
Preiss et al. 
(1988)
groBX22/TM3, Sb
Deficiency that 
removes several 
genes from the 
Enhancer of split 
(E(spl)) complex
Amy Bejsovec Preiss et al. (1988)
Dme/2* + v  a/ TM3^Sj^
W;~SM6b': ~+‘ CyO,wgIacZ; TM6,Hu
3 I $
„  Dmef2* TM3, Sb Dmef2* TM6, HuF,: Wm ■ ■ x W;1 ’ CyO, wg lacZ ’ + CyO, wg lacZ +
3 I ?1
_  Dme/2* TM6, HuF  • w-
2 ’ CyO, wg lacZ ’ TM3, Sb
®  + gro* If Sb
W; —  ; —— x  W;
+ TM3, act GFP, Ser CyO TM3, act GFP, Ser
S I ?
Fj: w; If ; gr0* x w CyO . gro'
+ TM3, act GFP, Ser ; + TM3, act GFP, Ser
3 I ?
F,: w;
V . gro*
2* CyO TM3, act GFP, Ser
Figure 2.3: Generation of Dmef2 or^ra mutant balanced stocks.
(A) Males carrying a Dmef2 mutant allele were crossed with virgin females 
carrying dominant markers and a blue balancer on the second chromosome. FI 
males carrying CyO, wg lacZ; TM3,Sb and females carrying CyO, wg lacZ; 
TM6,Hu were selected and crossed together. F2 flies carrying CyO, wg lacZ; 
TM3,Sb/TM6,Hu were kept and expanded into a stock. (B) Males carrying a gro 
mutant allele were crossed with virgin females carrying dominant markers and a 
green balancer on the third chromosome. FI males carrying If; TM3,actGFP,Ser 
and females carrying CyO; TM3,actGFP,Ser were selected and crossed together. 
F2 flies carrying IfI CyO; TM3,actGFP,Ser were kept and expanded into a stock.
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For making the Dmef2-mu.tant balanced stocks (Figure 2.3A), the CyO, wg lacZ 
blue balancer was used. Females w; If/CyO, wg lacZ; TM3, Sb/TM6, Hu were crossed 
with Dmef2* males. Fi males carrying CyO, wg lacZ and TM3, Sb, but not I f  were 
crossed with Fi virgin females carrying CyO, wg lacZ and TM6, Hu but not I f  Males 
and virgin females of the F2 carrying CyO, TM3 and TM6 were selected to make the 
following stock: w; Dmef2*/CyO, wg lacZ; TM3, Sb/TM6, Hu.
For the gro mutant alleles (Figure 2.3B), the TM3, actin GFP, ser green balancer 
was used. Females w; If/CyO; TM3, act GFP, Ser/Sb were crossed with males w; +/+; 
gro*/TM3, Sb. Fi males carrying I f  and TM3, act GFP, Ser, but not Sb were crossed 
with Fi virgin females carrying CyO and TM3, act GFP, Ser, but not Sb. Males and 
virgin females of the F2 carrying If, CyO and TM3, act GFP, Ser were selected to make 
the following stock: w; If/CyO; gro*/TM3, act GFP, Ser.
2.3.3 The GAL4-UAS Expression System
The GAL4/UAS system was used to mis-express particular genes in specific cells 
or tissues within the embryo (Brand et al., 1994; Brand and Perrimon, 1993). There are 
two components to this system: the driver stock that expresses the yeast transcriptional 
activator protein, GALA, under the regulation of a tissue/cell specific promoter/enhancer, 
and the UAS stock that carries a transgene whose expression is regulated by the GALA 
upstream activation sequence (UAS). When GAL4 and UAS stocks are crossed, the 
transgene is expressed in the same pattern as the GAL4 protein. Thus, ectopic 
expression of the transgene depends on the promoter that regulates GAL4 expression.
The activity of the GALA protein is temperature dependent in Drosophila such 
that more severe phenotypes are observed at higher temperatures (Brand et al., 1994). In
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my over-expression experiments, the crosses were kept at 18°C, 21°C or 25°C (see text 
in results sections) to generate different strengths of phenotype.
2.3.4 GAL4 and UAS lines used
Tables 2 and 3 list the GAL4 and UAS lines used together with comments, origin 
and relevant references. To make sure that the phenotypes observed in the different 
over-expression experiments are not due to the insertion of the transgenes, at least three 
UAS lines were tested in each case. Appendix 1 lists all the UAS lines tested together 
with informations on the phenotype.
2.3.5 Generation of new UAS and GAL4 lines 
UAS-Dmesol7A-RNAi and Dmesol 7A-GAL4 lines were generated by injection of
the constructs described in section 2.1.11 and 2.1.14 into one hour old embryos.
For each construct, midipreparations of DNA were made using the QLAfilter 
Plasmid Midi Kit (Qiagen). Generally, 20pg of DNA were then precipitated with 
ethanol and resuspended in lOpl of double distilled H2O in order to obtain a 
concentration of 2pg/pl. The injection mix was then prepared in IX Spradling buffer 
(ImM Sodium Phosphate buffer pH6.8, 0.5mM KC1) with the DNA to be injected at a 
final concentration of 1 pg/pl and the helper DNA (which is a source of transposase that 
will promote the mobilisation of the constructs from the plasmid into the genome) at a 
final concentration of 0.25pg/pl. The mix was spun for 10 minutes at full speed and 0.5- 
lpl was loaded into the injection needles prepared by pulling capillaries (1.0mm x 
0.78mm, Harvard Apparatus) with a needle puller (KOPF Instruments).
Embryos for injection were obtained from young yellow-white females. Flies were 
grown as described in section 2.3.1 and the stock was expanded to obtain as many 
young flies as possible. A minimum of 150 young females and approximately 50 males 
were placed into laying cages and allowed to lay eggs onto apple juice-agar plates for
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Table 2: List of GAL4 lines used
Stock Comments Origin References
w, twist-GAL4; twist - 
GAL4 
(twist/twist-GAL4)
Two copies of twist- 
GAL4, on the X and 2nd 
chromosome. GAL4 
expression is driven by a 
twi enhancer and promoter 
included within a 1.4kb 
Hindlll-Clal fragment that 
includes the elements 
necessary for proper twi 
expression.
Mary Baylies
Baylies and 
Bate 
(1996)
Bap-GAL4
Gal4 line driving 
expression in the visceral 
mesoderm from stage 10
Ruth Palmer Zaffran et al. (2001)
24B-GAL4
GAL4 line driving 
expression in the 
mesoderm from stage 10.
Mar Ruiz Gomez
Brand and 
Perrimon 
(1993)
69B-GAL4
GAL4 line driving 
expression in the ectoderm 
from stage 9
Andrea Brand
Brand and 
Perrimon 
(1993)
Dmef2-GAL4
GAL4 line that drives 
expression in the 
mesoderm from stage 7
G.Ranganayakulu
Ranganayakulu 
et al 
(1996)
Dmesol 7A-GAL4
GAL4 line that drives 
expression in the somatic 
mesoderm from stage 10 
to 12 and in the pericardial 
cells from stage 11 until 
the end of embryogenesis
David Liotta unpublished
w;twist-GAL4;
TM3/TM6
GAL4 line that drives 
expression in the 
mesoderm from 
gastrulation
Alan Michelson unpublished
1151-GAL4
Gal4 line that drives 
expression in the 
adepithelial cells 
associated with the wing 
and leg imaginal discs. 
Expression continues in 
the pupa and the adult 
muscles.
Uppendra
Nongthomba
Roy and 
VijayRaghavan 
(1998)
Table 3: List of UAS lines used
Stock Comments Origin
UAS-Dmesol 7A (J7)
Full length Dmesol 7A 
coding sequence under 
the control of UAS 
regulatory sequences.
The stock is 
homozygous on the 2nd 
chromosome.
Mike Taylor, 
Clare Garvey
UAS-Dmesol 7A (J1S)
Full length Dmesol 7A 
coding sequence under 
the control of UAS 
regulatory sequences.
The stock is 
homozygous on the 3rd 
chromosome.
Mike Taylor, 
Clare Garvey
UAS-Dmesol 7A- 
AWRPW(la)
Dmesol 7A coding 
sequence lacking the last 
9 base pairs under the 
control of UAS 
regulatory sequences.
The stock is 
homozygous on the 2nd 
chromosome
Mike Taylor, 
Clare Garvey
UAS-Dmesol 7A- 
AWRPW(lb)
Dmesol 7A coding 
sequence lacking the last 
9 base pairs under the 
control of UAS 
regulatory sequences.
The stock is 
homozygous on the 3rd 
chromosome
Clare Garvey
UAS-Dmesol 7A-RNAi 
(Ll.4.2)
Full length Dmesol 7A 
coding sequence cloned 
sense and antisense 
under the control of 
UAS regulatory 
sequences. The stock is 
homozygous on the 3rd 
chromosome
David Liotta
Stock Comments Origin
UAS-Dmesol 7A-RNAi 
(L4.2)
Full length Dmesol 7A 
coding sequence 
cloned sense and 
antisense under the 
control of UAS 
regulatory sequences.
The stock is 
homozygous on the 2 
chromosome
David Liotta
UAS -Dmef2
Entire Dmef2 coding 
sequence under the 
control of UAS 
regulatory sequences.
The stock is 
homozygous on the 3rd 
chromosome
Kathryn Beatty
UAS-human HDAC5- 
SA
Constitutively active 
form of human 
HDAC5. A serine 
changed to alanine 
prevents the 
exportation out of the 
nucleus. The stock is 
homozygous on the 3rd 
chromosome.
E.N. Olson
UAS-flag-Drosophila
HDAC4-AC
Constitutively active 
form of fly HDAC4 
where the nuclear 
export signal has been 
deleted. The stock is 
homozygous on the 2nd 
chromosome
E.N. Olson
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few days until they reached their “laying peak” (usually 3-4 days). On the day of 
injection, plates were changed 3-4 times before the injection and then every 30 minutes 
during injection. Embryos from the 30 minutes lays were collected into a mesh basket 
and dechorionated in 50% sodium hypochlorite (Sigma). They were then aligned onto a 
coverslip, covered with glue (prepared by placing double side Scotch TM tape in 50- 
100ml of heptane), posterior end at the edge. Aligned embryos were dessicated for 
approximately 10 minutes, by placing them in a pot containing Silica-gel 6-16 mesh 
self-indicating (Fisher), and then covered with halocarbon oil (Voltalef, HI OS). They 
were injected using a micromanipulator connected to a pump (Narishige) and a Nikon 
microscope.
Coverslips with injected embryos were placed into a humidified chamber (apple 
juice-agar plate supplemented with fresh yeast and fixed with damp Whatman paper) at 
18°C. Embryos were allowed 48 to 50 hours to recover and hatch. Newly hatched first 
instar larvae were then collected and transferred into a vial containing fly medium 
described in section 2.3.1. Vials were placed at 25°C until Fo adults emerged.
Fo males were individually mated with three virgin females carrying balancer 
chromosomes and dominant markers in a white background (w; If/CyO; TM3, Sb/TM6, 
Hu). Fi generation was then screened for transformants by looking at the eye colour.
Fi virgins carrying CyO and TM3, Sb were crossed with Fi males carrying I f  and 
TM6, Hu. This cross produces homozygous flies and allows chromosome mapping of 
the insertion. I assumed that all Fi flies have the same insertion. Coloured-eyed F2 flies 
carrying two markers on the same chromosome were crossed together to make a stock. 
When the insertion was on the X chromosome, males transformants were individually 
crossed with flies carrying a balancer chromosome and dominant markers on the X 
chromosome (y,ct/ FM7, ftz lacZ).
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New stocks were maintained and expanded as described in section 2.3.1.
2.3.6 Generation of double UAS stocks
Table 4 lists the double UAS stocks generated.
To test genetic interactions, stocks homozygous for two different UAS constructs 
were made. Lines were generated as follow (Figure 2.4): stocks homozygous for each 
UAS construct were crossed together. Progeny flies carrying two markers (CyO and 
TM3 females and males) were selected and crossed again together. F2 males and 
females without any markers were kept as a stable stock. For all UAS flies, markers 
were first put on the chromosome that does not carries the insert. To do so, UAS flies 
were crossed with a balancer stock (w; If/CyO; TM3, Sb/TM6, Hu) and the progeny 
carrying three markers selected and crossed together.
2.3.7 Insertion of UAS-Dmesol 7A, UAS-Dmesol 7A-RNAi, Twist-GAL4 
and Dmesol 7A-GAL4 into either a Dmef265 or a gro mutant 
backgrounds.
Table 5 lists the UAS lines put into mutant backgrounds.
In order to analyse the effect o f Dmesol 7A gain-of or loss-of-function when either 
gro or Dmef2 function is reduced, UAS and GALA flies were recombined in gro or 
Dmef2 mutant backgrounds (Figure 2.5).
All UAS and GAL4 flies were first crossed with either blue or green balancer flies 
in order to facilitate subsequent crosses and to allow the identification of homozygous 
mutant embryos.
For insertion in a gro mutant background (Figure 2.5A), flies homozygous for 
either UAS or GAL4 constructs and carrying TM6, Hu/ TM3, act GFP, Ser, were
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Table 4: List of the double UAS stocks generated
Genotype
w; UAS-Dmesol 7A; UAS-Dmesol 7A-RNAi
w; UAS-Dmesol 7A; UAS-AWRPW
w; UAS-Dmesol 7A; UAS-Dmef2
w; UAS-Dmesol 7A; UAS-hHDAC5-SA
w; UAS-flag-DHDAC4-AC; UAS-Dmesol 7A
w; UAS-Dmesol 7A-RNAi; UAS-hHDAC5-SA
w; UAS-flag-DHDAC4-AC; UAS-Dmesol 7A-RNAi
w; UAS-Dmesol7A-AWRPW; UAS-hHDAC5-SA
w; UAS-flag-DHDAC4-AC; UAS-Dmesol7A-AWRPW
w; UAS-flag-DHDA C4-AC; UAS-Dmef2
O UAS TM 3 UAS
^  W 'U A S ’ TM 6 W ’  UAS
F •r i* w \
W \
UAS UAS
C y O TM 3
X
UAS UAS
$
C y O TM 3
?
F r
UAS UAS
W ;
UAS UAS
Figure 2.4: Generation of double UAS stocks.
Males and virgin females carrying dominant markers and homozygous for 
different UAS constructs were crossed together. FI males and females with 2 
markers were selected. These were crossed and F2 flies, which did not have any 
markers, were kept and expanded into a stock.
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crossed with w; If/ CyO; gro*/ TM3, act GFP, Ser flies. FI males and females with the 
following genotype: w; UAS or GAL4/ CyO; gro*/ TM3, act GFP, Ser were then 
crossed together. F2 flies w; UAS or GAL4/ UAS or GAL4; gro*/ TM3, act GFP, Ser 
were crossed together to make stable stocks.
For insertion in a Dmef2 mutant background (Figure 2.5B), flies homozygous for 
either UAS or GAL4 constructs and carrying If/ CyO, wg lacZ, were crossed with w; 
Dmefl65/  Cyo, wg lacZ; TM3, Sb/ TM6, Hu flies. FI males and females with the 
following genotype: w; Dmef265/CyO, wg lacZ; UAS or GAL4/ TM3, Sb were then 
crossed together. F2 flies w; Dmef265/CyO, wg lacZ; UAS or GAL4/ UAS or GAL4 were 
crossed together to make stable stocks.
2.3.8 Embryo collection and fixation
Embryos were collected on apple juice-agar plates supplemented with fresh yeast. 
Collections were made according to the stage at which the embryos were required and 
the temperature at which the flies were kept.
For fixation, embryos were transferred from the apple juice-agar plate to a basket 
with a wire mesh base, washed with water and placed in 50% bleach until the chorion 
membrane was removed (approximately 2 minutes). Dechorionation was monitored 
under a dissecting microscope. Dechorionated embryos were rinsed, dried and 
transferred into a 2ml tube containing heptane. They were then fixed for 20 minutes in 
heptane: 4% paraformaldehyde/PBS (1:1), and the vitelline membrane removed by 
vortexing in a mix of heptane and methanol (1/1). The embryos were then washed and 
stored in methanol at -20°C until required.
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Table 5: List of the UAS and GAL4 lines inserted into mutant 
backgrounds
Genotype
w; UAS-Dmesol 7A; groBX22/TM3, act GFP, Ser
w; twist-GAL4; groE48/TM3, act GFP, Ser
w; Dmef265/CyO, wglacZ; UAS-Dmesol 7A-RNAi
w; Dmef265/CyO, wg lacZ; Dmesol 7A-GAL4
A U A S  T M 3 ,  a c t  GFP, Servtv-,— ;-------------------  X ------; -------------------
U A S  TM6, Hun
F • 
1"
w ;
g r o U A S
x w ; — — >
g r o
CyO TM3, act GFP, Ser.
s  1  $
U A S
F2: tv; ,
g r o
U A S  T M 3 ,  a c t  G F P , S e r
B w; i f
C y O , w g
s
F •
V  D m e f 2 *tv; ; ----
U A S  D m e f 2 *  T M 6 ,  H u
  X w ;---------------; — —
C y O ,  w g  l a c Z  T M 3 ,  S b
?i
C y O ,  w g  l a c Z  T M 3 ,  S b
S
Dmef2*
X tv ;------------- ; --------
1 C y O ,  w g  l a c Z  T M 3 ,  S b$
D m e f 2 U A S
F2: tv ;----------------, ------
C y O ,  w g  l a c Z  U A S
Figure 2.5: Insertion of UAS or GAL4 transgenes into either gro or Dmef2 
mutant background.
(A) Males homozygous for a UAS construct and carrying dominant markers and a 
green balancer on the third chromosome were crossed with virgin females carrying a 
gro mutant allele over a green balancer and dominant markers on the second 
chromosome. FI males and females carrying Cyo;TM3,actGFP,Ser were selected. 
These were crossed and F2 flies carrying only TM3,actGFP,Ser were kept and 
expanded into a stock. (B) Males homozygous for a UAS construct and carrying 
dominant markers and a blue balancer on the second chromosome were crossed with 
virgin females carrying a Dmefl mutant allele over a blue balancer and dominant 
markers on the third chromosome. FI males and females carrying 
Cyo,wglacZ\ TM3,Sb were selected and crossed together. F2 flies carrying only 
CyO,wglacZ were kept and expanded into a stock. The same method was used to 
insert the different GAL4 transgenes into the mutant backgrounds.
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2.4 Cell Biology
2.4.1 RNA In Situ Hybridisation
In situ hybridisations were carried out essentially as described by Noordermer and 
Kopczynski (1997) with the use of Digoxigenin-labelled RNA probes. Fixed embryos 
were rehydrated in MeOH: 4% paraformaldehyde/PBS before fixing for a further 10 
minutes in 4% paraformaldehyde/PBS. After 3 washes in IX PBS containing 0.1% 
tween-20 (PBT), embryos were prehybridised at 55°C for 1 hour in hybridisation buffer 
(50% formamide (Fluka), 4X SSC (Sigma), IX Denhardt’s solution (Sigma), 250pg/ml 
yeast tRNA (BRL), 250pg/ml salmon testis DNA (Sigma), 50pg/ml heparin (Sigma), 
0.1% Tween-20). Embryos were then hybridised overnight at 55°C with 0.125pg of 
DIG-labelled RNA probe in 0.5ml hybridisation buffer. The next morning, embryos 
were washed with 4 changes of washing solution at 55°C (50% formamide, 2X SSC, 
0.1% tween-20) during the day, the last wash was overnight .For the detection, embryos 
were incubated for 90 minutes at room temperature with anti-DIG antibody (Roche) in 
PBT (1:2000). The stain was developed in the dark at room temperature by incubation 
in colour solution: 9pl/ml NBT and 7 p 1/ml BCIP (both Roche) in 0.3ml detection buffer 
(lOOmM Tris pH 9.5, lOOmM NaCl, 50mM MgCh, 0.1% Tween-20). Embryos were 
mounted in 80% glycerol and analysed using an image grabbing system and processing 
set up (Axiocam digital camera + Axiovision software) linked to a Zeiss Axioskop 
microscope.
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2.4.2 Immunohistochemistry
Single antibody staining was performed essentially as in Rushton et al. (1995). 
Fixed embryos were washed in IX PBS containing 0.3% Triton X-100 (PBS-TX) and 
then blocked in PBS-TX + 0.5% bovine serum albumin (BSA) (Sigma) for 30 minutes 
at room temperature. They were then incubated overnight at 4°C with primary 
antibodies diluted in PBS-TX (see table 6 for the list of antibodies used and the working 
dilutions). All the primary antibodies were preabsorbed against very young fixed OR 
embryos. Embryos were then washed with PBS-TX and incubated with a 1:200 dilution 
of biotinylated secondary antibodies (anti-mouse, anti-rabbit or anti-guinea pig, all from 
Vector Laboratories) for one hour at room temperature. The signal was amplified using 
the Vectastain Elite ABC kit (Vector Laboratories) and, for Dmesol7A, Twist, Zfhl 
stainings, the Tyramide Signal Amplification (TSA) kit (PerkinElmer) following the 
manufacturer’s instructions. The stain was then developed with 0.5mg/ml 
diaminobenzadine (DAB) (Sigma) and 0.02% hydrogen peroxide. Embryos were 
mounted either in an acetone: araldite mixture (1 :1 ratio), or in 80% glycerol. OR 
embryos were stained in each case and used as controls. Embryos were viewed on a 
Zeiss Axioskop microscope in bright field and photographed using the axiovision 
software connected to a digital camera.
2.4.3 Double antibody staining
Double antibody stainings were performed essentially as described in the previous 
section with the following modifications:
When primary antibodies were raised in different species, both were added at the 
same time and developed sequentially. After the overnight incubation, embryos were 
washed, the first secondary antibody was added and the stain developed using nickel
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Table 6: Primary antibodies used
Antibody Animal raised in Working dilution Origin
Anti-p3-tubulin Rabbit 1:1500 R. Renkawitz-Pohl
Anti-pgalactosidase Mouse 1:5000 Promega
Anti-Dmesol7A Guinea pig 1:1500 Mike Taylor 
Huw Williams
Anti-Even-skipped Rabbit 1:3000 Manfred Frasch
Anti-Fasciclin HI Mouse 1:100 Cory Goodman
Anti-Kruppel Guinea pig 1:1000 Dave Kosman
Anti-DMef2 Rabbit 1:1000 Bruce Patterson
Anti-Muscle Myosin Rabbit 1:500 Daniel Kiehart
Anti-Odd Rabbit 1:500 James Skeath
Anti-Twist Rabbit 1:5000 Siegfried Roth
Anti-Zfh-1 Mouse 1:100 Zhe-Chun Lai
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salts (which gives a black colour). Embryos were then washed and blocked with 0.5% 
BSA and incubated for one hour at room temperature with the second secondary 
antibody. This was developed without nickel salts to give a light brown precipitate.
When primary antibodies were raised in the same animal, embryos were incubated 
overnight at 4°C with the first antibody and developed using nickel salts. Embryos were 
then washed, blocked with 0.5% BSA and incubated overnight at 4°C with the second 
primary antibody. This was developed the next day without nickel salts.
Embryos were visualised and analysed as previously described.
For fluorescent double stainings, secondary antibodies conjugated with fluorescent 
dyes were used (Vector laboratories). In all cases, primary antibodies were raised in 
different animals. Embryos were incubated in the dark with the secondary antibodies at 
room temperature for 2 hours and, after washing, they were mounted in vectashield 
(Vector laboratories) fluorescent mounting media. Embryos were viewed on a Zeiss 
Axioskop microscope using appropriate filters. They were photographed using the 
axiovision software connected to a digital camera.
2.4.4 Visualisation of the Him:GFP reporter
Flies homozygous for a 4.0 Kb Him:GFP reporter construct (Rebeiz et al., 2002) 
were allowed to lay overnight. Embryos were collected into a mesh basket, 
dechorionated and rinsed thoroughly with water. They were then transferred onto a 
microscope slide, covered with halocarbon oil (Voltalef, HI OS) and overlaid with a 
coverslip. They were analysed using an appropriate filter on a Zeiss Axioskop 
microscope.
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For the observation of larvae, embryos were incubated at 25°C until hatching and 
the larvae aged up to the desired stage. GFP expressing larvae were then simply rinsed 
before being transferred onto a microscope slide and then treated as the embryos.
2.4.5 Cell death assay by Acridine Orange staining
Acridine orange staining was performed essentially as described in Sullivan, 
Ashbumer and Hawley (Drosophila Protocols, 2000). Embryos from overnight lays 
were collected into mesh baskets, dechorionated in 50% bleach and rinsed thoroughly 
with water. They were then transferred into 1.5ml microcentrifuge tubes and shaken 
vigorously for 5 minutes in 750pl of heptane plus 750pl of freshly made acridine orange 
(5 pg/ml in sodium phosphate buffer pH 7.2) in 0.1 M sodium phosphate buffer (pH 7.2). 
After all the liquid was carefully removed, the embryos were rinsed 2X with heptane 
and transferred onto microscope slides with a paint brush. They were then covered with 
halocarbon oil and overlaid with a coverslip. Stained embryos were visualised and 
analysed using an appropriate filter on a Zeiss Axioskop microscope. Photographs were 
taken using the grabbing system described previously.
2.4.6 Imaginal Wing Disc dissection and staining
Wandering third instar larvae were dissected as described in Sullivan, Ashbumer 
and Hawley (Drosophila Protocols, 2000) in cold IX PBS. Discs were fixed for 30 
minutes at room temperature in 4% paraformaldehyde/PBS with gentle shaking, 
dehydrated in an Ethanol series (30, 50, 70, 90 and 100%) and stored in 100% Ethanol 
at -20°C until required.
In situ hybridisation on the dissected discs was carried out essentially as described 
for the embryos in section 2.4.1 with the exception that Ethanol, instead of Methanol, 
was used for the rehydration of the discs.
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For the observation of GFP, dissected discs were placed on a slide in a drop of 
halocarbon oil and overlaid with a coverslip. They were then observed as described for 
the embryos and the larvae in section 2.4.4.
2.4.7 Cuticle preparation
Males homozygous for a UAS-Dmesol 7A construct were crossed with females 
homozygous for 69B-GAL4. OR flies were used as a control. Flies were allowed to lay 
eggs for 4h on apple-juice agar plate supplemented with fresh yeast. Embryos were then 
incubated until hatching and the larvae were aged up to the desired stage at 25°C. 
Larvae were then transferred into a Petri dish containing 70% glycerol and they were 
pricked with a fine tungsten needle. They were then transferred into a 1.5ml 
microcentrifuge tube containing fixative (glycerol: acetic acid [4:1]) and incubated 
overnight at 60°C. Larvae were mounted in lactic acid:H20 [3:1] and incubated 
overnight at 60°C. The edges of the coverslip were sealed with nail varnish. Larval 
cuticles were observed on a Zeiss Axioskop microscope using phase contrast and 
photographed with the grabbing system described previously.
2.4.8 Adult thorax dissection and observation
For analysis of the indirect flight muscles (IFMs) in adult flies, hemithoraces were 
prepared following a method adapted from the procedure described in Nongthomba and 
Ramachandra, 1999. Whole flies were anesthetised in ether, frozen in liquid nitrogen 
and immediately bisected longitudinally with a razor blade. Sectioned flies were then 
dehydrated through an alcohol series (50, 70, 80, 90 and 100% ethanol; 2 hours 
minimum for each step) and cleared in methyl salicylate (BDH). Heads, wings, halteres 
and abdomens were then removed and clean thoraces were mounted in DPX (BDH).
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The sections were observed and photographed with a Zeiss Axioskop microscope using 
polarised light optics and the grabbing system described previously.
2.4.9 Larval muscle scoring and analysis
Qualitative analysis of the effect on somatic musculature in the different 
experiments was performed by precise examination of the muscle pattern. Each of the 
30 muscle was analysed systematically in three abdominal hemisegments (A2 to A4) 
following specific criteria: presence/absence; shape; size; number; nuclei organisation. 
Defects in any of these characteristic for individual muscles were noted. The wild-type 
muscle pattern was used as a reference for comparison.
For each muscle and each criterion the percentage of hemisegments affected was 
calculated.
Due to the variability of phenotype observed from segment to segment and from 
embryo to embryo, a minimum of 50 embryos were analysed in each experiment.
2.4.10 Embryo selection and Larval Hatching and Survival Assay
Females homozygous for different GAL4 drivers were crossed with males 
homozygous for each UAS construct. Crosses were set up in cages where flies were 
allowed to lay eggs on apple juice-agar plates at 18°C for 4 hours or at 25°C for 2 hours. 
The plates were then further incubated at 18°C for 14 hours or at 25°C for 7 hours to 
allow the embryos to reach stage 12. Developing embryos were selected and staged by 
looking at the yolk autofluorescence using a filter. Unfertilised embryos were discarded.
Three hundred developing embryos from each cross were collected, aligned on 
new plates covered with a very thin layer of fresh yeast paste and incubated at 18°C or 
at 25°C. Newly hatched larvae (first instar larvae) were scored after 34, 82 and 130
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Figure 2.6: Larval hatching and survival assay at 18°C.
Stage 12 embryos were aligned on apple juice-agar plate supplemented with fresh yeast. 
Hatching larvae were collected and transferred on new plates after 17, 41 and 65 hours. 
The percentages of hatching from each collection were combined to obtain a total 
percentage of hatching. Larvae were then monitored for survival to 3rd instar. At each 
stage the surviving larvae were transferred on new plates. The percentage of survival to 
each larval stage was calculated. Surviving 3rd instar larvae were then transferred into 
tubes. The percentage of survival to adulthood was calculated. Wild-type embryos were 
always used as a control.
Stage 12 em bryos
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% Hatching 
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collection 2
% Hatching 
collection 1 Hatching
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hours at 18°C or after 17, 41 and 65 hours at 25°C to ensure that even the weak ones 
have had enough time to hatch. For each collection, the percentage of hatching larvae 
was calculated and reported as a percentage of hatching after collection 1, collection 2 
and collection 3. The total percentage of hatching was then calculated by addition of the 
percentages from each collection.
For each collection, newly hatched larvae were placed onto new plates 
supplemented with fresh yeast and monitored for survival to second and third instar 
stage, i.e. after 48 and 96 hours at 18°C or after 24 and 48 hours at 25°C. At each time 
point, surviving larvae were transferred onto new plates and the percentage of survival 
to each larval stage was calculated as described for the hatching. After 144 hours at 
18°C or 72 hours at 25°C, surviving 3rd instar larvae were put in tubes and allowed to 
develop until adulthood. Eclosing flies were scored and the percentage of survival to 
adulthood was calculated as described previously (Figure 2.6 shows how the hatching 
an survival assay was done at 18°C).
2.4.11 Muscle polarised Light Assay
This assay was performed as described in Drysdale et al., 1993. Briefly, one 
hundred embryos from the previous crosses (see larval hatching and survival assay) 
were put on new plates as before and allowed to hatch. Newly hatched larvae were then 
placed on a microscope slide, covered with water and overlaid with a cover slip. Water 
was then withdrawn with paper tissue until the larvae flattened leading the viscera out of 
the body and leaving the epidermis with muscles still attached to it. Unhatched embryos 
were first dechorionated and then prepared in the same way. Larvae and embryos were 
viewed in polarised light using a Zeiss Axioskop microscope. Because of their form and 
structure, muscles are highly birefringent allowing their observation under polarised
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light. By rotating the larvae or embryos with respect to the plane of polarisation, all 
muscles can be observed. Photographs were taken using the axiovision software linked 
to a digital camera.
2.4.12 Buffers
Sodium phosphate buffer pH 7.2: 68.4mM Na2HPC>4, 31.6mM NaH2PC>4
PBS 20X: 2.7M NaCl, 53.6mM KC1, 0.2M Na2HP04, ImM KH2P04
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3.1 Introduction
Much can be learned from the expression pattern of a gene. A simple, yet detailed 
analysis of its expression can provide information on the possible roles of a gene during 
a developmental process. Of course, one has to be careful extrapolating from pattern to 
function, but this information can nevertheless guide the strategy to adopt for the study 
of a gene. Thus, the first step in the analysis of Dmesol7A was to analyse its pattern of 
expression.
The second step in the investigation of the role of DmesoHA was to analyse both 
its DNA and protein sequence. This type of analysis, complementing the information 
given by the expression pattern, can provide crucial elements to refine the strategy to 
adopt. For example, it can help finding orthologs in other species and/or known 
domains of functional importance like DNA binding domains or protein/protein 
interaction motifs. The Drosophila Genome Project (BDGP) and all the bioinformatic 
tools available on line greatly facilitate this analysis. Furthermore, the available 
genomic sequences of other species and their annotations, now allow phylogenetic 
footprinting analysis of orthologous gene sequences. This approach compares sequences 
between species to identify functional regions by their evolutionary conservation and 
therefore highlights regions in genes likely to mediate biological function.
In the following sections, I will present the results I obtained for the initial analysis 
of DmesoHA. First, its expression pattern was examined using RNA in situ 
hybridisation and immunohistochemistry, and then its DNA and protein sequences were 
analysed using various bioinformatic tools.
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3.2 The expression pattern of Dmesol 7A
3.2.1 Dmesol 7A expression declines as muscle differentiation starts
In situ hybridisation revealed a very specific pattern of expression for Dmesol 7A. It 
is transiently expressed in the developing mesoderm and, as muscle differentiation starts, 
it declines and only persists in the adult muscle precursors (AMPs) and the pericardial 
cells of the heart.
DmesoHA transcripts appear at stage 9 in the developing mesoderm (Figure 3.1 A 
arrow). From stage 11, as the mesoderm becomes subdivided along the A/P and D/V 
axes (for review see Baylies et al., 1998), DmesoHA expression appears segmentally 
repeated in the somatic mesoderm compartments (figure 3.IB arrow) and, dorsally, it is 
found in the precursors of the heart (Figure 3. IB arrowhead).
During germ band retraction (stage 12) (Figure 3.1 C and D), DmesoHA expression 
is clearly restricted to the somatic mesoderm (figure 3.1C and D arrow, figure 3.2A) and 
dorsally, to the precursors of the heart (figure 3.1C arrowhead), which are now forming 
a continuous line of cells on both sides of the embryo (for reviews see Cripps and Olson, 
2002; Zafffan and Frasch, 2002). DmesoHA is also found in the precursors of the 
pharyngeal muscles (Figure 3.1C asterisk).
By the end of stage 12, as the appearance of ventral muscle precursors signals the 
onset of muscle differentiation (Bate, 1990), DmesoHA expression begins to decrease 
in the somatic mesoderm and dorsally is restricted to the heart pericardial cells. AMPs 
expressing DmesoHA becomes visible in the dorsal and lateral part of the somatic 
mesoderm (figure 3.ID arrowhead).
By stage 13, more muscle precursors are identifiable (Bate, 1990) and muscle 
differentiation markers such as Myosin Heavy Chain can be clearly detected. Dmesol 7A
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Figure 3.1: Dmesol7A expression rapidly declines as muscle differentiation 
starts.
Whole mount in situ hybridisation o f stage 10-17 wild-type embryos with a 
Dmesol 7A RNA probe. In this and all subsequent figures, embryos are shown 
as a lateral view with anterior to the left and dorsal uppermost unless stated 
otherwise. (A) Stage 10 embryo showing Dmesol 7A expression in the 
mesoderm (arrow). (B) Stage 11. DmesoHA expression becomes restricted to 
the somatic mesoderm (arrow) and the precursors of the heart (arrowhead). (C) 
Stage 12. DmesoHA expression is restricted to the somatic mesoderm (arrow), 
and the pericardial cells (PCs) (arrowhead). Expression is also detected in the 
precursors of the pharyngeal muscles (asterisk). (D) At the end of stage 12, 
DmesoHA is still expressed in the somatic mesoderm (arrow), but begins to 
decrease dorsally and become restricted to the adult muscle precursors (AMPs) 
(arrowhead). (E) Stage 13. DmesoHA has disappeared from the differentiating 
somatic mesoderm, but remains in the AMPs (arrow), the PCs (arrowhead) and 
the adepithelial cells (asterisk). (F) Stage 15. DmesoHA expression persists in 
the PCs but starts to decrease in the AMPs (arrowhead). (G) Stage 16. 
DmesoHA has almost completely disappeared from the AMPs, but remains 
expressed in the PCs and the adepithelial cells. (H) Stage 17. Persistent 
expression of DmesoHA in the PCs (arrowhead). Expression in the adepithelial 
cells begins to fade (arrow).
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has then completely disappeared from the somatic mesoderm. It only remains expressed 
in cells that are set aside from muscle differentiation: the pericardial cells (Figure 3.IE 
arrowhead, Figure 3.2B) that do not differentiate into muscle (Cripps and Olson, 2002; 
Zaffran and Frasch, 2002), and the AMPs (Figure 3.IE arrow, Figure 3.2C) that remain 
in an undifferentiated state and only proliferate and differentiate in the larva to form the 
adult muscles (Bate et al., 1991; Bate, 1993). In the thoracic segments, DmesoHA 
persists in the adepithelial cells (Figure 3.IE asterisk) that associate with the imaginal 
discs and will form adult muscles (Bate et al., 1991; Bate 1993). DmesoHA remains 
expressed in these cells until stage 15.
By the end of stage 15, DmesoHA is still expressed in the pericardial cells and the 
adepithelial cells, but it starts to disappear from the AMPs (Figure 3.IF arrowhead). By 
stage 16, it has disappeared from most of the AMPs (Figure 3.1G) and at stage 17, 
DmesoHA transcripts are only detected in the pericardial cells (Figure 3.1H arrowhead) 
and adepithelial cells (Figure 3.1H arrow). In the larvae, DmesoHA transcripts are 
found in the adepithelial cells associated with the wing imaginal discs (Figure 3.2D) 
(Rebeiz et al., 2002; Butler et al., 2003).
Thus, like twist (see Chapter 1 section 1.5.1), the disappearance of DmesoHA 
correlates with the onset of muscle differentiation and it persists in the precursors of the 
adult myoblasts. This striking pattern of expression suggests that DmesoHA plays a role 
in somatic muscle and pericardial cell development. It might function, like twist (see 
Chapter 1 section 1.5.1), to switch cells towards a myogenic fate or alternatively as an 
inhibitor of muscle development. Its rapid disappearance and its expression in the 
pericardial cells, which do not differentiate into muscle, suggest that a role of inhibitor 
of muscle development for Dmesol 7A is more probable.
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Figure 3.2: Dmesol 7A expression.
Whole mount in situ hybridisation of wild-type embryos with a DmesoHA RNA 
probe. (A) Stage 12. High magnification of DmesoHA expression in the somatic 
mesoderm at stage 12. (B and C) Stage 13. Two rows o f PCs expressing DmesoHA 
are clearly visible (B), but DmesoHA is not expressed in the somatic mesoderm 
anymore (arrow in C) and is restricted to the AMPs (arrowhead in C). (D) During 
larval life, DmesoHA persists in the adepithelial cells (arrow) associated with the 
wing imaginal discs.
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3.2.2 DmesoHA protein expression follows that of its transcript
As described above, Dmesol 7A RNA disappears very rapidly at the onset of muscle 
differentiation. Since this characteristic feature of its expression might be related to 
DmesoHA function, it was important to establish whether DmesoHA protein 
disappears at the same time.
In order to determine if DmesoHA protein followed the same dynamic of 
expression as that observed for the transcript, I used an antibody made in the laboratory. 
Laboratory members have made several attempts to produce an antibody against 
DmesoHA but, to date, I have only obtained a specific staining with one of them. 
Unfortunately, this antibody also gives a lot of non-specific background staining. Using 
higher dilutions and developing the staining for a very short time, I have been able to 
minimise the background and, as shown in Figure 3.3, the staining revealed that 
DmesoHA protein accumulates at the same time and place as the transcript.
DmesoHA protein is found in the mesoderm from stage 9-10 (Figure 3.3A arrow). 
By stage 11, it becomes restricted to the somatic mesoderm compartments (Figure 3.3B 
arrow) and dorsally, in the precursors of the heart (Figure 3.3B arrowhead). During 
stage 12, DmesoHA is restricted to the progenitors of somatic muscles (Figure 3.3C 
and D arrow) and in the pericardial cells (Figure 3.3C and D arrowhead).
At stage 13, it has disappeared from differentiating somatic mesoderm and only 
remains expressed in the AMPs (Figure 3.3E arrow), the pericardial cells (Figure 3.3E 
arrowhead) and the adepithelial cells (Figure 3.3E asterisk). Like its transcript, 
DmesoHA remains in those cells until stage 15 when it starts to disappear from dorsal 
AMPs (Figure 3.3F arrowhead).
By stage 16, DmesoHA is only found in the pericardial cells (Figure 3.3G and H 
arrows) and in the adepithelial cells (Figure 3.3H arrowhead). At this stage, staining of
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Figure 3.3: Dmesol7A protein expression follows that of its transcript.
Wild-type embryos were stained with a guinea pig anti-Dmesol7A antibody. (A) Stage 
10. Dmesol7A is expressed in the mesoderm (arrow). (B) Stage 11. Dmesol7A 
expression becomes restricted to the somatic mesoderm (arrow) and the precursors of 
the heart (arrowhead). (C and D) Stage 12. DmesoHA expression is restricted to the 
somatic mesoderm (arrows), and PCs (arrowheads). (E) Stage 13. DmesoHA has 
disappeared from the differentiating somatic mesoderm, but remains in the AMPs 
(arrow), the PCs (arrowhead) and the adepithelial cells (asterisk). (F) Stage 15. 
DmesoHA expression persists in the PCs but starts to decrease in the AMPs 
(arrowhead). (G and H) Stage 16. DmesoHA remains expressed in the PCs (arrow in 
G), and is also found in the pharyngeal muscles (arrowhead in G). DmesoHA also 
remains expressed in the adepithelial cells (arrowhead in H).
Figure 3.4: Expression of a Dmesol7A-GFP reporter construct.
(A and B) Stage 17. GFP expression is detected in the PCs. (C) During the first instar 
larval stage, GFP expression persists in the PCs. (D) In a third instar larva, GFP is found 
in the adepithelial cells associated with the wing imaginal discs.
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the pharyngeal muscles can also be observed (Figure 3.3G arrowhead). This has never 
been observed by in situ hybridisation at this stage.
At stage 17, even with a very short developing time, the background masks any 
specific staining. Nonetheless, I have been able to assess the expression of a GFP- 
reporter construct which contains 4.0 Kb of the DmesoHA enhancer region (4.0kb 
Him:GFP) and which was kindly provided by J. Posakony (Rebeiz et al., 2002). This 
construct shows GFP expression in the pericardial cells of a late stage 17 embryo 
(Figure 3.4 A and B).
Using this reporter construct, I also assessed GFP expression in larvae. GFP is 
clearly expressed in the pericardial cells (Figure 3.4C) and, as also shown by Rebeiz et 
al. (Rebeiz et al., 2002), in the adepithelial cells associated with the wing imaginal discs 
(Figure 3.4D).
DmesoHA protein expression therefore follows that of its transcript. This result is 
consistent with the hypothesis that DmesoHA might play a role in the mesoderm as an 
inhibitor of differentiation
In addition, I tested the anti-Dmesol7A antibody on Western blot (Figure 3.5). I 
used protein extracts from stage 12 embryos over-expressing Dmesol 7A (UAS- 
Dmesol 7A will be described in Chapter 4). The antibody reveals one major band 
(Figure 3.5, arrow) which has a molecular weight corresponding to that of DmesoHA 
(23 KDa). This, together with DmesoHA RNA expression, suggests that the expression 
pattern described above is that of DmesoHA.
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Figure 3.5: The anti-Dmesol7A antibody detects a 23kDa protein.
Western blot showing that the anti-Dmesol7A antibody reveals a 
major band at 23kDa which is the size o f DmesoHA. Extracts were 
from 50 stage 12 embryos, p-tubulin was assayed as a control
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3.3 Dm esol 7A sequence
3.3.1 Dmesol 7A DNA sequence
As mentioned in the Introduction, DmesoHA cDNA has been isolated in a 
subtractive hybridisation-based screen (Taylor, 2000). Using this cDNA sequence to 
perform a blast search against the Drosophila genome (NCBI BLAST at 
http://flvbase.net/blast). I have accessed the Flybase report concerning the gene 
DmesoHA (flybase annotation database at http://flvbase.net). In the database, 
DmesoHA (CGI5064) has been named Him because it is located next to the HES- 
related gene, Her (Rebeiz et al., 2002). Nevertheless, all through this dissertation I will 
continue to refer to it as DmesoHA.
DmesoHA is located on the X chromosome and its cytologic location is 17A2. It 
has a simple structure with only two exons and has a length of 1314 nt on the genomic 
sequence (Figure 3.6). The annotation predicts that DmesoHA 5’ UTR spans 103 nt 
upstream of the translation start site and that its 3’ UTR reaches 237 nt downstream of 
the stop codon. No other motifs or domains within DmesoHA sequence is shown in the 
database. Nevertheless, a personal communication to Flybase (Posakony, 2002) 
mentions that the DmesoHA 3’ UTR contains a Bearded (Brd) box (AGCTTTA) (Lai 
and Posakony, 1997) and a K box (TGTGAT) (Lai et al., 1998). These two motifs, 
when present in the 3’ UTR of genes, have been shown to confer instability to 
transcripts (Lai and Posakony, 1997; Lai et al., 1998). This mode of regulation of 
mRNA stability is consistent with the dynamic expression observed for DmesoHA 
transcript. I have also found a polyadenylation signal (Wickens and Stephenson, 1984) 
217 nt downstream of the stop codon.
Comparison of the DmesoHA DNA sequence with other Drosophila species 
genomes revealed the presence of putative orthologs in Drosophila yakuba, mojavensis,
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Figure 3.6: TheDmeso!7A genomic locus.
Dmesol7A has two exons and including its 5’ and 3’ UTRs has a 
length of 1314nt. Its 5’ UTR spans 103nt and its 3’ UTR 237nt. The 3’ 
UTR contains a Brd box (light blue) and a K box (dark blue), which 
are both implicated in RNA stability (see text), together with a 
polyadenylation signal (red).
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pseudoobscura, ananassae and virilis (Assembly/Alignment/Annotation of 12 
Drosophila Genomes at http://rana.lbl.gov/drosophila/multipleflies.htmlE Alignment of 
the sequences of these orthologs and DmesoHA using the ClustalX software (available 
at ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX/) showed a conserved region spanning 117 
nt upstream of the stop codon. This strong homology across six Drosophila species 
suggests that this 117 nt region is important for Dmesol 7A function.
3.3.2 Dmesol7A protein sequence
Analysis of DmesoHA protein sequence using the PSORT (http://psort.nibb.ac.jp/) 
and ScanProsite (http://www.expasv.org/tools/scanprosite/) programs revealed that 
DmesoHA is a putative nuclear protein and that it contains a bipartite nuclear 
localisation signal (Robbins et al., 1991) at amino acids 37 to 53 (Figure 3.7) . The 
nuclear localisation of DmesoHA is confirmed by double antibody staining showing 
that it co-localises with the transcription factor Twist in the nuclei of the AMPs and the 
adepithelial cells (Figure 3.8E and F arrowheads).
DmesoHA also possesses a WRPW motif at its C-terminus (Figure 3.7). This 
tetrapeptide motif is found in transcriptional repressors, e.g. Hairy, that interact with the 
Groucho protein (Gro) (for review see Courey and Songtao, 2001). Drosophila Gro is a 
key member of a family of co-repressors that have roles in many aspects of 
development including D/V patterning and Wg signalling (Chen and Courey, 2000). 
Therefore, the presence of this WRPW motif, together with its nuclear localisation, 
suggest that DmesoHA is a transcriptional inhibitor.
BLAST search against the genomes of other Drosophila species revealed proteins 
similar to DmesoHA in the five Drosophila species mentioned above 
(Assembly/Alignment/Annotation of 12 Drosophila Genomes at
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Figure 3.7: DmesoHA protein sequence.
The predicted Dmesol7A protein sequence is 192 amino acids in length and 
contains a bipartite nuclear localisation signal (NLS) at amino acids 37-53 
(blue) and a WRPW motif at its C-terminus (red). This tetrapeptide is found 
in transcriptional repressors that interact with the co-repressor Gro.
Twist B  Tw ist
Twist/Dmesol7A F  T w ist D m esoH A
Figure 3.8: Dmesol7A co-localises with Twist in both the thoracic and 
abdominal adult muscle precursors.
Stage 13 wild-type embryos were double stained with anti-Twist and anti- 
Dmesol7A antibodies. (A-B) Twist is expressed in the nuclei o f the abdominal 
AMPs (blue arrowheads) and the thoracic adepithelial cells (white arrows). (C-D) 
Dmesol7A is expressed in the same cells. (E-F) Merged image showing that 
DmesoHA and Twist co-localise in the nuclei o f the AMPs (blue arrowheads) and 
the adepithelial cells (white arrows).
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http://rana.lbl.gov/drosophila/multipleflies.htmn. As for its DNA sequence, alignment 
of Dmesol7A with its orthologs using ClustalX (available at ftp://ftp-igbmc.u- 
strasbg.fr/pub/ClustalXE) showed a conserved region across the six Drosophila species 
(boxed in Figure 3.9). This portion of almost perfect homology at the protein level is 
located at amino acids 154 to 192. This high degree of conservation strongly suggests 
that this segment of Dmesol7A sequence is essential for its function in the somatic 
mesoderm. It contains the WRPW motif and the MotifScan program 
(http://scansite.mit.edu) predicts a putative phosphorylation site at serinel58 (Figure 3.9 
arrowhead). However, I have not found any sequence similar to DmesoHA in other 
organisms.
3.4 Discussion
3.4.1 Dmesol7A: inhibitor or promoter of muscle differentiation?
The aim of Dr. Taylor’s screen was to isolate novel genes specifically expressed in 
the mesoderm before and during the early steps of muscle differentiation (Taylor, 2000). 
DmesoHA fulfils this aim. It is expressed early in the developing somatic mesoderm 
and it disappears from it as muscle differentiation starts. However, it remains expressed 
in the progenitors of the adult muscles and also in the pericardial cells. This specific 
pattern of expression is very similar to that of the transcription factor twist (Currie et al., 
1991; Bate and Rushton, 1993; Dunin Borkowski et al., 1995), with the exception of the 
pericardial cells, and therefore is consistent with an important role for Dmesol 7A in 
somatic myogenesis.
twist is expressed very early and specifies the mesoderm (Thisse et al., 1988; Leptin 
1991), but it disappears as muscle differentiation starts and only persists in the AMPs
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Figure 3.9: Dmesol7A sequence alignment with its orthologs in different 
Drosophila species.
Alignment o f Dmesol7A orthologs from five Drosophila species with Drosophila 
melanogaster Dmesol7A. Similar or conserved residues are coloured. A region of 
almost perfect homology is found at amino acids 154-192 (black box). This region 
contains the WRPW motif (red box) and a putative phosphorylation site at 
serine 158 (arrowhead).
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(Currie et al., 1991). Studies have shown that high levels of Twist are necessary for 
somatic muscle differentiation (Baylies and Bate, 1996; Castanon et al., 2001) whereas 
low levels of Twist can repress it (Castanon et al., 2001). This differential Twist activity 
is dependent on its dimerisation partner (Castanon et al., 2001). Moreover, it has been 
shown that Twist can act as a repressor during adult muscle differentiation (Anant et al., 
1998).
Given that DmesoHA is expressed in the same cells as twist in the somatic 
mesoderm and that it disappears at the same time, there are two possibilities for its 
action:
It could act with or like Twist, propelling cells toward a myogenic fate.
- It could act as an inhibitor of muscle development, keeping cells in an 
undifferentiated state, maybe by blocking Twist action.
DmesoHA is also expressed in the pericardial cells. These cells arise, like the 
cardioblasts, from the progenitors of the heart but, unlike the cardioblasts, they do not 
differentiate into muscle (reviewed in Cripps and Olson, 2002; and Zaffran and Frasch, 
2002). This, together with the quick disappearance of Dmesol7A from the somatic 
mesoderm, is consistent with a role of inhibitor of muscle development. Nevertheless, 
the differentiation and function of pericardial cells is poorly understood and one cannot 
rule out the possibility that the role of Dmesol7A in these cells is different than its role 
in the somatic mesoderm.
In addition to the information given by the DmesoHA pattern of expression, it is 
important to note that the antibody against DmesoHA obtained in the laboratory as well 
as the GFP reporter construct provided by the Posakony laboratory (Rebeiz et al., 2002) 
are very useful tools. Indeed, they can be used for studying both the AMPs and the 
pericardial cells for which there are very few markers available.
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3.4.2 Dmesol7A is a putative inhibitor of transcription
Sequence analysis of Dmesol7A revealed that it is a nuclear protein and, because 
of the presence of a WRPW motif, that it is a putative Groucho interactor.
Gro is the key member of a family of transcriptional co-repressors. It is a non-DNA 
binding protein and it is recruited to the DNA via protein-protein interactions with 
transcriptional repressors that possess a WRPW motif (reviewed in Gasperowicz and 
Otto, 2005). For example, Gro is recruited by Hairy to regulate neurogenesis and 
segmentation (Rushlow et al., 1989; Paroush et al., 1994). The WRPW motif present at 
the C-terminus of the Hairy protein is necessary and sufficient for the interaction with 
Gro (Paroush et al., 1994; Fisher et al., 1996).
Dmesol7A is a nuclear protein and possesses a WRPW motif at its C-terminus. It is 
therefore possible that, even though it does not possess a DNA-binding domain, 
Dmesol7A interacts with Gro maybe acting as an adaptor protein. DmesoHA might 
function as a link between Gro and DNA-binding repressors.
In addition to this, a study, based on a computational approach on the whole 
Drosophila genome, led to the identification of DmesoHA as a target of the Notch- 
regulated transcription factor Suppressor o f Hairless (Su(H)) (Rebeiz et al., 2002). They 
showed that the expression of Dmesol 1 A in the wing imaginal discs is dependent on 
Su(H) activity. Su(H) is a DNA-binding protein and is a key component of the Notch 
pathway, which is known to be crucial for cell fate decisions. Moreover, there is 
evidence indicating that Notch/Su(H) regulates twist both directly and indirectly. In the 
embryo, Notch/Su(H) directly represses twist expression and its indirect action is 
through the activation of proteins that repress Twist (Tapanes-Castillo and Baylies, 
2004). Some of these Notch/Su(H)-regulated proteins could be encoded by the genes of
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the enhancer o f split (E(spl')) complex, which includes gro (Tapanes-Castillo and 
Baylies, 2004). Tapanes-Castillo and Baylies also showed that individual genes from 
the E(spl) complex are not sufficient to repress Twist and suggest that they might work 
with another factor. Thus, these results correlate with my analysis and reinforce the idea 
that Dmesol 7A plays an important role in the mesoderm and that it might function with 
Gro to keep cells in an undifferentiated state.
Dmesol A sequence analysis also revealed the presence of a Brd box (Lai and 
Posakony, 1997) and a K box (Lai et al., 1998) in its 3’ UTR (Posakony, 2002, personal 
communication to Flybase). These motifs could provide another level of regulation for 
Dmesol 7A controlling the accumulation of its transcript. The presence of these motifs is 
not only consistent with DmesoHA dynamic pattern of expression, but it also suggests 
that there is a need for a precise regulation of Dmesol 7A transcript accumulation.
Finally, phylogenetic analysis of Dmesol7A sequence showed a strong 
conservation in five Drosophila species of a region spanning 38 amino acids including 
the WRPW motif and a putative phosphorylation site. Even though this high degree of 
conservation suggests a functional importance for this region, there are no significant 
similarities in other organisms. Nevertheless, my subsequent results (described in 
Chapter 5) indicate that DmesoHA is involved in a complex formed by highly 
conserved proteins, e.g. Gro and HDAC. This suggests that even if there is no 
significant conservation in higher organisms, DmesoHA function in muscle 
development could be conserved. Moreover, motifs such as the WRPW tetrapeptide, 
even if well characterised, are too short to give significant values in alignments. It is 
therefore possible that, even using BLAST search for short nearly exact matches 
(http://www.ncbi.nlm.nih.gov/BLASTL I have missed short motifs that are conserved.
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3.4.3 Conclusion: Dmesol7A, a novel inhibitor of myogenesis?
Taken together, the results I obtained with the analysis of Dmesol7A expression 
pattern and sequence suggests that it might be a novel inhibitor of muscle development. 
The presence of a WRPW motif in its sequence links Dmesol7A with the co-repressor 
Gro suggesting that Dmesol7A inhibits transcription during somatic myogenesis. 
Moreover, in the wing imaginal discs, Dmesol 7A is positively regulated by Notch/Su(H) 
(Rebeiz et al., 2002), which, in the embryo, might activate gro to down-regulate Twist 
(Tapanes-Castillo and Baylies, 2004). This is consistent with the hypothesis that 
Dmesol7A function with Gro and that together they can inhibit muscle development. If 
Twist promotes myogenesis by regulating mef2 expression, DmesoHA could prevent 
cells from differentiating. Analysis of DmesoHA function could therefore be highly 
informative and might provide new insights in the understanding of the mechanisms 
underlying muscle development.
The strategy I have adopted to study Dmesol 7A during my PhD is based on these 
hypotheses. As described in the next chapters, my approach to test these hypotheses has 
been to utilise both gain-of-function and loss-of-function using the GAL4/UAS system.
I first analysed the phenotype of DmesoHA gain-of and loss-of-function and then I 
investigate the link between DmesoHA and Gro. I also tested genetic interactions 
between DmesoHA and known regulators of muscle development, Dmef2 and histone 
deacetylases (HDACs).
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4.1 Introduction
The GAL4/UAS system (Brand and Perrimon, 1993; Brand et al., 1994; see 
Chapter 2 section 2.3.3) is a powerful tool for studying gene function giving researchers 
the ability to mis-express any given target gene in a spatially and temporally-controlled 
way. Over the last decade, it has become a crucial element for many studies and the list 
of applications for this system has rapidly grown (for review see Duffy, 2002). For 
instance, it provides an excellent alternative when mutant phenotypes are too severe or 
if there is no mutant available and there are many examples in the literature of genes 
whose function has been determined, at least in part, using the GAL4/UAS system. For 
example, it has been used for studying twist function in somatic myogenesis (Bate and 
Baylies, 1996). In twist mutants, no mesoderm is formed (Simpson, 1983; Leptin, 1991), 
making studies of subsequent mesodermal differentiation very hard to achieve. 
Although in this case temperature sensitive twist alleles were available and proved 
useful, the GAL4/UAS system provided an excellent complement to unravel twist 
function. Another example is Dmef2 whose regulation of expression and function have 
also been studied using this system (Taylor et al., 1995; Cripps et al., 1998, Gunthorpe 
et al., 1999).
Because there was no mutant or P-element insertion available for DmesoHA, I 
decided to use the GAL4/UAS system to study Dmesol7A function and test whether it 
can inhibit muscle differentiation. My approach was to first analyse the effect of full- 
length DmesoHA over-expression. I then achieved DmesoHA loss-of-function using 
RNAi and dominant negative approaches (these will be described in the next Chapter).
-73-
Chapter 4 : DmesoHA Gain-of-Function
Using a range of specific GAL4 drivers, I promoted Dmesol 7A expression in the 
mesoderm before and during differentiation of the mesodermal derivatives. The effects 
of Dmesol 7A mis-expression on each mesodermal derivative were then analysed. I also 
induced ectopic expression of Dmesol 7A in the ectoderm to determine whether it can 
affect the development of non-mesodermal tissues. The GAL4 drivers used and the 
results of my analysis are described in the following sections.
4.2 Dmesol7A: a novel inhibitor of myogenesis
4.2.1 The over-expression phenotype: DmesoUA over-expression 
disrupt somatic myogenesis
To over-express DmesoHA, flies homozygous for a UAS-DmesoHA construct
were crossed to stocks homozygous for specific GAL4 drivers (All the UAS-Dmesol7A 
lines tested are listed in Appendix 1). In order to test the effect of DmesoHA over­
expression on the different mesodermal derivatives and, as presented in Chapter 6, to 
test genetic interactions, I used several GAL4 drivers. Each one of them drives 
DmesoHA expression in different times and places (these drivers are described in 
section 4.2.3). As a consequence, different degrees of severity of phenotype can be 
obtained for each driver used. The severity can be further modulated by changing the 
temperature at which the crosses are kept. More severe effects can be obtained at higher 
temperature (see below and section 4.2.3). Here I present two examples of the effect of 
DmesoHA over-expression on somatic muscle development using two different GAL4 
drivers: Dmef2-GAL4 and twist/twist-GAL4. The temperature used is stated for each 
experiment.
As revealed by muscle myosin expression, over-expression of DmesoHA driven by 
Dmef2-GAL4 at 25°C leads to disruption of the somatic musculature, with considerable
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reduction of the number of myosin-expressing cells. Fusion of the remaining myoblasts 
occurs, but muscle formation and differentiation is dramatically impaired. Only a few 
incorrectly shaped muscles are able to form (Figure 4.1; compare A-B with C-D). In 
these embryos, the midgut also fails to constrict and has a swollen appearance. As 
visceral musculature is essential for the formation of these constrictions (Reuter and 
Scott, 1990), this suggests that the differentiation of the visceral muscles is impaired. 
Cardioblast differentiation is also affected in these embryos (the effect of DmesoHA 
over-expression on heart and visceral muscles development is described in sections 
4.2.5.1 and 4.2.5.4 respectively). This result, consistent with its pattern of expression, 
shows that Dmesol 7A can inhibit muscle development.
Using twist/twist-GAL4, the effect of DmesoHA over-expression at 18°C is less 
severe with relatively high number of myosin-expressing cells (Figure 4.2). In contrast 
to the phenotype induced when using Dmef2-GAL4, the visceral musculature is not 
affected as the midgut constricts normally. This difference could be explained by the 
fact that twist/twist-GAlA does not drive strong expression in the visceral mesoderm 
after stage 11 (Baylies and Bate, 1996), whereas Dmef2-GAL4 drives expression in all 
muscle lineages from stage 7 until the end of embryogenesis (Ranganayakulu and Olson, 
1996). In these embryos, two rows of cardioblasts expressing myosin were always 
present. This is probably due to the fact that twist/twist-GAL4 does not drive strong 
expression in the heart.
In order to precisely analyse the effect of DmesoHA over-expression driven by 
twist/twist-GAlA on somatic musculature, the muscle pattern was examined. Each of 
the 30 muscles was analysed systematically in three abdominal hemisegments (A2 to 
A4). Variation from embryo to embryo was observed with a range of severity. Segment 
to segment variation within the same embryos was also frequently noticed. Nevertheless,
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Figure 4.1: Dmesol7A over-expression disrupts myogenesis.
A \JAS-Dmesol7A line was crossed with Dmef2-GALA at 25° C to over­
express DmesoHA in the mesoderm. Stage 17 embryos were stained with an 
antibody against muscle Myosin. (A-B) Wild-type embryo showing the normal 
muscle pattern. (C-D) DmesoHA over-expressing embryo. Muscle 
differentiation is profoundly affected with missing (arrow) or misshapen 
(arrowhead) muscles.
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some muscles, such as DTI or VA3 for example, are affected in more than 70% of the 
embryos analysed (see Figure 4.2 right column).
Figure 4.2 shows the different severity of phenotype obtained. In 25 to 30% of the 
embryos, the phenotype is weak and the muscle pattern is almost complete, but never 
were all muscles wild-type in appearance, (Figure 4.2A). For example, DTI and the 
ventral muscles are misshapen in 40% of these embryos. A moderate phenotype is 
observed in 15-20% of the embryos with more muscles missing or misshapen (Figure 
4.2B). In this category, DTI is misshapen in 80% of the embryos and D 03, D 05 and 
LL1 are missing in more than 30% of the cases. In the most represented category (50- 
55% of the embryos), the effect on muscle differentiation is much more severe (Figure 
4.2C). DTI is misshapen in more the 90% of the embryos and more than 70% lack 
muscles like DA3, D03-5, LL1, LOl and VA3. Finally, 5-10% o f the embryos 
presented an extreme muscle phenotype with just a few myosin-expressing cells and no 
muscles formed correctly (Figure 4.2D).
This variation in the severity o f the phenotype can be attributed to the use o f the 
GAL4/UAS system (Brand et al., 1994; see section 4.2.3), but it also suggests that 
muscle differentiation is very sensitive to the DmesoHA level.
When the over-expression of DmesoHA  using twist/twist-GAL4 is performed at 
25°C instead of 18°C, similar variations are observed, but the proportion of the different 
categories of phenotype has changed (Figure 4.3). Embryos like those in Figure 4.2A 
and 4.2B represent only 5-10% and 10-15% respectively (Figure 4.3 A and B), whereas 
those from the third category, in Figure 4.2C, now represent 70 to 75% of the embryos 
(Figure 4.3C). A very dramatic effect is still observed in 5-10% of the embryos (Figure 
4.3D). The severity of the phenotype has therefore increased. Together, these results
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A 25-30%
DTI misshapen in 40% of the 
embryos. D05 missing in 
>30%.
1 or 2 VO muscles often 
missing.
g  15-20%
DTI misshapen in 80% of 
the embryos. D03, D05and 
LL1 missing in >30%. VA3 
missing in 40% of the 
embryos.
C 50-55% DTI and ventral muscles 
misshapen in 90% of the 
embryos. DA3, D03-5, LL1, 
LOl and VA3 missing in 
>70%. 8-10 ventral muscles 
present but often misshapen.
J )  5-10%
No muscle formed 
correctly
Figure 4.2: Muscle phenotype variations in Dmesol7A over-expressing 
embryos.
Dmesol 7A was over-expressed using twist/twist-GAL4 at 18°C. Stage 17 
embryos were stained with an antibody against muscle Myosin. A range of 
phenotypes is observed: (A) Weak. The muscle pattern is almost complete. (B) 
Moderate. More muscles are missing or misshapen. (C) Severe. The muscle 
pattern is considerably affected. (D) Extreme. No muscle formed correctly. The 
proportion of each category is given, together with details of the muscle pattern 
defects.
UAS-Dmesol7A X  twist/twist-GA L4 25°C
Figure 4.3: The severity of the DmesoHA over-expression 
phenotype increases with the temperature.
The muscle phenotype of embryos over-expressing DmesoHA 
using twist/twist-GAL4 was analysed at 25° C. Stage 17 embryos 
were stained with an antibody against muscle Myosin. At this 
temperature, the range of phenotypes obtained is similar to that 
described at 18° C (see Figure 4.2): weak (A), moderate (B), 
severe (C) and extreme (D). However, the proportion of embryos in 
each category has changed with a considerable increase in the 
proportion of severely affected embryos (C; compare with Figure 
4.2C).
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clearly indicate that an increase o f DmesoHA level can have a substantial effect on 
muscle differentiation.
In conclusion, over-expression of Dmesol 7A in the mesoderm results in disruption 
of somatic myogenesis and the severity o f the phenotype obtained can be influenced by 
the choice of the GAL4 driver used and the temperature at which the crosses are kept. 
As mentioned, differentiation of other mesodermal derivatives can also be affected. 
These results are consistent with the hypotheses formulated after the analysis of 
DmesoHA expression, and suggest that DmesoHA is a novel inhibitor of muscle 
development in Drosophila.
4.2.2 Quantitation of the phenotype: Hatching/ Survival and polarised 
light assays
Although it was now clear that Dmesol 7A can inhibit muscle differentiation, it was 
necessary to quantify the effect of its over-expression in order to be able to compare it 
with the phenotypes obtained by over-expression or loss-of-function of other genes, and 
ultimately to assess genetic interactions. One way in which this can be achieved, is by 
assessing the hatching efficiency, as muscles are essential for this to happen. I therefore 
scored the number of embryos able to hatch, both at 25°C and 18°C, compared to wild 
type (Figure 4.4A and B). 90% and 80% of the embryos over-expressing DmesoHA 
using twist/twist-GAL4 were able to hatch at 18°C and 25°C respectively. However, 
most of these larvae were smaller, slower and very translucent compared to wild type. I 
also observed that most of them were not able to survive until adulthood, 18% gave 
adult flies at 18°C and only 4% did at 25°C. Thus, although the remaining muscles in 
embryos over-expressing Dmesol 7A are sufficient to produce hatching movements, the 
defects lead to a substantial lethality o f the larvae. Nevertheless, because of the
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Figure 4.4: Larval Hatching and Survival.
Embryos over-expressing DmesoHA were aligned on plates and the 
frequency of hatched and surviving larvae was scored at 18°C (A) and 25°C 
(B) (see Chapter 2 section 2.4.10). At both temperatures, hatching is not 
substantially affected, but the percentage of survival to adulthood is 
considerably reduced compared to wild-type. This assay was used as a 
quantitative measure of the effect of DmesoHA over-expression on muscle 
differentiation.
In this experiment and the following hatching and survival assays, three 
groups of one hundred embryos were aligned for each genotype at either 18°C 
or 25°C. Standard deviations (S.D) were calculated in each case. Results are 
indicated as mean percentages ±  S.D.
Here, mean percentages±S.D are: (A) Wild-type, hatching=99%±0.081, 
Survival=97%+0.16; DmesoHA, Hatching=90%+0.24, Survival=18%±0.31 
(B) Wild-type, hatching=98% +  0.081, Survival=98%+0.0.82; DmesoHA, 
Hatching=80%± 0.2, Survival=4% ±  0.9.
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considerable hatching efficiency and the fact that the larvae were able to move, I wanted 
to test whether the phenotype o f the larvae correspond to that observed in the late stages 
of embryogenesis and therefore if  the lethality observed was really a consequence of 
muscle disruption.
In order to analyse the muscle phenotype of the larvae, I used a polarised light 
assay (Drysdale et al., 1993). The somatic muscles are visible under polarised light 
because of their bireffingent properties allowing the analysis of a large number of larvae 
without having to perform dissection or staining. This analysis revealed that the 
phenotype o f these larvae is comparable to that observed in embryos, with similar 
variations in severity (Figure 4.5 shows the phenotype o f one o f these larvae at 18°C). 
The unhatched embryos, analysed in the same way, correspond to the more severe 
phenotype observed. This confirms that the muscle defects do not prevent the larvae 
from hatching, but they result in a strong diminution of the survivability. Larval 
hatching is only prevented when the muscle phenotype is dramatic.
Taken together, these results show that larval hatching and survival can be used as a 
clear quantitative measure of the effect o f a gene’s over-expression on muscle 
differentiation. Given the variability o f phenotype observed, this assay has been crucial 
in my analysis of DmesoHA , in particular to assess genetic interactions.
4.2.3 GAL4 drivers used
As mentioned previously, I used several specific GAL4 drivers to induce 
DmesoHA expression in different times and places. This was to test the effect of 
DmesoHA over-expression on the different mesodermal derivatives and to test genetic 
interactions. Each GAL4 driver was chosen for where and when it drives expression 
(see Chapter 2, Table 2), and also for the strength of phenotype induced. The GAL4
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UAS-Dmesol 7A 
twist/twist-GAL4
Figure 4.5: Severe muscle defects do not prevent hatching.
The muscle pattern of DmesoHA over-expressing larvae was analysed under 
polarised light. (A) Wild-type first instar larva showing the normal pattern of 
muscles. (B) DmesoHA over-expressing larva. The muscle pattern is severely 
affected, as in Figure 4.2C, but this larva was still able to hatch. The orientation is 
the same as in wild-type.
Chapter 4 : Dmesol 7A Gain-of-Function
drivers used will be stated for each of my subsequent experiments. Here I present the 
effect of Dmesol 7A over-expression, induced at 18°C by the different Gal4 drivers that 
I used, on somatic muscle development (All UAS-Dmesol7A lines tested gave similar 
results, see Appendix 1).
Figure 4.6 shows stage 17 embryos over-expressing DmesoHA using Dmesol 7A- 
GAL4 (Figure 4.6A-B), twist/twist-GAL4 (Baylies and Bate, 1996) (Figure 4.6C to E), 
twist-GAL4 (Figure 4.6F to H), 24B-GAL4 (Brand and Perrimon, 1993) (Figure 4.61 to 
K) or Dmef2-GAL4 (Ranganayakulu et al., 1996) (Figure 4.6L). All the embryos are 
stained with an antibody against muscle myosin.
Comparison o f the phenotypes shows that, as described in section 4.2.1 for Dmef2- 
GAL4 and twist/twist-GAL4, these drivers induce different strength o f phenotype. For 
example, expression o f DmesoHA driven by Dmef2-GAL4 (Figure 4.6L) has a much 
stronger effect on somatic myogenesis than when twist-GAL4 is used (Figure 4.6F). 
These differential effects can be attributed to the fact that DmesoHA expression is 
driven in different times and places, but also that each of these drivers induces different 
levels of Dmesol 7A.
Moreover, for each driver used I obtained a range o f severity o f phenotype. This 
variation can be due to the use of the GAL4/UAS system which is known to give 
variable effects (Brand et al., 1994). Variation has also been reporter in studies 
analysing muscle pattern defects in mutant embryos (for examples see Drysdale et al., 
1993; Lai et al., 1993). Three categories (weak to very severe) are presented in Figure 
4.6, but for some drivers there could be more or less variation. For instance, embryos 
over-expressing DmesoHA using Dmesol 7A-GAL4 can only be classified into two 
categories of phenotype (Figure 4.6 A-B), and only one category of phenotype is 
obtained when Dmef2-GAL4 is used (Figure 4.6L). In contrast, as described in section
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Figure 4.6: Different GAL4 drivers induce different strength of phenotype.
Several GAL4 drivers were used to promote Dmesol 7A expression in different times 
and places at 18°C. For each driver used, stage 17 embryos were stained with an anti­
muscle Myosin antibody to assess the muscle phenotype. Each driver produces a 
range of phenotype. Three phenotypic categories are shown: weak (left column), 
severe (central column) and extreme (right column). The different drivers induce 
different strength of phenotype (graded blue arrowhead). (A-B) Dmesol 7A-GAL4. 
(C-E) twist/twist-GAL4. (F-H) twist-GAL4. (G-K) 24B-GAL4. (M) Dmef2-GAL4.
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4.2.1, the use o f twist/twist-GAL4 results in four categories of phenotype (Figure 4.2 and 
4.3). The different categories have been established on the basis o f muscle scoring 
(described in Chapter 2, section 4.9). As a general rule, in the “very severe phenotype” 
category (Figure 4.6 right column) there are very few muscle formed and in the “severe 
phenotype” category (Figure 4.6 central column) more muscles are present and in a 
better shape. In the “weak phenotype” category (Figure 4.6 left column), muscle pattern 
is close to wild-type.
In addition to this variation, it is possible to modulate the severity o f the phenotype 
induced by each driver simply by increasing or decreasing the temperature. As 
described in section 4.2.1, more severe effects are observed at higher temperature. I 
used this property of the GAL4/UAS system (Brand et al., 1994) in some of my 
experiments in order to obtain different strength o f phenotype for a given GAL4 driver.
4.2.4 Dmesol7A over-expression disrupts myogenesis during the 
differentiation phase
In the somatic muscle forming domains o f the mesoderm, the formation o f each 
muscle is initiated by the specification o f a distinctive class o f myoblast: the founder 
cell. Founders arise from the asymmetric division o f muscle progenitors and express 
genes characteristic of an individual muscle or a subset of muscles, the “identity genes” 
(reviewed in Baylies et al., 1998; Ruiz-Gomez, 1998). Neighbouring myoblasts, the 
fusion competent myoblasts (FCMs), are recruited to this pattern of expression during 
the fusion process (reviewed in Baylies et al., 1998; Taylor, 2002; Taylor, 2003). Fusion 
of founders with FCMs gives rise to small syncytia that will enlarge by further fusion 
and differentiate to form a fully functional muscle.
In embryos over-expressing Dmesol 7A using the twist/twist-GAL4 driver, 
myogenesis is disrupted with missing or misshapen muscles. This could be the
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consequence of the disruption o f founder specification, the fusion process or the 
differentiation phase. It was therefore necessary to establish which step of the muscle 
formation is affected in order to define the role of Dmesol 7A and to identify putative 
interactor(s) and/or target(s).
One way in which one can follow the first steps o f myogenesis- specification of 
founders and fusion- is to examine the expression o f founder cell markers, the “identity 
genes”. The sequence o f events, i.e. order of appearance, position within a segment and 
increase in number during fusion, for each founder is very stereotyped and easy to 
follow. To analyse the DmesoHA over-expression phenotype, I used the markers Even- 
Skipped (Eve) and Kriippel (Kr) (Figure 4.7 and 4.8). These two genes have a very 
specific pattern o f expression and are required for the acquisition of identity of the 
founders in which they are expressed (Ruiz-Gomez et al., 1997; Su et al., 1999).
At stage 12, in a wild type embryo, Eve is expressed in the founder of the dorsal 
muscle DAI (Figure 4.7A, arrowhead) and in the founders o f two pericardial cells 
(Figure 4.7A, arrows) (Frasch et al., 1987; Carmena et al, 1998; Su et al., 1999). At 
stage 13, the DAI founder has started fusing with neighbouring myoblasts. There are 
now two or three nuclei expressing Eve in the precursor o f DAI (Figure 4.7C, 
arrowheads). At stage 16, eve-expressing nuclei are organised in two “arches” facing 
each other at both extremities of DAI (Figure 4.7E, arrows). When DmesoHA  is over­
expressed using the twist/twist-GAL4 driver at 25°C, the pattern o f Eve-expressing cells 
at stages 12 and 13 is identical to that of the wild type (Figure 4.7B and D, arrowheads). 
This suggests that the precursors expressing Eve segregate normally and that the first 
fusions of the founders with FCMs are not affected. Nevertheless, at stage 16, the 
organisation of Eve-expressing nuclei is deranged (Figure 4.7F, arrows) suggesting that
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Figure 4.7: Dmesol7A  over-expression affects DAI in the late stages of 
differentiation.
Embryos were stained with an anti-Eve antibody. (A, C, E) wild-type. (B, D, F) 
Embryos over-expressing Dmesol7A using the twist/twist-Gal4 driver at 25°C. (A-B) 
Stage 12. Wild-type Eve expression pattern (A) in the DAI founder (arrowheads) and in 
two PCs founders (arrows) is unchanged in embryos over-expressing DmesoHA (B). 
(C-D) Stage 13. Wild-type Eve expression (C) in the two or three nuclei o f the DAI 
muscle precursor (arrowheads) is unaffected by Dmesol 7A over-expression (D). (E-F) 
Stage 16. Whereas DAI nuclei expressing Eve are well organised in the wild-type 
(arrows in E), they are deranged in embryos over-expressing DmesoHA (arrow in F).
Figure 4.8: DmesoHA  over-expression does not affect the early steps of 
development of K r expressing muscles.
Wild-type (A, C, E) and embryos over-expressing Dmesol 7A using twist/twist-GAL4 at 
25 °C (B, D, F) were stained with an anti-Kriippel antibody. (A-B) Stage 11. The wild- 
type Kr expression pattern (A) in four muscle progenitors (arrows) is unaffected when 
DmesoHA is over-expressed (B). (C-D) Stage 12. In the wild type (C), Kr is expressed 
in thb founders resulting from the division o f  the progenitors in which it was initially 
expressed (arrows) and also in additional founders (arrowhead). In embryos over­
expressing DmesoHA (D), this Kr pattern is unchanged. (E-F) Stage 14. The number 
and position o f  Kr expressing cells is identical in the wild-type (E) and in embryos 
over-expressing Dmesol 7A (F).
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the effect of Dmesol 7A over-expression is taking place later in the myogenic program, 
probably during the differentiation phase.
In order to test whether the segregation o f the founders and the formation of muscle 
precursors are affected in muscles other than DAI, I examined the expression of Kr. Kr 
encodes a transcriptional regulator that is initially expressed in the founders of a subset 
of body wall muscles. These founders then fuse with surrounding myoblasts to form a 
Kr-expressing muscle precursor (Gaul et al., 1987; Ruiz-Gomez et al., 1997). At stage 
11, in a wild type embryo, Kr is found in the nuclei of two muscle progenitors dorsally 
and in two ventrally (Ruiz-Gomez et al., 1997) (Figure 4.8A, arrows). At stage 12, Kr is 
detected in the founders resulting from the asymmetric division o f the progenitors in 
which it was initially expressed (Ruiz-Gomez et al., 1997) (Figure 4.8C, arrows). Its 
expression is also initiated in other founders (Figure 4.8C arrowhead). At the beginning 
of stage 14, Kr-expressing muscles (DAI, DOl, LL1, LT2-4, VL3, VA2, and V02-4) 
can be identified by their position (Ruiz-Gomez et al., 1997) (Figure 4.8E). At the end 
of stage 14 and during stage 15, Kr expression decreases and later is absent from 
differentiated muscles (Ruiz-Gomez et al., 1997). In embryos over-expressing 
Dmesol 7A using the twist/twist-GAL4 driver at 25°C (Figure 4.8B, D and F), the 
number and position of Kr expressing cells remain unchanged compared to wild-type 
(Figure 4.8, compare A, C and E with B, D and F). This confirms the result obtained by 
the analysis o f Eve expression: Dmesol 7A over-expression does not affect the early 
steps of muscle development, i.e. the specification of the founders and their subsequent 
fusion with the FCMs.
As Kr disappears from differentiating muscles, late effects o f Dmesol 7A over­
expression are difficult to monitor. Nevertheless, Eve expression at stage 16 suggests 
that the effects of Dmesol 7A over-expression occur during the differentiation phase. In
-82-
Chapter 4 : Dmesol 7A Ciam-of-Function
order to test this, I assessed the expression of DMef2 in embryos over-expressing 
Dmesol 7A using the twist/twist-GAL4 driver at 25°C (Figure 4.9). DMef2 is expressed 
in all myogenic cells of the somatic mesoderm at the onset of muscle development and 
it persists in the differentiating muscles until the end of embryogenesis (Lilly et al., 
1994; Bour et al., 1995; Taylor et al., 1995). Therefore, if  only the differentiation phase 
of myogenesis is affected, one might expect to see a normal DMef2 expression before 
then and alteration of DMef2 expression as muscles differentiate. Indeed, in embryos 
over-expressing Dmesol 7A, DMef2 expression is normal at stage 13 (Figure 4.9, 
compare A with B), but during stage 14, alterations o f DMef2 expression are observed 
in places (Figure 4.9 arrows, compare C and D). By stage 16, DMef2 expression is 
clearly disrupted (Figure 4.9, compare E and F). This result confirms that in embryos 
over-expressing Dmesol 7A, the muscle development program is disrupted during the 
differentiation phase.
Finally, because there are fewer muscles formed in embryos over-expressing 
Dmesol 7A, I wanted to test what is happening to the cells that do not differentiate into 
muscle and in particular, I wanted to assess whether they are dying. To assess cell death, 
I used acridine orange (AO) staining (Figure 4.10). At stage 13, embryos over­
expressing Dmesol 7A do not show more cell death than the wild type (Figure 4.10, 
compare A with B). At stage 14, whereas in the wild type most apoptotic cells are 
concentrated in the dorsal part of the head and the ventral midline (Figure 4 .10C) 
(Abrams et al., 1993), in embryos over-expressing Dmesol 7A using the twist/twist- 
GAL4 driver at 25°C there are numerous additional AO-positive cells (Figure 4.10D). 
By stage 16, the number of AO positive cells in embryos over-expressing Dmesol 7A 
increases and is substantially more than in the wild type (Figure 4.10, compare E with 
F). This result is consistent with an effect o f Dmesol 7A over-expression during
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Figure 4.9: Dmesol 7A over-expression disrupts myogenesis during the 
differentiation phase.
Wild-type (A, C, E) and embryos over-expressing Dmesol 7A using twist/twist-GAL4 at 
25°C (B, D, F) were stained with an anti-DMef2 antibody. (A-B) Stage 13. DMef2 
expression is identical in the wild-type (A) and in embryos over-expressing Dmesol 7A 
(B). (C-D) Stage 14. As muscles differentiate, the wild-type expression pattern o f  
DMef2 (C) is altered in places when Dmesol 7A is over-expressed (D; arrows). (E-F) 
Stage 16. Compared to wild-type (E), DMef2 expression is substantially disrupted in 
embryos over-expressing Dmesol 7A (F).
Figure 4.10: Dmesol 7A over-expression increases cell death during muscle 
differentiation.
Acridine orange (AO) staining was carried out on wild-type (A, C, E) and embryos 
over-expressing Dmesol7A using twist/twist-GAL4 at 25°C (B, D, F). (A-B) Stage 13. 
Only a few AO positive cells are detected in both wild-type (A) and embryos over­
expressing Dmesol 7A (B). (C-D) Stage 14. As muscles differentiate, cell death in the 
wild type (C) is largely in the dorsar part o f  the head and 'in the ventral midline. In 
contrast, in embryos over-expressing Dmeso 17A (D), additional apoptotic cells are 
detected laterally. (E-F) Stage 16. Whereas in the wild-type (E) there are only a few AO 
positive cells, many more are detected when Dmeso 17A is over-expressed (F).
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differentiation and suggests that the cells that do not differentiate into muscle undergo 
apoptosis.
In conclusion, disruption of somatic muscle development in embryos over­
expressing Dmesol 7A is the consequence of an effect during the differentiation phase of 
the myogenic program. Founder cells are specified normally and the first fusions occur, 
but newly formed syncytia fail to differentiate.
4.2.5 Effect of Dmesol 7A over-expression on other mesodermal 
derivatives
The results presented in the previous sections show that Dmeso 17A over-expression 
can inhibit somatic muscle differentiation. Nevertheless, other tissues or cells are 
derived from the mesoderm and it was interesting to test whether their development can 
be affected by Dmeso 17A over-expression. This is especially important for the 
pericardial cells, the AMPs and the adepithelial cells in which Dmesol 7A is normally 
expressed during embryogenesis. I used the GAL4/UAS system to drive Dmesol 7A 
expression in these cells. I also tested the effect o f Dmesol7A over-expression on 
cardioblasts and visceral mesoderm differentiation. These results are detailed in the 
following sections.
4.2.5.1 Over-expression of Dmesol 7A disrupts heart development
As described in Chapter 1, the Drosophila heart is composed of two cell types: the 
cardioblasts and the pericardial cells (for reviews see Cripps and Olson, 2002; Zaffran 
and Frasch, 2002). At the end o f embryogenesis, two rows o f cardioblasts are 
surrounded by four rows of pericardial cells at the dorsal midline of the embryo (Figure
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4.11, drawn after Ward and Skeath, 2000). The cardioblasts are contractile and express 
muscle proteins, but the role o f the pericardial cells is poorly understood.
In the heart, Dmesol 7A is only expressed in the pericardial cells and it was 
necessary to know if its over-expression could affect their differentiation. As very little 
is known about the differentiation of these cells, this could be informative. I also wanted 
to test the effect o f Dmesol 7A over-expression on the cardioblasts. Over-expression in 
the pericardial cells was achieved by using the Dmesol 7A-GAL4 driver and expression 
in the cardioblasts by using the Dmef2-GAL4 driver both at 25°C (Ranganayakulu et al., 
1996). I then used markers specific for each cell type to assess their development.
When over-expressed in the pericardial cells, Dmesol 7A disrupts aspects of their 
development (Figures 4.12D-F; 4.14B; 4.15B and D). Pericardial cells were visualised 
using anti-Zfh-1, anti-Odd or anti-Eve antibodies. Each of these markers is specific for 
subsets o f pericardial cells. Zfh-1 is expressed in most pericardial cells (Lai et al., 1991); 
Odd identifies four cells per hemisegment (Ward and Coulter, 2000; Ward and Skeath, 
2000) and Eve marks two pericardial cells per hemisegment (Frasch et al., 1987).
As revealed by Zfh-1 staining, the general organisation of the Zfh-1-expressing 
pericardial cells when Dmesol 7A is over-expressed is deranged. Arrowheads in Figure 
4.12 point at examples o f regions where the organisation of Zfh-1-expressing cells is 
different in the wild type and embryos over-expressing Dmesol 7A (compare A-C with 
D-F). Yet, as pericardial cells are loosely attached to the heart and the effect of 
Dmesol 7A over-expression is not very strong, the analysis o f the organisation of the 
pericardial cells is problematic. Therefore, in order to confirm my observations, I 
concentrated on the number of cells and counted the number of Zfh-1-expressing cells 
in both wild type and embryos over-expressing Dmesol 7A at stage 17. Figure 4.13 
shows a graphic representation of the numbers obtained. There are on average 10 more
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Figure 4.11: Structure of the Drosophila heart.
Schematic representation o f  a dorsal view o f  a mature wild-type embryonic heart 
showing the two rows o f the cardioblasts (red squares) surrounded by four rows o f  
pericardial cells (PCs) (blue, yellow and orange ovals). Only one segment is represented. 
This figure was inspired by Ward and Skeath, 2000.
Figure 4.12: Dmesol7A  over-expression disrupts the organisation of Zfh-l- 
expressing pericardial cells.
Stage 17 embryos, were stained with an anti-Zfh-1 antibody. (A-C) In the wild-type, 
Zfh-1 is expressed in a large number o f PCs. (D-F) In embryos over-expressing 
Dmeso 17A using Dmesol 7A-GAL4 at 25°C, the general organisation o f these cells is 
deranged. Arrowheads point at regions o f  the heart where the organisation o f Zfh-l- 
expressing PCs is different in the wild-type and in embryos over-expressing Dmeso 17A.
Figure 4.13: D m esol7A  over-expression increases the num ber of Zfh-l-expressing 
pericardial cells.
The number o f  Zfh-l-expressing cells was scored in both wild type and embryos over­
expressing Dmeso 17A using Dmesol7A-GAL4 at stage 17. Twenty embryos were 
analysed in each case. 80 cells on average were found in the wild-type whereas, in 
embryos over-expressing Dmeso 17A, there were 90. A paired t-test was carried out to 
test the significance o f this difference. The p value obtained (p= 1.12x10'15) with a 95% 
confidence interval shows a significant difference in Zfh-l-expressing PCs number 
between the wild-type and in embryos over-expressing Dmeso 17A. Error bars indicate 
standard deviation.
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Zfh-l-expressing cells in the heart of embryos over-expressing Dmeso 17A. A paired t- 
test confirmed the significance of this difference (see legend of Figure 4.13).
I then looked at another subset of pericardial cells that does not express Zfh-l at 
this stage: the Eve-expressing pericardial cells (Figure 4.14). It is important to note that 
Eve and Zfh-1 expression overlap in the progenitors of the pericardial cells (early stage 
11), but by stage 17 Zfh-1 expression is lost from the Eve-expressing cells (Su et al., 
1999). In stage 17 embryos over-expressing Dmesol 7A, there are defects in the 
arrangement of the Eve-expressing cells compared to the wild type (Figure 4.14 
arrowheads in A and B). However, the number of Eve-expressing cells remains 
unchanged. One possible explanation for these results taken together is that, under the 
influence of persistent Dmesol 7A over-expression, some Eve cells have retained Zfh-1 
expression during their differentiation.
Finally, I assessed the expression of Odd in embryos over-expressing Dmesol 7A 
(Figure 4.15). By stage 14 in the wild type, four pericardial cells per hemisegment 
express Odd. These Odd-expressing cells also express Zfh-1, but not Eve (Ward and 
Skeath, 2000). At this stage, in embryos over-expressing Dmesol 7A, although the 
general aspect of the Odd staining looks normal (Figure 4.15 compare A with B), cell 
counting reveals that 4.49 cells per hemisegment are now expressing Odd when 4.18 are 
in the wild type (Figure 4.16). A paired t-test confirmed that this difference is 
significant (see legend of Figure 4.16). At stage 17, these embryos show defects in the 
organisation of Odd-expressing cells (Figure 4.15 arrows, compare C and D). At this 
stage, I have also observed gaps in the Odd expression pattern in some embryos (Figure 
4.15 arrowhead in D).
In summary, Dmesol 7A over-expression in the pericardial cells results in defects in 
their organisation. Moreover, it seems that persistent Dmesol 7A over-expression can
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Figure 4.14: Dmesol7A over-expression affects the organisation of Eve-expressing 
pericardial cells.
Stage 17 embryos were stained with an anti-Eve antibody. In the wild-type (A) two Eve 
PCs are found in every hemisegment. When Dmeso 17A is over-expressed using 
Dmeso 17A-GAL4 at 25°C (B), this organisation can be deranged (arrowheads).
Figure 4.15: Dmesol7A over-expression affects the development of Odd-expressing 
pericardial cells.
Wild type (A, C) and embryos over-expressing Dmesol7A using Dmeso 17A-GAL4 at 
25°C (B, D) were stained with an anti-Odd antibody. (A-B) Stage 14. The organisation 
of Odd PCs appear identical in the wild-type (A) and in embryos over-expressing 
Dmesol 7A (B). (C-D) Stage 16. Whereas in the wild-type (C) Odd PCs are well 
organised in two rows, in embryos over-expressing Dmeso 17A (D) there are gaps 
(arrowhead) and defects in their organisation (arrow).
Figure 4.16: Dmesol7A over-expression increases the number of Odd-expressing 
pericardial cells.
The number of Odd-expressing cells per hemisegment was scored in both wild type and 
embryos over-expressing Dmeso 17A using Dmesol 7A-GAL4 at stage 14. 144 
hemisegments were analysed in each case. There was an average of 4.18 cells per 
hemisegment in the wild-type whereas, in embryos over-expressing Dmeso 17A, there 
were 4.49 cells. A paired t-test showed that this difference is significant. The p value = 
0.006 with a 95% confidence interval. Error bars indicate standard deviation.
UAS-Dmesol 7A X Dmesol 7A-GAL4
UAS-Dmesol 7A X  Dmesol 7A-GAL4
6 
5 
4 
3 
2 
1 
0
□ Wild-type ■ Dmesol7A
Odd PC per hemisegment
Chapter 4 : Dmeso 17A Gain-of-Function
increase the number of Zfh-l and Odd-expressing cells. This could be due to an increase 
of the total number of pericardial cells or to a change in Odd and Zfh-1 regulation of 
expression. For example, it is possible that Zfh-1 expression persists in the Eve cells.
Nevertheless, although these results show that Dmesol7A over-expression can 
affect the development of the pericardial cells, further investigation is needed to 
understand these effects and to determine Dmesol7A function in these cells. Moreover, 
the function and differentiation of pericardial cells is poorly understood. It is possible 
that their differentiation is not finished at the end of embryogenesis, but that it is rather 
starting. Indeed, changes in shape, size and organisation have been reported for the 
pericardial cells during larval and pupal life (Curtis et al., 1999; personal 
communication from A. Paululat). Persistent Dmesol 7A over-expression could 
therefore have more effect during larval life than it does during embryogenesis. As a 
preliminary experiment, I have over-expressed Dmeso 17A, using Dmesol 7A-GAL4, in 
the 4.0 Kb Him:GFP background (Figure 4.17). As mentioned in the previous Chapter 
(section 3.2.2), this reporter construct drives GFP expression in the pericardial cells of 
the larvae. Larvae over-expressing Dmesol 7A show defects in the organisation and 
possibly the number of their pericardial cells.
In first instar larvae, the heart of the wild type has a similar organisation as that 
seen in the embryo (Figure 4.17A). When Dmeso 17A is over-expressed, in some larvae, 
I have observed disorganisation of the pericardial cells and an apparent increase in their 
number (Figure 4.17B, compare cells in brackets in A and B).
In third instar larvae, the pericardial cells of the wild type are orderly arranged 
around the heart tube (Figure 4.17C, arrowhead). In larvae over-expressing Dmeso 17A, 
there seem to be fewer pericardial cells around the heart tube and their organisation is 
deranged (Figure 4.17D). Moreover, in these larvae, the nuclei of the pericardial cells
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Figure 4.17: Dmesol 7A over-expression affects the organisation of pericardial 
cells in the larva.
Dmeso 17A was over-expressed using Dmeso 17A-GAL4 at 25°C in a Him-GFP 
background. The expression of GFP in the PCs was monitored in larvae (B, D) and 
compared to wild-type (A, C). (A-B) In first instar larvae, the wild-type heart (A) has 
a similar organisation to that in the embryo. This organisation can be disrupted by 
Dmeso 17A over-expression (B; brackets). (C-D) In third instar larvae, whereas in the 
wild-type (C) PCs are well organised around the heart tube (arrowhead), in 
Dmeso 17A over-expressing embryos (D) they appear randomly positioned and 
smaller (arrowhead). Their number also seems to be reduced.
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look smaller than in the wild type (Figure 4.17, arrowheads). These results come from 
- simple observations, but they at least show that the effect of Dmesol 7A over-expression 
on the pericardial cells should not be only considered in the embryo, but need to be 
investigated in the larvae and maybe later during pupal development.
When expressed in the cardioblasts, Dmesol 7A disrupts their differentiation (Figure 
4.18). At stage 17, in the wild type, there are six pairs of cardioblasts per segment 
forming the dorsal vessel (Ward and Skeath, 2000). They all express DMef2 (Lilly et al., 
1994; Taylor et al., 1995) (Figure 4.18A) and myosin (Figure 4.18E), but only four pairs 
out of six express p3-tubulin (Damm et al., 1998) (Figure 4.18C). When Dmesol 7A is 
expressed in the cardioblasts (Figure 4.18B, D and F), DMef2 and p3-tubulin 
expression in these cells, at stage 17, is not affected (Figure 4.18B and D). This suggests 
that cardioblasts are specified correctly and that at least some aspects of their 
differentiation are not affected. However, myosin expression in the cardioblasts of these 
embryos is severely impaired (Figure 4.18F). This resembles the Dmef2 mutant 
phenotype (Ranganayakulu et al., 1995; Damm et al., 1998) and suggests that, even 
though the cardioblasts can form and develop to a certain extent, the presence of 
Dmeso 17A disrupts their differentiation. Moreover, this result is consistent with that 
obtained for Dmesol7A over-expression in the somatic mesoderm, i.e. Dmesol7A over­
expression can inhibit differentiation, but not specification of myoblasts.
4.2.5.2 Investigation of the effect of Dmesol 7A over-expression on 
AMPs
After mesoderm subdivision, progenitors of the somatic muscles divide 
asymmetrically to give rise to either two founder myoblasts or a founder and an AMP 
(reviewed in Baylies et al., 1998 and Taylor, 2005). Whereas the founders fuse with
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Figure 4.18: Dmesol 7A over-expression disrupts cardioblast
differentiation.
Stage 17 embryos were stained with anti-DMef2 (A-B), anti~p3-tubulin (C-D) 
or anti-Myosin (E-F) antibodies. Dmeso 17A was over-expressed using 
Dmef2-GAL4 at 25°C. (A-B) DMef2 expression in embryos over-expressing 
Dmeso 17A (B) is identical to wild-type (A). (C-D) p3-tubulin expression in 
embryos over-expressing Dmeso 17A (D) is comparable in wild-type (C). (E- 
F) Myosin expression is severely affected by Dmeso 17A over-expression (F) 
when compared to wild-type (E) (arrowheads).
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FCMs and subsequently differentiate, the AMPs are set aside and remain 
undifferentiated throughout embryogenesis. Their proliferation and subsequent 
differentiation is triggered later in development (during larval life) to make adult muscle 
(Bate, 1993; reviewed in Taylor 2005).
Dmesol 7A is specifically expressed in the AMPs and, as a putative inhibitor of 
differentiation, it could play a role in maintaining the AMPs in an undifferentiated state. 
It was therefore interesting to test the effect of Dmesol 7A over-expression in these 
precursors. Dmeso 17A over-expression was achieved by using the twist-GAL4 driver 
(described in 4.2.1) at 25°C. Twist was used as a specific marker for the AMPs (Bate et 
al., 1991).
In the wild type, AMPs are clearly identifiable as single Twist-expressing cells 
(Figure 4.19 A and B, arrowheads point at one of the most ventral AMPs). In embryos 
over-expressing Dmesol 7A, the Twist-expressing AMPs are present and in the right 
place (Figure 4.19 C and D, black arrowheads point at one of the most ventral AMP). 
Nevertheless, other Twist-expressing cells can also be detected (Figure 4.19C and D, 
blue arrowheads). In embryos where this effect is seen, these cells are located just next 
to each of the normal most ventral AMPs and seem to be slightly more internal. In some 
embryos, I have also observed these cells next to the lateral or dorsal AMPs.
This result shows that Dmesol 7A over-expression can increase the number of 
persistent Twist-expressing cells. The origin of these extra Twist-expressing cells 
remains to be determined. Nevertheless, one can speculate that they could be the result 
of the division of the AMPs or they could be founder cells that have retained Twist 
expression and remain undifferentiated.
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Figure 4.19: Dmesol 7A can increase the number of persistent Twist- 
expressing cells.
Stage 14 embryos were stained with an anti-Twist antibody. (A-B) In the 
wild-type, Twist-expressing AMPs appear as single cells (arrowhead). 
(C-D) In embryos over-expressing Dmeso 17A using twist/twist-GAL4 at 
25°C, the normal Twist-expressing AMPs are present (black arrowheads 
point at one of them), but extra Twist-expressing cells can also be 
detected (blue arrowheads).
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4.2.5.3 Dmesol 7A over-expression affects adult muscle development
In addition to the pericardial cells and the abdominal AMPs, Dmesol 7A is also 
expressed in the adepithelial cells. These cells associate with imaginal discs and form 
the adult thoracic and leg muscles (Bate et al., 1991; Broadie and Bate, 1991). 
Therefore, to test the effect of Dmeso 17A over-expression on adepithelial cell 
differentiation, I examined the formation of adult muscles in embryos over-expressing 
Dmeso 17A. In particular, I assessed the formation of the thoracic indirect flight muscles 
(IFMs) in these embryos.
I used the 1151-GAL4 driver at 25°C to drive expression in the wing imaginal disc- 
associated myoblasts (the adepithelial cells) (Roy and VijayRaghavan, 1998). As 
described in Chapter 1, section 1.4.4, these cells, during pupal metamorphosis, give rise 
to the two kind of adult thoracic muscles: the direct flight muscles (DFMs) and the 
indirect flight muscles (IFMs). IFMs are subdivided in two subclasses of muscles: the 
Dorso-Ventral Muscles (DVMs) and the Dorso-Lateral Muscles (DLMs) (Bate, 1993; 
Roy and VijayRaghavan; 1999; Taylor, 2005; see Chapter 1 section 1.4.4) (Figure 4.20). 
I analysed the effect of Dmeso 17A over-expression on both DVMs and DLMs (Figure 
4.21).
In the wild type, the DLMs comprises six muscles (Figure 4.21 A, muscles are 
marked with red asterisks) and the DVMs consist of three groups of muscles (Figure 
4.21C, red brackets). Each of these DVM groups is composed of two or three muscles. 
When Dmesol 7A is over-expressed, the development of the IFMs is impaired. The 
number of muscles present in both DLMs and DVMs is reduced with only two to three 
DLMs and two DVM groups present (Figure 4.2IB and D). Moreover, the remaining 
DLMs appear bigger than in the wild-type (Figure 4.2IB).
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Figure 4.20: The indirect flight muscles.
Schematic representation of an adult Drosophila hemithorax showing the number and 
relative position of the indirect flight muscles (IFMs). Dorso-lateral muscles (DLMs) 
are in blue and dorso-ventral muscles (DVMs) in red.
Figure 4.21: Dmesol 7A over-expression affects IFM development.
IFMs were visualised under polarised light (see chapter 2, section 2.4.8). (A) In the 
wild-type, DLMs are constituted of six muscles (red asterisks). (B) Flies over­
expressing Dmeso 17A driven by the 1151-GAL4 driver at 25 °C (B) have only two or 
three DLMs. These remaining DLMs appear bigger than in the wild-type. (C) Wild-type 
DVMs consist of three groups of two muscles (red brackets). (D) Dmeso 17A over- 
expression results in the loss of one or two of these groups.
IFMs
DLMs
DVMs
DLMs
DVMs
W ild-type UAS-Dmesol 7A X1151-GAL4
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This result shows that Dmesol 7A over-expression can disrupt the development of 
the adult muscles. This is consistent with the effect observed in the embryo and 
therefore suggests that the results I obtained for the larval somatic muscles can be 
extended to adult muscle differentiation. Nevertheless, further investigation is required 
to determine which step of the adult myogenesis if affected and see if the role of 
Dmesol 7A is the same as that suggested in larval somatic myogenesis.
4.2.5.4 Expression of Dmesol 7A in the visceral mesoderm impairs 
visceral muscle development
To test the effect of Dmesol 7A over-expression on visceral muscle development, I 
used the Bagpipe-GAL4 (Bap-GAL4) driver which drives expression in the trunk 
visceral mesoderm from stage 10 (Zafffan et al., 2001). Crosses were kept at 25°C. 
Development of visceral muscles was monitored using an antibody against Fasciclin III 
(FasIII). FasIII is an Ig-domain adhesion molecule and represents an early and specific 
marker for midgut musculature (Patel et al., 1987). At stage 11, in the wild type embryo, 
FasIII is expressed in two populations of cells in the developing midgut. The first 
population of cells are the progenitors of the circular visceral muscles, which also 
express Dumbfounded (Duf). These cells can be compared to the founder cells of the 
somatic muscles (Bate, 1993; San Martin et al., 2001; Klapper et al., 2002). The second 
population of cells in which FasIII is expressed is adjacent to these progenitors and can 
be compared to the fusion competent myoblasts of the somatic mesoderm. These cells 
express Sticks and stones (Sns) (San Martin et al., 2001). FasIII expression is much 
stronger in the progenitors of the circular visceral muscles (San Martin et al., 2001). At 
stage 12, these progenitors have divided and are orderly arranged in two rows of 
columnar cells (San Martin et al., 2001) (Figure 4.22A arrows). At this stage, in
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Figure 4.22: Dmeso 17A over-expression impairs visceral mesoderm 
development.
Wild-type (A, C) and embryos over-expressing Dmeso 17A using the bap-GAL4 
driver at 25°C (B, D), were stained with an anti-FasIII antibody. (A-B) Stage 12. 
In wild-type embryos, the progenitors of the circular visceral muscles are 
arranged in two rows of columnar cells (arrows). In embryos over-expressing 
Dmeso 17A, two rows of progenitors are also present (arrows), but their 
organisation is disturbed in the posterior part of the visceral mesoderm 
(arrowheads). (C-D) Stage 16. Compared to wild-type (C), Dmeso 17A over­
expression affects midgut constrictions (D; arrows).
Wild-tvpe UAS-Dmesol 7AXDmef2-GAL4
Myosin Myosin
*
Figure 4.23: Dmesol 7A over-expression disrupts visceral muscle 
development.
Stage 17 embryos were stained with an anti-Myosin antibody. (A) Wild-type 
embryo showing normal midgut constrictions (arrow). (B) In embryos over­
expressing Dmeso 17A using the Dmef2-GAL4 driver at 25°C, midgut 
constrictions are severely disrupted (arrow).
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arrows). At this stage, in embryos over-expressing Dmesol 7A, two rows of cells are 
visible (Figure 4.22B, arrows), but their organisation is deranged especially in the most 
posterior portion of the visceral mesoderm (Figure 4.22, arrowheads, compare A with 
B). By stage 16, embryos show abnormal constrictions of the midgut when compared to 
wild type (Figure 4.22, arrows, compare C with D).
This result is consistent with what I observed when Dmesol 7A is over-expressed 
using the Dmef2-GAL4 driver at 25°C (see section 4.2.1). In these embryos, anti myosin 
staining revealed that the midgut fails to constrict and has a swollen appearance (Figure 
4.23, arrows, compare A with B). This effect is stronger than that observed in Figure 
4.22D. This can be attributed to the fact that Dmef2-GAL4 drives strong expression in 
all muscle lineages from stage 7 until the end of embryogenesis (Ranganayakulu et al., 
1996), whereas Bap-GAL4 driven expression decreases after segregation of the trunk 
visceral mesoderm (Zaffran et al., 2001). Nevertheless, these results show that ectopic 
expression of Dmesol 7A can impair midgut constriction and, as visceral musculature is 
essential for the formation of the constrictions (Reuter and Scott, 1990), they also 
suggest that ectopic expression of Dmesol 7A can inhibit midgut muscle development.
4.2.6 The effect of Dmesol 7A over-expression is limited to the 
mesoderm
In order to test whether Dmesol 7A over-expression can affect the differentiation of 
other tissues, I ectopically-expressed it in the ectoderm. I used the 69B-GAL4 line that 
drives GAL4 expression in epidermal precursors from late stage 9 and then in the 
epidermis (Brand and Perrimon, 1993). Crosses were kept at 25°C. Cuticle preparations 
were carried out to assess the effect of ectopic Dmeso 17A expression on the epidermis 
(Figure 4.24). The final pattern of the cuticle of the Drosophila larvae depends on
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Figure 4.24: Dmeso 17A over-expression does not affect epidermal
differentiation.
Dmeso 17A was over-expressed in the ectoderm using the 69B-GAL4 driver at 
25°C. Cuticle preparations did not reveal any difference between wild-type (A-B) 
and Dmeso 17A over-expressing (C-D) larvae.
V
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epidermis (for review see Payre, 2004) and is therefore a good measure of normal 
epidermal differentiation. Ectopic Dmesol 7A expression in the ectoderm did not result 
in visible changes of the cuticular pattern of the larvae (Figure 4.24 compare A-B with 
C-D). This implies that, despite the presence of Dmesol 7A, the epidermis of these 
larvae can still secrete a normal cuticle and therefore that epidermal differentiation is 
not affected. This result shows that, although Dmesol 7A over-expression profoundly 
inhibits the differentiation of somatic muscles and other mesodermally-derived cell 
types, it does not inhibit all differentiation processes.
4.3 Discussion
4.3.1 Dmesol 7A over-expression inhibits somatic muscle differentiation
Muscle differentiation is a finely tuned process and a central issue for correct 
muscle development is the balance between influences that promote and restrain 
differentiation. A slight perturbation of this equilibrium can have dramatic 
repercussions on muscle development and functionality. Key positive regulators such as 
Mef2 (reviewed in Taylor 2005; see Chapter 1 section 1.5.2) have been extensively 
studied in both Drosophila and vertebrates, but there is little information on the role of 
specific negative regulators during normal muscle development (reviewed in Taylor, 
2005; see Chapter 1 section 1.2). Some candidates have been identified, largely in 
mammalian cell culture. For example, Histone deacetylases (HDACs), which can bind 
and regulate Mef2 activity (Lu et al., 2000; for review on HDAC function in muscle 
development see McKinsey et al., 2001; see Chapter 6, section 6.4). Identification of 
negative rgulators and analysis of their function during muscle differentiation in 
Drosophila is therefore crucial to gain new insight into the molecular events that 
regulate this process. My results indicate that Dmesol 7A could be one such molecule.
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I have shown that over-expression of Dmesol 7A can lead to a profound inhibition 
of somatic myogenesis. Muscle myosin expression revealed that maintenance of a high 
level of Dmesol 7A dramatically impairs muscle development, suggesting that 
Dmesol 7A is a novel inhibitor of myogenesis. Analysis of its function could therefore 
bring new information for a better understanding of the mechanisms underlying muscle 
differentiation.
In embryos over-expressing Dmesol 7A, there is variability in the severity of the 
phenotype. This can be attributed to the fact that the level of GAL4-mediated 
transcription can vary from cell to cell (Brand et al., 1994). Variability has also been 
noted in previous studies analysing muscle pattern defects in mutant embryos (Drysdale 
et al., 1993; Lai et al., 1993). For example, mutants for Zjh-l display a variety of pattern 
errors and range of severity (Lai et al., 1993). Moreover, it is known that different levels 
of Dmef2 can affect distinct aspects of muscle differentiation (Gunthorpe et al., 1999). 
Taken together, these results suggest that variations of Dmesol 7A level can affect 
muscle development, but also that small variations in its level of expression can affect 
different muscles in different ways.
The somatic muscle phenotype of embryos over-expressing Dmesol 7A can be 
characterised by specific criteria: shape; size; presence/absence; number, nuclei 
organisation. In my experiments, I used these criteria as a way of comparing muscle 
phenotypes and assessing genetic interactions. Furthermore, I have shown that the larval 
hatching and survival assay is a clear and quantitative measure of the effect produced by 
the over-expression. Together with the qualitative assessment mentioned above, this 
allowed me to deal with the variation of phenotype and was essential in assessing 
genetic interactions.
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The formation of the muscle pattern is a multi-step process and can be divided into 
the specification of myoblasts, their fusion with FCMs and finally the differentiation of 
the muscle precursors (for review see Baylies et al., 1998; Ruiz-Gomez, 1998). It was 
therefore necessary to establish which step of muscle development is affected by the 
increase in Dmesol 7A level. To do so, I examined the expression of specific markers in 
embryos over-expressing Dmesol7A. In these embryos, as revealed by Eve and Kr 
expression, muscle founders are specified and the first fusion events leading to the 
formation of muscle precursors are not affected. In the wild type, at the end of germ 
band shortening (stage 13), the location of these precursors containing two to three 
nuclei prefigures the future muscle pattern (Bate, 1990). At this stage in embryos over­
expressing Dmesol 7A, Eve and Kr-expressing precursors are in place and their relative 
position is identical to that seen in the wild type. Therefore, the effect of Dmesol 7A 
over-expression takes place later during the myogenic program as muscle precursors 
increase in size by further fusions and acquire their characteristics (size, shape, point of 
attachment) (Bate, 1990). Indeed, analysis of later stages of embryogenesis showed that 
the pattern of Eve-expressing cells is then deranged. This was confirmed by defects in 
the DMef2 expression pattern from stage 14 onward as muscle precursors differentiate. 
Taken together, these data suggest that the inhibition of muscle development by 
Dmesol 7A over-expression occurs during the differentiation of somatic muscle 
precursors.
In addition, I have shown that, in embryos over-expressing Dmesol 7A, there is an 
increase in cell death from stage 14 onward. As muscle precursors are specified and 
properly located in these embryos, the dying cells are likely to be FCMs that do not fuse. 
However, I have observed that the apoptotic bodies are of different size. It is possible 
that this is because they contain one or more nuclei, which could mean that muscle
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precursors that do not differentiate can undergo apoptosis, as well as FCMs can. 
Another indication that syncytial muscle precursors can die is that, at the end of 
embryogenesis, Kr expressing muscles such as LL1 are missing in a large proportion of 
the embryos even though their precursors were present earlier. Interestingly, cell death 
increase during the differentiation phase of muscle development has also been reported 
in Dmef2 mutants (Ranganayakulu et al., 1995). In these mutants, somatic myoblast are 
specified normally, but they fail to differentiate (Lilly et al., 1995; Ranganayakulu et al., 
1995). Taken together, these results confirm that, in embryos over-expressing 
Dmesol 7A, muscle differentiation is affected, and they show that the cells that do not 
differentiate undergo apoptosis. This is consistent with the results of Abrams et al., who 
have shown that during normal development, the embryo has the ability to eliminate 
cells unable to complete their differentiation program (Abrams et al., 1993).
4.3.2 Dmesol 7A over-expression can affect the development of other
mesodermal derivatives
It was now clear that Dmesol7A can inhibit somatic muscle differentiation. 
However, the expression of Dmesol 7A in the pericardial cells, the AMPs and the 
adepithelial cells suggests that it could play a role in these cells too. It was therefore 
important to test this hypothesis. It was also interesting to know what would be the 
effect of the expression of Dmesol 7A on other mesodermally-derived tissues, such as 
the cardioblasts and the visceral muscles, in which it is not normally expressed. I 
therefore induced Dmesol 7A expression using specific GAL4 drivers in each of these 
mesodermal derivatives. The analysis of the effect using specific markers revealed that 
Dmesol 7A can affect their formation.
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Pericardial cell development is disrupted by Dmesol 7A over-expression. Zfh-1, 
Eve and Odd stainings revealed that, at stage 17, the organisation of pericardial cells is 
deranged suggesting that their differentiation is affected. Cell counting was used to 
assess this effect and it showed that in these embryos the number of Zfh-1 and Odd- 
expressing cells increases compared to the wild type. The disruption of pericardial cells 
organisation can therefore be due to an increase in their number. This could be the result 
of extra divisions of the pericardial cells precursors or from changes in the fate of 
neighbouring cells (cardioblasts or dorsal muscles precursors). However, the number of 
Eve-expressing cells does not change. During wild type development, as Eve cells 
differentiate, they normally lose Zfh-1 expression (Su et al., 1999). Thus, it is possible 
that in embryos over-expressing Dmesol 7A, Zfh-1 expression is retained in the 
differentiating Eve cells and that the increase in cell number observed is due to a change 
in the expression pattern of Zfh-1 and Odd. It is apparent that further investigation is 
required to understand the effect of Dmesol 7A over-expression and to determine its 
function in the pericardial cells. Moreover, there is evidence that these cells continue 
their differentiation during larval and pupal life (Curtis et al., 1999; personal 
communication from A. Paululat). It is therefore possible that it will be necessary to 
analyse pericardial cell differentiation during larval and pupal stages too in order to 
assess any effect of Dmesol 7A. My preliminary observations are consistent with this 
possibility.
AMPs, at the end of germ band retraction, appear as single Twist-expressing cells 
at specific positions within each abdominal segment (Bate et al., 1991). In embryos 
over-expressing Dmesol 7A, some of these Twist-expressing cells appear as doublets at 
this stage. These extra cells are located internally compared to the AMPs. As AMPs are 
more external than the somatic muscles (Bate et al., 1991), one might speculate that
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these extra Twist-expressing cells are founders that did not differentiate and have 
retained Twist expression. It is also possible that they result from the division of the 
AMPs. The nature and origin of these extra cells remains to be determined, but one 
possibility is that Dmesol 7A could act to keep cells in an undifferentiated state.
AMPs normally proliferate and differentiate during larval life to produce the 
abdominal adult muscles (Bate, 1991; Bate, 1993). However, little is known about the 
mechanism that holds them in an undifferentiated state during embryogenesis. Given 
my results, one can imagine that Dmesol 7A acts to prevent the AMPs from 
differentiating. Drosophila AMPs can be compared to vertebrate satellite cells, which 
remain undifferentiated and can participate to muscle growth and regeneration 
(reviewed in Seale and Rudnicki, 2000; Taylor, 2005). Therefore, if Dmesol 7A 
functions to keep AMPs undifferentiated, analysis of its mechanism of action in these 
cells could be of great interest.
Dmesol 7A is also expressed in the adepithelial cells that give rise to the adult 
thoracic muscles. Over-expression of Dmesol7A in these cells leads to a reduction of 
the number of these muscles. This suggests that the inhibitory role of Dmesol 7A is not 
limited to embryogenesis, but it is also implicated in adult muscle formation. Adult 
muscles in Drosophila, like the larval somatic muscles, are in many respects similar to 
vertebrate skeletal muscles. Yet, Drosophila adult muscles and skeletal muscles are 
more comparable. For example, in contrast to the larval somatic muscles, the adult 
muscle precursors migrate to the muscle forming region and differentiated adult 
muscles can be constituted of multiple fibres like in vertebrates (reviewed in Taylor, 
2005; see Chapter 1 section 1.4.4). The analysis of Dmesol 7A function and mechanism 
of action in adult muscle formation could therefore be relevant to skeletal muscle 
development.
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Finally, expression of Dmesol!A in visceral muscle and cardioblasts disrupts their 
development. This is consistent with what happens in somatic muscles and suggests that 
a Dmesol7A target(s) is also present in these tissues. One common factor between the 
three muscle types is Dmef2, the key promoter of muscle differentiation (Lilly et al., 
1994; Taylor et al., 1995). The effect o f Dmesol 7A over-expression in the cardioblasts 
resembles the phenotype observed in Dmef2 mutant (Ranganayakulu et al., 1995; 
Damm et al., 1998). In these mutants, like in embryos over-expressing Dmesol 7A, 
cardioblasts express p 3-tubulin, but Myosin expression is disrupted. This suggests that 
there is a relationship between Dmesol 7A and Dmef2, and maybe that in the cardioblast 
Dmef2 is a Dmesol 7A target. Moreover, Dmesol 7A over-expression can affect all three 
muscle types (somatic, visceral and heart), and Dmef2 is required for the differentiation 
of all these muscles (Bour et al., 1995; Lilly et al., 1995; Ranganayakulu et al., 1995, 
Gunthorpe et al., 1999). One can therefore imagine that the relationship between 
Dmesol 7A and Dmef2 can be extended to the somatic and visceral muscles. I have 
explored the link between Dmesol 7A and Dmef2 in the somatic muscles. This will be 
described in Chapter 6.
4.3.3 Conclusion
Taken together, my results show that Dmesol 7A is an inhibitor of muscle 
differentiation. As discussed above, there are indications of a relationship with the key 
promoter of muscle differentiation, Dmef2. My data also suggest that Dmesol 7A could 
affect the adult muscle precursors maybe keeping them in an undifferentiated state. 
Consistent with this, I have shown that Dmesol 7A over-expression can affect the 
development of adult muscles.
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As mentioned at the beginning of this section, a detailed understanding of muscle 
differentiation requires the identification and in vivo analysis of negative regulators. My 
results show that Dmesol 7A is one such molecule. Its analysis could provide new 
insights on how muscle cell differentiation is controlled in vivo.
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5.1 Introduction
To achieve Dmesol 7A loss-of-function, I chose to use RNA interference (RNAi) 
from a splice-activated UAS hairpin vector (Reichhart et al, 2002). This method has at 
least two advantages compared to dsRNA injection. First, the transgene is stably 
inherited and second, with the use of the GAL4/UAS system, it allows cell, tissue 
and/or stage specific knock down of the gene of interest. Injection of dsRNA interferes 
with gene expression only transiently and is not stably inherited (Kennerdell and 
Carthew, 1998; Kennerdell and Carthew, 2000; Yang et al., 2000). Moreover, it can 
induce mosaic effects (Kennerdell and Carthew, 1998).
In addition to the RNAi approach, I have used a UAS line previously made in the 
laboratory that carries a form of Dmesol 7A lacking the WRPW motif. The reason for 
using this truncated form of Dmesol7A is based on the assumption that the WRPW 
motif has a functional importance for Dmesol7A and that Dmesol7A interacts with 
proteins other than Gro and/or with DNA. Over-expression of a transgene of this 
truncated form of Dmesol7A will then have a dominant negative effect on the 
endogenous protein, and therefore it will provide a mechanistically distinct way of 
knocking down Dmesol 7A function.
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5.2 Dmesol 7A loss-of-function results in aberrant muscle
differentiation
Analysis of a loss-of-function is crucial to the analysis of gene function and was 
necessary for my analysis of Dmesol7A. I used RNAi and dominant negative 
approaches to knock down Dmesol 7A function. I used similar assays for my analysis of 
the Dmesol 7A loss-of-function phenotype to those adopted for the gain-of-function. I 
tested the specificity of the effects of Dmesol 7A-RNAi and Dmeso 17A-AWRPW by 
determining whether they suppressed the inhibitory effect of Dmesol 7A gain-of- 
function on muscle differentiation. In the next sections, I will present the results I 
obtained. All UAS-Dmesol7A-RNAi and UAS-Dmesol7A-DWRPW lines tested are 
listed in Appendix 1.
5.2.1 The RNAi approach
5.2.1.1 The Dmesol7A-RNAi phenotype
As for gain-of-function, several GAL4 drivers were used to express Dmesol 7A- 
RNAi in the somatic mesoderm. Although the phenotypes obtained with the different 
GAL4 drivers were comparable, stronger effects were obtained using Dmesol 7A-GAL4 
at 25°C.
In embryos expressing Dmesol 7A-RNAi using Dmeso 17A-GAL4, the overall 
muscle pattern looks normal (Figure 5.1, compare A with C). However, a close 
observation revealed that although muscles are able to form, several of their 
characteristics are altered. Their morphology (shape and/or size), the organisation of 
their nuclei, their attachment and even their number can be affected. For example, in a 
large proportion of the embryos, the shape of the ventral oblique (VO) muscles is 
deranged (Figure 5.1, compare B with D, V04 is outlined). This result suggests that in
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Figure 5.1: Dmesol 7A -RNAi disrupts muscle development.
Dmeso 17A-RNAi was expressed using Dmeso 17A-GAL4 at 25°C. Stage 17 
embryos were stained with an anti-muscle Myosin and compared to wild-type. (A- 
B) Wild-type embryo showing the normal muscle pattern (A) and correctly shaped 
VO muscles (brackets in B). (C-D) In embryos expressing Dmeso 17A-RNAi, the 
overall muscle pattern is essentially normal (C). However, aspects o f muscle 
development are affected. For example, VO muscles can be misshapen (brackets in 
D) compared to wild type (B).
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Dmesol 7A-RNAi-expressing embryos, muscles are specified and can develop, but the 
acquisition of specific characteristics of differentiated muscle is impaired.
However, before undertaking a detailed analysis of the phenotype, it was necessary 
to assess the efficiency of Dmesol 7A-RNAi. I therefore tested whether its expression 
could induce Dmesol 7A mRNA degradation. Semi-quantitative RT-PCR revealed that 
in embryos expressing Dmeso 17A-RNAi, the level of Dmesol7A mRNA is reduced by 
half compared to the wild type (Figure 5.2, compare lanes 1 and 2). This result shows 
that Dmesol 7A-RNAi induces a knock down of Dmesol 7A.
In addition to the RT-PCR, I tested whether Dmesol 7A-RNAi could suppress the 
Dmesol 7A over-expression phenotype. The prediction was that, as Dmesol 7A-RNAi 
induces Dmeso 17A knock down, it should be able to suppress, at least partially the 
muscle differentiation inhibitory effect of Dmesol 7A over-expression. Indeed, when 
both Dmesol 7A and Dmesol 7A-RNAi transgenes are expressed using Dmesol 7A-GAL4, 
the phenotype is rescued towards wild type. Figure 5.3 shows the rescue of four muscles 
affected when Dmesol 7A is over-expressed alone using Dmesol 7A-GAL4. In more than 
50% of the embryos over-expressing Dmesol 7A, muscles DTI and D03 appear 
misshapen compared to the wild type (Figure 5.3, arrows, compare A with B). When 
both transgenes are expressed, these muscles appear wild type (Figure 5.3, arrows, 
compare A, B and C). Other muscles are misshapen in a large (>40%) proportion of 
embryos over-expressing Dmeso 17A. These include VA1 and VA2 which appear 
elongated (Figure 5.3, arrows, compare D with E). The expression of Dmesol?A-RNAi 
together with Dmesol 7A rescues these muscles (Figure 5.3, arrows, compare D, E and 
F).
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Figure 5.2: Dmesol 7A-RNAi reduces the level of Dmesol 7A RNA.
Semi-quantitative RT-PCR was carried out to assess the efficiency of Dmeso 17A-RNAi. 
The level of Dmesol7A RNA in embryos expressing Dmeso 17A-RNAi using 
Dmeso 17A-GAL4 at 25°C (Lane 2) is reduced by half compared to wild-type (Lane 1). 
rp49 was used as a control. Quantification of the bands was performed using the Gene 
tool software (Syngene).
Figure 5.3: Dmesol7A-RNAi can suppress the effects of Dmesol7A over-expression.
Dmesol7A was over-expressed either alone or together with Dmeso 17A-RNAi using 
Dmeso 17A-GAL4 at 25°C. Stage 17 embryos were stained with an anti-muscle Myosin 
antibody and the muscle phenotypes were analysed and compared to wild-type. The 
muscles described are outlined and labelled in each picture. (A-C) Rescue of muscles 
DTI and D03 by Dmeso 17A-RNAi. (A) Wild-type DTI and D03. (B) In embryos over- 
expressing Dmeso 17A, these two muscles are clearly misshapen. (C) Expression of 
Dmeso 17A-RNAi can suppress the effect of Dm esol7A and rescues DTI and D03 
towards wild-type. (D-F) Rescue of muscles VA1 and VA2. (D) In the wild-type, VA1 
and VA2 have a very characteristic kinked shape. (E) Over-expression of Dmeso 17A 
disrupts the shape of these muscles. They now are straighter and elongated. (F) In 
embryos expressing both Dmesol7A and Dmeso 17A-RNAi, VA1 and VA2 are rescued 
towards wild-type.
Dmesol 7A + 
Dmesol 7A-RNAi
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Taken together, these results show that Dmesol 7A-RNAi can induce a partial loss- 
of-function and that this reduction of Dmesol 7A level of activity is sufficient to alter 
muscle differentiation.
As shown in Figure 5.4, in depth analysis of the Dmeso 17A-RNAi phenotype adds 
some details to these observations:
- In more than 50% of the embryos, there were defects of the shape of muscles. For 
example, the LT muscles are frequently affected and in particular LT4 (Figure 5.4, 
dotted outline, compare A with B). VO muscles are also often misshapen (Figure 5.ID, 
V04 is outlined). Muscles such as DAI, DA3, D04-5 or VA1-2 are misshapen only in 
a few embryos.
- The same proportion of embryos (>50%) have defects in the organisation of the 
nuclei within muscles. This effect was observed for all the muscles, but it is most 
frequent in the dorsal muscles (DO 1-2, DA 1-3) and the ventral muscles (V04-6, VA1- 
3). Figure 5.4D shows nuclear disorganisation in muscle V04 (compare C with D, 
nuclei are outlined). It is worthy of note that nuclear disorganisation is sometimes 
observed in muscles that are normal in appearance.
- In 30% of the embryos, the size of some muscles is increased compared to the wild 
type. I found this for muscles such as D04 (Figure 5.4, compare E with F, D04 is 
outlined), DA3, and V04. Occasionally, DOl-2, DAI-2 and VA1-2 also appear bigger.
- In a smaller proportion of embryos (20%), some muscles are attached incorrectly. In 
most of these cases, DA3 is incorrectly attached (Figure 5.4, arrowheads, compare G 
with H), but DAI or DOl can also be affected.
- Finally, about 10% of the embryos have duplications of muscles. In all the embryos I 
analysed, I only observed this effect for VA3 (Figure 5.4, arrowheads, compare I with J) 
and DO 1-2.
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Figure 5.4: Dmesol 7A  loss-of-function results in aberrant muscle differentiation.
The muscle phenotype of stage 17 embryos expressing Dmeso 17A-RNAi using 
Dmesol 7A-GAL4 at 25°C (B, D, F, H, J) was analysed in detail and compared to wild- 
type (A, C, E, G, I). Anti-Myosin staining revealed defects in muscle shape (A-B), in 
the distribution of nuclei within a muscle (C-D), in muscle size (E-F), attachment (G-H) 
and number (I-J). (A-B) In embryos expressing Dmeso 17A-RNAi (B) the shape of 
muscles such as LT4 (dotted outlines in A and B) can be altered compared to wild-type 
(A). (C-D) The organisation of the nuclei within muscles such as V04 is often deranged 
when Dmeso 17A-RNAi is expressed (compare C and D; nuclei in V04 are outlined). 
(E-F) Dmeso 17A-RNAi expression can also result in an increase in muscle size. For 
example, D04 (dotted outlines in E and F) appear bigger than in wild-type. (G-H) 
Muscles such as DA3 can be incorrectly attached in Dmeso 17A-RNAi expressing 
embryos. Arrowheads show the attachment points of DA3 in the wild-type (G) and in 
Dmeso 17A-RNAi expressing embryos (H). (I-J) In a small proportion of embryos 
expressing Dmeso 17A-RNAi, there is duplication of muscles such as VA3 (arrowheads 
in J  and I).
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Taken together, these results show that expression of Dmesol7A-RNAi can affect 
muscle differentiation. The range of effects observed suggests that Dmesol 7A is not 
implicated only in one particular aspect of muscle differentiation, but rather is involved 
in a more general way in the regulation of the process.
5.2.1.2 The effect of Dmesol7A-RNAi occurs during muscle 
differentiation
As described earlier, I have shown that Dmeso 17A over-expression disrupts 
myogenesis during the differentiation phase. Given the Dmesol 7A-RNAi phenotype 
and given that Dmesol 7A RNAi induces knock down of Dmesol 7A function, it was 
likely that only the differentiation phase was affected in embryos over-expressing 
Dmeso 17A-RNAi. Yet, this needed to be confirmed. I therefore tested which step of 
myogenesis was affected using the same assays as described for Dmesol 7A gain-of- 
function.
In embryos expressing Dmeso 17A-RNAi using Dmesol 7A-GAL4, the number and 
position of Kr and Eve-expressing founders is unchanged compared to wild type (Figure 
5.5, compare A with B and C with D). This suggests that the first steps of the myogenic 
program are not affected. Moreover, in these embryos, defects in DMef2 expression are 
only detected during the muscle differentiation phase (Figure 5.6). At stage 13, DMef2 
expression in embryos expressing Dmesol 7A-RNAi is identical to that of the wild type 
(Figure 5.6, compare A with B). Later, as revealed by MHC/DMef2 double staining, 
defects such as disorganisation of DMef2-expressing nuclei within a muscle can be 
observed (Figure 5.6C-F). These results suggest that Dmesol7A knock down does not 
affect the early stages of muscle development, but rather affects muscle differentiation. 
This is consistent with my results on Dmesol 7A over-expression.
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Figure 5.5: Dmesol!’A-RNAi expression does not affect the early steps of muscle 
development.
Wild-type and embryos over-expressing Dmeso 17A-RNAi using Dmesol7A-GAL4 at 
25°C were stained with anti-Kriippel (A-B) or anti-Eve (C-D) antibodies. (A-B) Stage 
14. The number and position of Kr expressing cells is identical in the wild-type (A) and 
in embryos over-expressing Dmeso 17A-RNAi (B). (C-D) Stage 12. Wild-type Eve 
expression pattern (C) in the DAI founder (arrowheads) and in two PCs founders 
(arrows) is unchanged in embryos over-expressing Dmeso 17A-RNAi (D).
Figure 5.6: The effect of Dmeso 17'A-RNAi occurs during muscle differentiation.
Wild-type and embryos over-expressing Dmeso 17A-RNAi using Dmeso 17A-GAL4 at 
25°C were either stained with an anti-DMef2 antibody (A-B) or double stained with 
anti-Myosin and anti-DMef2 antibodies (C-F). (A-B) Stage 13. DMef2 expression is 
comparable in the wild-type (A) and in embryos over-expressing Dmeso 17A-RNAi (B). 
(C-F) Stage 17. The overall DMef2 expression pattern looks essentially normal in 
embryos expressing Dmeso 17A-RNAi (compare C and D). However, there are defects 
such as the disorganisation of DMef2-expressing nuclei in the V04 muscle (arrowheads 
in E and F).
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Figure 5.7: Dmesol?A-RNAi expression increases cell death during 
muscle differentiation.
Acridine orange (AO) staining was carried out on wild-type (A, C, E) and 
embryos over-expressing Dmeso 17A-RNAi using Dmesol 7A-GAL4 at 25°C 
(B, D, F). (A-B) Stage 13. Only a few AO positive cells are detected in 
both wild-type (A) and embryos over-expressing Dmeso 17A-RNAi (B). (C- 
D) Stage 14. As muscles differentiate, cell death in the wild type (C) is 
largely in the dorsal part o f the head and in the ventral midline. In embryos 
over-expressing Dmeso 17A-RNAi (D), some additional apoptotic cells are 
detected laterally. (E-F) Stage 16. Whereas in the wild-type (E) there are 
only a few AO positive cells, more are detected when Dmesol 7A-RNAi is 
expressed (F).
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Although no muscles were missing in embryos expressing Dmeso 17A-RNAi, 
acridine orange staining revealed an increase in apoptosis as muscle differentiate. 
Figure 5.7 shows increased cell death in these embryos at stage 14 and 16. One 
possibility for this result is that some FCMs do not fuse and undergo apoptosis. 
However, I have not found a significant reduction in the number of muscle nuclei in 
embryos expressing Dmesol 7A RNAi, and the reasons for this increase in apoptosis 
remain unclear.
5.2.1.3 The effect of Dmeso 17A-RNAi expression on other mesodermal 
derivatives
Given the mechanism of RNAi (reviewed in Agrawal et al., 2003) and my results, 
Dmesol 7A-RNAi can only be effective in the cells were Dmesol 7A is normally 
expressed. Therefore, expressing Dmeso 17A-RNAi might have an effect on pericardial 
cells, the AMPs and the adepithelial cells, but no effect on visceral muscle and 
cardioblasts development should be expected. I tested the effect of Dmesol 7A-RNAi 
expression on the development of these tissues or cells. The strategy was identical to 
that adopted for the gain-of-function analysis.
I first tested the effect of Dmesol?A-RNAi on the cells where Dmesol7A 
expression is detected, i.e. the pericardial cells, the AMPs and the adepithelial cells. In 
embryos expressing Dmesol 7A-RNAi using Dmesol 7A-GAL4 at 25°C, cell counting 
did not reveal any significant difference in the number of Odd-expressing cells, at stage 
14, and Zfh-1-expressing cells, at stage 17, when compared to the wild type (Figure 
5.9A and B). This was confirmed by a paired t-test (see legend of Figure 5.9). 
Nevertheless, pericardial cells organisation is somewhat deranged and occasionally 
there are gaps in markers expression (Zfh-l, Eve and Odd) (Figure 5.8 arrowheads,
- 106-
Chapter 5: Dmeso 17A Loss-of-Function
Figure 5.8: Dmeso 17A-RNAi expression affects pericardial cells development.
Stage 17 embryos, wild-type or expressing Dmeso 17A-RNAi using Dmeso 17A-GAL4 at 
25°C, were stained with anti-Zfh-1 (A-B), anti-Eve (C-D) or anti-Odd (E-F) antibodies. 
(A-B) Compared to wild-type (A), the pattern of Zfh-1-expressing PCs in embryos 
expressing Dmeso 17A-RNAi is disrupted (B). Gaps are occasionally observed 
(arrowheads). (C-D) Compared to wild-type (C), the pattern of Eve-expressing PCs can 
also be disrupted when Dmeso 17A-RNAi is expressed (arrowhead in D). (E-F) whereas 
in the wild-type (E) Odd PCs are well organised in two rows, in embryos over- 
expressing Dmeso 17A-RNAi (F) there are gaps (arrowhead) and defects in their general 
organisation.
Figure 5.9: Dmesol 7A-RNAi expression does not affect pericardial cells number.
(A) The number of Odd-expressing cells per hemisegment was scored in both wild type 
and embryos over-expressing Dmeso 17A-RNAi at stage 14. 144 hemisegments were 
analysed in each case. There was an average of 4.18 and 4.22 cells per hemisegment in 
the wild-type and in embryos over-expressing Dmeso 17A-RNAi respectively. A paired t- 
test showed that there is no significant difference between these numbers. The p value = 
0.37 with a 95% confidence interval. (B) The number of Zfh-1 -expressing cells was also 
scored in both wild type and embryos over-expressing Dmeso 17A-RNAi at stage 17. 
Twenty embryos were analysed in each case. 80 and 83 cells on average were found in 
the wild-type and in embryos over-expressing Dmeso 17A-RNAi respectively. A paired t- 
test was carried out to test the significance of this difference. The p value obtained (p= 
0.054) with a 95% confidence interval shows that the difference in Zfh-1 -expressing 
PCs number between the wild-type and in embryos over-expressing Dmeso 17A is not 
significant. Error bars indicate standard deviation.
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compare A, C and E with B, D and F). This suggests that even though the effect is not 
very strong, Dmesol 7A-RNAi expression can affect pericardial cells development. In 
contrast, as shown in Figure 5.10, Twist staining did not reveal any effect on the AMPs 
(compare A-B with C-D). These results taken together suggest that Dmesol 7A-RNAi 
expression can have an effect in cells, other than somatic myoblasts, where Dmesol 7A 
is normally expressed. The weakness of the effect on the pericardial cells or the absence 
of phenotype for the AMPs suggests that the level of Dmesol 7A required for the proper 
development of these cells is lower than in somatic muscles.
I then assessed the development of IFMs in flies expressing Dmesol 7A-RNAi using 
the 1151-GAL4 driver at 25°C. In these flies both the DLMs and the DVMs are formed 
correctly (Figure 5.11, compare A with B and C with D). This result, as mentioned 
above, suggests that the level of Dmesol 7A required for the development of these 
muscles is lower than for the larval somatic muscles.
Finally, I analysed the effect of Dmesol 7A-RNAi expression on the visceral 
muscles and the cardioblasts. As revealed by FasIII and Myosin expression, visceral 
muscles develop normally in embryos expressing Dmesol 7A-RNAi at 25°C using bap- 
GAL4 or Dmef2-GAL4. Visceral myoblasts are well organised and midgut constrictions 
occur as in the wild type (Figure 5.12, compare A, C with B, D; Figure 5.13, compare A 
with B). Cardioblast development is also not affected either in these embryos. Two 
rows of cardioblasts expressing DMef2, p3-tubulin or myosin are always present in the 
dorsal midline of the embryo as in the wild type (Figure 5.14, compare A, C and E with 
B, D and F). These results confirm that, as expected, Dmesol 7A-RNAi has no effect in 
tissues or cells where Dmesol 7A is not normally expressed.
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Figure 5.10: Dmesol7A-RNAi expression does not affect the number of persistent 
Twist-expressing cells.
Stage 14 embryos were stained with an anti-Twist antibody. Twist expression in the 
AMPs is identical in the wild-type (A-B) and in embryos expressing Dmesol7A-RNAi 
using Dmesol 7A-GAL4 at 25°C (C-D).
Figure 5.11: Dmesol7A-RNAi expression does not affect the development of IFMs.
IFMs were visualised under polarised light (see chapter 2, section 2.4.8). DLMs and 
DVMs appear identical in both the wild-type (A, C) and Embryos expressing 
Dmesol 7A-RNAi using the 1151-GAL4 driver at 25°C (B, D).
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Figure 5.12: Dmesol7A-RNAi expression does not affect visceral mesoderm 
development.
Wild-type (A, C) and embryos over-expressing Dmeso 17A-RNAi using the bap-GAL4 
driver at 25 °C (B, D), were stained with an anti-FasIII antibody. Expression of 
Dmeso 17A-RNAi using bap-GAL4 affects neither the organisation of the circular 
visceral muscle progenitors nor the midgut constrictions (compare A with B, and C 
with D).
Figure 5.13: Dmesol 7A-RNAi expression does not affect visceral muscle 
development.
Stage 17 embryos were stained with an anti-Myosin antibody. In embryos over­
expressing Dmeso 17A-RNAi using the Dmef2-GAL4 driver at 25°C (B), midgut 
constrictions occur as in the wild-type (A).
Figure 5.14: Dmesol 7A-RNAi expression does not affect cardioblast differentiation.
Stage 17 embryos were stained with anti-DMef2 (A-B), anti-(33-tubulin (C-D) or anti- 
Myosin (E-F) antibodies. Expression of these three markers in the cardioblasts of 
embryos expressing Dmesol 7A-RNAi using Dmef2-GAL4 at 25°C (B, D, F) is 
comparable to that of the wild-type (A, C, E).
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5.2.2 The dominant-negative approach: Dmesol 7A-AWRPW
5.2.2.1 The Dmesol 7A-AWRPWphenotype
Dmesol7A-AWRPWwas expressed using the twist/twist-GAL4 driver at 25°C. The 
phenotype revealed by myosin staining is very similar to that of Dmeso 17A-RNAi. 
There are defects in muscle shape, attachment and number (Figure 5.15 and 5.18)
As for Dmeso 17A-RNAi, in embryos expressing Dmeso 17A-AWRPW the main 
features of muscle differentiation have occurred as in the wild type (Figure 5.15, 
compare A with C). However, close analysis reveals, for example, misshapen muscles 
such as DA3 (Figure 5.15, compare B with D, DA3 is outlined). This indicates that, like 
Dmeso 17A-RNAi, Dmesol7A-AWRPW expression results in aberrant muscle 
differentiation.
In order to test that these effects on muscle differentiation are due to a dominant 
negative effect and not a residual activity of Dmesol 7A, I over expressed both 
Dmesol7A-AWRPW and Dmesol7A transgenes together using twist/twist-GAL4. This 
was done at 18°C. Figure 5.16 shows that Dmesol7A-AWRPW can rescue the 
phenotype towards wild type. Comparison with Dmesol7A over-expression using 
twist/twist-GAL4 revealed that 55-60% of the embryos now have a phenotype close to 
wild-type when only 25-30% did with Dmesol 7A alone (Figure 5.16, compare A with 
D). Moreover, only 15-20% of the embryos expressing both transgenes present a very 
severe phenotype when more than 50% did with Dmesol 7A alone (Figure 5.16, 
compare C with F). The proportion of embryos with a moderate phenotype does not 
significantly change (Figure 5.16, compare B with E). These results show that, even 
though a variety of phenotype is still observed, Dmesol7A-AWRPW can suppress the 
inhibitory effect of Dmeso 17A and therefore that it acts as a dominant negative.
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Figure 5.16: Dmesol 7A-AWRPW acts as a “dominant negative”.
Dmeso 17A and Dmesol7A-AWRPW were over-expressed together using twist/twist- 
GAL4 at 18°C. (A-C) Variation of phenotype in Dmeso 17A over-expressing embryos 
(categories are the same as in Figure 4.2). (D-F) Dmesol7A-AWRPW rescues the 
phenotype towards wild-type. The proportion of weak (D) and moderate (E) phenotypes 
has substantially increased, whereas the number of severely affected embryos (F) is 
considerably reduced (compare with A, B and C respectively). This demonstrates a 
“dominant negative” effect.
Figure 5.17: Dmesol7A-AWRPW suppresses the lethality induced by Dmesol7A 
over-expression.
Larval hatching and survival assay was carried out as in Figure 4.4. The percentage of 
hatching of larvae over-expressing both Dmeso 17A and Dmeso 17A-AWRPW does not 
change substantially compared to that obtained with Dmeso 17A alone. However, the 
survival is considerably increased. Mean percentages ± S.D are: Dmeso 17A, 
Hatching=90% ±  0.24, Survivals 8% +  0.31; Dmesol 7A+Dmesol7A-AWRPW, 
Hatching=95%± 0.21, Survival=66%+0.43.
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Figure 5.15: Dmesol7A-AWRPWexpression disrupts muscle development.
Dmeso 17A-AWRPWwas over-expressed using twist/twist-GAL4 at 25°C. Stage 17 
embryos were stained with an anti-muscle Myosin and compared to wild-type. (A- 
B) Wild-type embryo showing the normal muscle pattern (A) and correctly 
shaped DA3 muscle (dotted outline in B). (C-D) In embryos expressing 
Dmeso 17A-AWRPW, the overall muscle pattern is essentially normal (C). 
However, aspects o f muscle development are affected. For example, DA3 can be 
misshapen (dotted outline in D) compared to wild type (B).
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Because of this variety of phenotype, it was necessary to quantitate this rescue. I 
therefore used the larval hatching and survival assay (described in Chapter 4 section 
4.2.2). 95% of the embryos expressing both Dmesol 7A and Dmesol 7A-AWRPW were 
able to hatch. 90% were able to do so with Dmesol 7A alone. Most importantly, 66% of 
the larvae expressing both Dmesol 7A and Dmeso 17A-AWRPW survived until adulthood, 
when only 18% survived with Dmesol 7A over-expressed alone (Figure 5.17). These 
results clearly show that Dmesol7A-AWRPW rescues the lethality induced by 
Dmeso 17A over-expression and confirm its “dominant negative” effect. The muscle 
defects observed are therefore probably due to a reduction of Dmesol 7A activity.
As for Dmeso 17A-RNAi, detailed analysis of the Dmeso 17A-AWRPW phenotype 
revealed a range of defects (Figure 5.18):
- In more than 40% of the embryos, some muscles are misshapen. These include the 
LT muscles (Figure 5.18, compare outlined LT4 in A and B), but also DA3 (Figure 5.15 
compare B with D), D03-4 or V04-6.
- Muscle attachment is affected in 20% of the embryos. In most of these cases, DAI is 
wrongly attached (Figure 5.18, arrowheads, compare C with D). This effect is also seen 
on DA3 and DOl.
- Finally, duplication of VA3 (Figure 5.18, arrowheads, compare E with F) or DOl-2 
occurs in a very small proportion (<5%) of the embryos.
- There was also abnormal distribution of the nuclei and increase muscle size, but 
these effects are less apparent than in embryos expressing Dmeso 17A-RNAi.
Taken together, these results are consistent with the phenotype obtained with 
Dmeso 17A-RNAi. The muscle defects in embryos expressing Dmesol 7A-AWRPW, due 
to a reduction of Dmesol 7A activity, are similar to those observed with Dmesol 7A- 
RNAi, where the level of Dmesol 7A is reduced. This suggests that level and activity of
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Figure 5.18: Dmeso 17A-AWRPW  expression results in aberrant muscle 
differentiation.
The muscle phenotype o f stage 17 embryos expressing Dmeso 17A-AWRPW using 
twist/twist-GAL4 at 25°C was analysed in detail and compared to wild-type. Anti- 
Myosin staining revealed defects in muscle shape (A-B), attachment (C-D), number 
(E-F). (A-B) In embryos expressing Dmeso 17A-AWRPW  (B) the shape o f muscles 
such as LT4 (dotted outlines in A and B) can be altered compared to wild-type (A). 
(C-D) Muscles such as DAI can be incorrectly attached in Dmeso 17A-AWRPW- 
expressing embryos. Arrowheads show the attachment points o f DAI in the wild- 
type (C) and in Dmesol 7A-DWRPW  expressing embryos (D). (E-F) In a small 
proportion o f embryos expressing Dmeso 17A-AWRPW, there is duplication o f 
muscles such as VA3 (arrowheads in E and F).
Chapter 5: Dmesol 7A Loss-of-Function
Dmeso 17A are correlated. Moreover, as without its WRPW motif Dmeso 17A can no 
longer inhibit muscle differentiation, these results suggests that this motif is required for 
Dmeso 17A action.
5.2.2.2 The effect of Dmesol7A-AWRPW effects are during muscle 
differentiation
As described for Dmeso 17A-RNAi, I tested whether Dmeso 17A-AWRPW expression 
affected muscle development during the differentiation phase. The results I obtained 
were identical.
The number and position of Kr and Eve-expressing founder cells is unchanged in 
embryos expressing Dmeso 17A-AWRPW using twist/twist-GAL4 at 25°C (Figure 5.19, 
compare A with B and C with D). Moreover, DMef2 expression is normal at stage 13 
(Figure 5.20, compare A with B), but is altered at stage 17 (Figure 5.20, compare C,E 
with E,F). MHC/DMef2 double staining revealed defects such as disorganisation of 
DMef2-expressing nuclei (Figure 5.20, compare E with F). These results show are 
consistent with an effect during the differentiation phase.
In addition, like for Dmesol 7A-RNAi, acridine orange staining revealed an increase 
in apoptosis as muscles differentiate (Figure 5.21). Again, I did not find a significant 
reduction in the number of muscle nuclei in embryos expressing Dmeso 17A-AWRPW, 
the reason for this increase in cell death is unclear.
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Figure 5.19: Dmeso 17A-AWRPW  expression does not affect the early steps of 
muscle development.
Wild-type and embryos over-expressing Dmeso 17A-AWRPW using twist/twist-GAL4 at 
25°C were stained with anti-Kriippel (A-B) or anti-Eve (C-D) antibodies. (A-B) Stage 
14. The number and position of Kr expressing cells is identical in the wild-type (A) and 
in embryos over-expressing Dmeso 17A-AWRPW (B). (C-D) Stage 12. Wild-type Eve 
expression pattern (C) in the DAI founder (arrowheads) and in two PCs founders 
(arrows) is unchanged in embryos over-expressing Dmeso 17A-AWRPW(D).
Figure 5.20: The effect of Dmesol 7A-AWRPW  occurs during muscle differentiation.
Wild-type and embryos over-expressing Dmeso 17A-AWRPW using twist/twist-GAL4 at 
25°C were either stained with an anti-DMef2 antibody (A-B) or double stained with 
anti-Myosin and anti-DMef2 antibodies (C-F). (A-B) Stage 13. DMef2 expression is 
identical in the wild-type (A) and in embryos over-expressing Dmeso 17A-AWRPW (B). 
(C-F) Stage 17. The overall DMef2 expression pattern looks essentially normal in 
embryos expressing Dmeso 17A-AWRPW (compare C and D). However, there are 
defects such as the disorganisation of DMef2-expressing nuclei in the V04 muscle 
(arrowheads in E and F).
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Figure 5.21: Dmeso 17A-AWRPW  expression increases cell death 
during muscle differentiation.
Acridine orange (AO) staining was carried out on wild-type (A, C, E) and 
embryos over-expressing Dmeso 17A-AWRPW  using twist/twist-GAL4 at 
25°C (B, D, F). (A-B) Stage 13. Only a few AO positive cells are detected 
in both wild-type (A) and embryos over-expressing Dmeso 17A-AWRPW
(B). (C-D) Stage 14. As muscles differentiate, cell death in the wild type
(C) is largely in the dorsal part o f the head and in the ventral midline. In 
embryos over-expressing Dmeso 17A-AWRPW  (D), some additional 
apoptotic cells are detected laterally. (E-F) Stage 16. Whereas in the wild- 
type (E) there are only a few AO positive cells, more are detected when 
Dmeso 17A-AWRPW  is expressed (F).
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5.2.2.3 The effect of Dmesol 7A-AWRPW expression on other 
mesodermal derivatives
Like for Dmeso 17A-RNAi, Dmeso 17A-AWRPW should only be effective in cells 
normally expressing Dmeso 17A. I therefore tested the effect of Dmeso 17A-AWRPW on 
the pericardial cells and the AMPs, which both express Dmeso 17A. Nevertheless, I also 
investigated the effect on visceral musculature and on the cardioblasts. The assays I 
used are identical to those employed for Dmeso 17A-RNAi.
In embryos expressing Dmeso 17A-AWRPW using Dmesol 7A-GAL4 at 25°C, 
pericardial cell marker expression (Zfh-1, Eve and Odd) did not reveal any defects 
(Figure 5.22, compare A, C and E with B, D and F). Moreover, cell counting did not 
reveal any significant difference in the number of Odd and Zfh-1-expressing pericardial 
cells when compared to the wild type (Figure 5.23A and B). This was confirmed by a 
paired t-test (see legend of Figure 5.23). In addition, Twist staining on embryos 
expressing Dmesol7A-DWRPW using twist/twist-GAL4 at 25°C did not show any 
difference in AMP number or position when compared to the wild type (Figure 5.24, 
compare A-B with C-D). Taken together these results suggest that the dominant 
negative effect is not strong enough to reduce Dmesol 7A activity to a level where it 
would have an effect. Embryos expressing Dmeso 17A-AWRPW at 25°C using bap- 
GAL4 or Dmef2-GAL4 display normal visceral musculature and cardioblast 
development. Visceral muscle precursors are present and organised as in the wild type 
(Figure 5.25, compare A with B). Midgut constrictions also are normal (Figure 5.25, 
compare C with D; Figure 5.26, compare A with B). Cardioblast development is not 
affected either in these embryos. DMef2, p3-tubulin or myosin expression are not affect 
and always show two rows of cardioblasts (Figure 5.27, compare A, C and E with B, D
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Figure 5.22: Dmeso 17A-AWRPW expression does not affect pericardial cell 
development.
Stage 17 embryos, wild-type or expressing Dmeso 17A-AWRPW using Dmesol 7A-GAL4 
at 25°C, were stained with anti-Zfh-1 (A-B), anti-Eve (C-D) or anti-Odd (E-F) 
antibodies. The pattern of the cells expressing these markers in the wild type (A, C, E) 
and in Dmesol7A-AWRPW-&vprQssmg embryos (B, D, F) are comparable.
Figure 5.23: Dmesol 7A-AWRPW expression does not affect pericardial cell number.
(A) The number of Odd-expressing cells per hemisegment was scored in both wild type 
and embryos over-expressing Dmeso 17A-AWRPW at stage 14. 144 hemisegments were 
analysed in each case. Almost the same average number of cells per hemisegment (4.18 
and 4.17) was found in the wild-type and in embryos over-expressing Dmesol 7A- 
AWRPW. A paired t-test confirmed that there is no significant difference. The p value = 
0.94 with a 95% confidence interval. (B) The number of Zfh-1 -expressing cells was also 
scored in both wild type and embryos over-expressing Dmeso 17A-AWRPW at stage 17. 
twenty embryos were analysed in each case. Again almost the same average number of 
cells (80 and 79) was found in the wild-type and in embryos over-expressing 
Dmeso 17A-AWRPW. A paired t-test was carried out to and confirmed that there is no 
difference. The p value= 0.6 with a 95% confidence interval. Error bars indicate 
standard deviation.
Figure 5.24: Dmesol7A-AWRPW expression does not affect the number of 
persistent Twist-expressing cells.
Stage 14 embryos were stained with an anti-Twist antibody. Twist expression in the 
AMPs is identical in the wild-type (A-B) and in embryos expressing Dmeso 17A- 
AWRPWusing twist/twist-GAL4 at 25°C (C-D).
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Figure 5.25: Dmeso 17A-AWRPW expression does not affect visceral mesoderm 
development.
Wild-type (A, C) and embryos over-expressing Dmeso 17A-RNAi using the bap-GAL4 
driver at 25°C (B, D), were stained with an anti-FasIII antibody. Expression of 
Dmeso 17A-AWRPW using bap-GAL4 affects neither the organisation of the circular 
visceral muscle progenitors nor the midgut constrictions (compare A with B, and C 
with D).
Figure 5.26: Dmeso 17A-AWRPW expression does not affect visceral muscle 
development.
Stage 17 embryos were stained with an anti-Myosin antibody. In embryos over­
expressing Dmeso 17A-AWRPW using the Dmef2-GAL4 driver (B), midgut constrictions 
occur as in the wild-type (A).
Figure 5.27: Dmeso 17A-AWRPW expression does not affect cardioblasts 
differentiation.
Stage 17 embryos were stained with anti-DMef2 (A-B), anti-p3-tubulin (C-D) or anti- 
Myosin (E-F) antibodies. Expression of these three markers in the cardioblasts of 
Dmeso 17A-AWRPW-QxprQssmg embryos using Dmef2-GAL4 at 25°C (B, D, F) is 
comparable to that of the wild-type (A, C, E).
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and F). These results confirm that, as expected, Dmeso 17A-AWRPW is not effective in 
tissues or cells where Dmeso 17A is not normally expressed.
5.2.3 Dmesol 7A-RNAi vs Dmesol 7A-AWRPW: different mechanisms of 
action but same effect
As described in the previous sections, my results show that Dmesol 7A-RNAi and 
Dmeso 17A-AWRPW provide two mechanistically different ways of knocking down 
Dmesol 7A function: Dmeso 17A-RNAi induces degradation of Dmesol 7A mRNA and 
therefore reduces Dmesol7A level, whereas Dmeso 17A-AWRPW has a dominant 
negative effect, which reduces Dmesol 7A activity. Strikingly, the detailed analysis of 
the phenotype induced by either of these transgenes showed that differentiation of the 
same muscles is affected in the same way. Figure 5.28 shows examples of similarities. 
In embryos expressing either Dmeso 17A-RNAi or Dmeso 17A-AWRPW, attachment of 
muscles can be affected. In particular, DA3 is often wrongly attached and is now 
parallel to D02 (Figure 5.28, arrowheads, compare A, B and C). Similar effects were 
observed for DAI. The shape of muscles can also be affected in these embryos. For 
example, in both cases, LT4 can have a similar kinked shape (Figure 5.28, LT4 is 
outlined in D, E and F). V04 or D04-5 can also be misshapen in a similar way. Finally, 
duplication of the same muscles has been observed when either Dmeso 17A-RNAi or 
Dmeso 17A-AWRPW is expressed. This can affect VA3 (Figure 5.28 arrowheads, 
compare G, H and I) and DO 1-2.
In conclusion, these two complete different approaches to knock down Dmesol 7A 
function have exactly the same effect on muscle differentiation. This indicates that the 
phenotype observed is due to a Dmeso 17A loss-of-function and therefore that normal 
level or activity of Dmeso 17A is required for correct muscle development.
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Figure 5.28: Dmesol 7A-RNAi and Dmeso 17A-AWRPW  induce the same effects.
The muscle phenotypes o f embryos expressing Dmeso 17A-RNAi using Dmesol7A- 
GAL4 or Dmeso 17A-AWRPW  using twist/twist-GAL4 (both at 25°C) were compared. 
Examples are given showing that the same muscles are affected in the same way. (A-C) 
Not only is DA3 is incorrectly attached in embryos expressing either Dmeso 17A-RNAi
(B) or Dmeso 17A-AWRPW  (C) (compare with wild-type in A), but the attachment 
points are similar (arrowheads in B and C). (D-F) Compared to wild-type (D), LT4 
has a similar kinked shape when either Dmesol 7A-RNAi (E) or Dmeso 17A-AWRPW (F) 
is expressed. (G-I) The same muscles are duplicated in embryos expressing 
Dmesol7A-RNAi or D m esol7A-DWRPW. VA3 is given as an example (arrowheads; 
compare G, H and I).
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5.3 Discussion
5.3.1 Dmesol7A loss-of-function results in aberrant somatic muscle 
differentiation
To achieve Dmesol 7A loss-of-function, I have used both RNAi {Dmeso 17A-RNAi) 
and a truncated form of Dmeso 17A, which behaves as a dominant negative {Dmesol 7A- 
AWRPW). Expression of either Dmesol 7A-RNAi or Dmeso 17A-AWRPW results in 
aberrant somatic muscle development with defects in size, shape, attachment and 
number of the muscles. Although RNAi and dominant negative effect are two 
mechanistically different approaches, they have the same effects on muscle 
development. These similarities and the fact that they both suppress the inhibitory effect 
of Dmesol7A suggest that the phenotype observed is specifically due to Dmesol7A 
loss-of-function. Moreover, Kr, Eve and DMef2 stainings revealed that these effects 
occur during the differentiation of muscle precursors. This is consistent with my results 
on the over-expression of Dmesol 7A.
As shown previously, Dmesol 7A is an inhibitor of muscle differentiation. 
Nevertheless, it is not obvious to know what would happen when an inhibitor function 
is removed. There are few examples in the literature. One of these is the phenotype of 
zfh-1 mutant embryos. Zfh-1 is a transcriptional repressor that may inhibit Dmefl 
expression (Postigo et al., 1999). In embryos lacking zfh-1 function, the muscle pattern 
revealed a variety of errors with misshapen, mispositionned or missing muscles. A 
range of severity was also reported (Lai et al., 1993). This analysis of Zfh-1 mutant 
phenotype was rather general and no detailed description was given. Nevertheless, it 
gives indications on the possible effects of the loss of an inhibitor of muscle 
differentiation and one can imagine different scenarios. Muscles might differentiate 
earlier than they normally do, leading to abnormal differentiation. Myoblasts might
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differentiate at the right time, but produce an excessive amount of muscle specific 
proteins such as myosin or actin for example. This would lead to abnormal 
differentiation, for example muscles misshapen and/or incorrectly attached. Finally, 
founder cells might fuse with more FCMs than they normally do, and this excessive 
fusion could lead to the formation of bigger muscles. In embryos expressing 
Dmesol!A-RNAi or Dmeso 17A-AWRPW, I found that muscle shape, size and 
attachment can be affected. This is consistent with a role of inhibitor of muscle 
differentiation for Dmeso 17A.
I also tested the effect of Dmeso 17A-RNAi or Dmeso 17A-AWRPW on other 
mesodermal derivatives. Given that these approaches directly target Dmeso 17A 
expression or activity, an effect was only expected where Dmesol 7A is expressed. As 
anticipated, none of the tissues where Dmesol 7A is not normally expressed was affected. 
However, among the cells normally expressing Dmesol 7A, only the pericardial cells, 
when Dmesol 7A-RNAi is expressed, showed defects in their organisation. 
Differentiation of the AMPs and the adepithelial cells was not affected. These results 
suggest that the level of Dmesol 7A required for their development is lower than in 
somatic muscles. A stronger loss-of-function of Dmesol 7A would therefore be 
necessary.
5.3.2 Conclusion
I have shown that Dmeso 17A-RNAi and Dmeso 17A-AWRPW can specifically 
knock-down Dmesol 7A function. The reduction in Dmesol 7A level or activity disrupts 
the differentiation of the muscles and the muscle defects observed are consistent with 
what one might expect from the loss-of-function of an inhibitor of differentiation.
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Together these results suggest that the inhibitory function of Dmesol 7A is required for 
proper muscle development.
Finally, I have shown that Dmeso 17A-RNAi and Dmeso 17A-AWRPW represent two 
useful tools to test genetic interactions between Dmesol 7A and putative interactor(s) or 
target(s) such as Dmef2.
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6.1 Introduction
My data presented in Chapters 4 and 5 show that Dmeso 17A is an inhibitor of 
muscle differentiation. The next step was to find interactor(s) and/or target(s) that could 
be used to dissect its mechanism of action. I therefore aimed to identify candidate genes 
that could interact with Dmesol 7A, and then tested whether they did.
6.2 Dmesol 7A and Dmef2
Being the key regulator of muscle differentiation, Dmef2 should be part of the study 
of an inhibitor of differentiation such as Dmeso 17A. Moreover, my results presented in 
Chapter 4 suggest that there might be a relationship between Dmesol 7A and Dmef2. A 
clear indication of a possible link is that over-expression of Dmesol 7A in the 
cardioblasts produces a phenotype very similar to that observed in Dmef2 mutant 
embryos (Ranganayakulu et al., 1995; Damm et al., 1998). I therefore started my 
analysis of Dmesol 7A mechanism of action by testing whether, it interacts with Dmef2.
Two approaches were taken to explore whether there are links between Dmesol 7A 
and Dmef2. First, I carried out a detailed comparison of the phenotypes of embryos 
over-expressing Dmesol 7A with that of Dmef2 hypomorphic mutants. Second, I tested 
whether there is an in vivo genetic interaction between Dmesol 7A and Dmef2. Details of 
these two approaches and the results obtained are described in the sections below.
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6.2.1 Dmesol7A over-expression phenocopies Dmef2 hypomorphic 
alleles.
In Dmef2 null mutants, there is an almost complete lack of myosin expressing cells 
within the somatic mesoderm (Bour et al., 1995; Lilly et al., 1995; Ranganayakulu et al., 
1995; Gunthorpe et al., 1999). Any detailed phenotypic comparison is therefore 
impossible. However, three Dmef2 hypomorphic alleles have been described 
(Ranganayakulu et al., 1995; Gunthorpe et al, 1999). They can be placed in an allelic 
series based on their somatic muscle phenotype. In the strongest allele (Dmef2113), there 
is an almost complete lack of correctly formed muscle, in the intermediate (Dmef2424) 
more muscles are formed, although not all are properly shaped, and in the weakest allele 
(Dmef265), only some muscles are missing. The differential effects of these alleles 
mimic in many instances the variations I observed when I over-expressed Dmesol7A. I 
therefore decided to carry a detailed comparison between the phenotypes of these three 
alleles and that induced by the over-expression of Dmesol 7A driven by the 24B-GAL4 
driver. The use of this driver seemed to be the most reasonable choice as it had already 
been used in several studies of Dmef2, including that of Gunthorpe et al. In this study, 
this driver was used to over-express a UAS-Dmef2 transgene at different temperatures, 
to induce different levels of Dmef2, in order to rescue different aspects of the Dmef2 
null mutant phenotype (Gunthorpe et al, 1999).
I also used this property of the GAL4/UAS system that different severity of 
phenotype can be obtained at different temperatures, with greater effect seen at higher 
temperatures (Brand et al., 1994) (see Chapter 4, section 4.2.3). This was done in order 
to obtain a similar range of severity by over-expressing Dmesol 7A as that observed in 
the different Dmef2 alleles. For this reason, I raised the embryos over-expressing
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Dmesol 7A at either 18°C, 21°C or 25°C. Figure 6.1 shows some of the striking 
similarities observed during the comparison of the phenotypes.
At 18C°, the Dmesol 7A over-expression phenotype is very similar to that of 
Dmef265 embryos (Figure 6.1A-D). For example, VO muscles appear as one big muscle 
in about 40% of the embryos in both cases (Figure 6.1, brackets, compare A-B with C- 
D). Moreover, muscles such as VA3, LOl or LT4 that are missing in more than 50% of 
Dmef265 embryos, are also missing or misshapen in a significant proportion of embryos 
over-expressing Dmesol 7A. VA3 is missing in 35% of these embryos, LOl in 40% and 
the LT muscles are misshapen in 53% of the embryos.
At 21°C, the phenotype of embryos over-expressing Dmesol 7A is comparable to 
that of Dmef2424 embryos (Figure 6.1E-H) with most muscles affected. For instance, VL 
muscles are misshapen in 40% of the embryos analysed in both cases. However, the 
most striking similarity is not so much related to the shape of the muscles, but more to 
the groups and the number of muscles that are absent in both cases. An example of this 
is given in Figure 6.1E-H where D03-4 and DA3 are missing in both Dmef2424 and 
Dmeso 17A -over-expressing embryos (arrowheads, compare E-F with G-H). I have 
therefore compared the number of muscles missing in different muscle groups in these 
embryos (Figure 6.2). For the ease of comparison, I have divided the muscles into three 
groups: the 9 dorsal muscles (DO 1-5, DAI-3 and DTI), the 7 lateral ones (LT1-4, LL1, 
LOl and SBM) and the 14 ventral muscles (VOl-6, VL1-4, VT1 and VA1-3). This 
analysis revealed that the number of muscles missing in each group is very similar.
Finally, the phenotype produced by a strong decrease in Dmef2 activity in the 
Dmef2113 hypomorph is very similar to the effect of Dmesol 7A over-expression at 25°C 
(Figure 6.1I-L). About 35% of Dmeso 17A -over-expressing embryos have a phenotype 
similar to that observed in the D m ef13 allele. Very few muscles are formed correctly in
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Figure 6.1: Dmesol 7A over-expression phenocopies Dmef2 hypomorphic alleles.
The phenotype of embryos over-expressing Dmeso 17A driven by 24B-Gal4 at 18°C, 
21°C or 25°C was compared to that of Dmef2 hypomorphic mutants: Dmef265, Dmef2424 
and Dmef2u  3. All embryos are stage 17 and stained with an antibody against muscle 
Myosin. A drawing of the wild-type muscle pattern is included for each part of the 
figure and the muscles described are in colour to facilitate their identification. (A-D) 
Comparison of the Dmef265 phenotype (A-B) with that produced by Dmeso 17A over- 
expression at 18°C (C-D). The two phenotypes are similar (compare A and C) and the 
same muscles are affected in the same way. For example, VO muscles (highlighted in 
red on the wild-type pattern) appear as one big muscle in both cases (brackets in C and 
D). (E-H) Comparison of the Dmef2424 phenotype (E-F) with that produced by 
Dmeso 17A over-expression at 21°C (G-H). In both cases, most muscles are affected 
(compare E and G) and the same muscles or subsets of muscles are absent. For instance, 
in both Dmef24 4 and Dmeso 17A -over-expressing embryos, D03-4 and DA3 
(highlighted in red in the wild-type pattern) are missing (arrowheads in F and H). (I-L) 
Comparison of the Dmef2113 phenotype (I-J) with that produced by Dmeso 17A over­
expression at 25°C (K-L). In both cases, very few muscles are formed correctly 
(compare I and K) and some muscles are affected in the same way with particular 
shapes (brackets in J  and L).
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Figure 6.2: Embryos over-expressing Dmesol7A at 21°C and Dmef2424 
mutants have similar phenotype.
The number of muscles missing in different muscle groups was compared 
between D m ef24 mutants and embryos over-expressing Dmeso 17A driven 
by 24B-GAL4 at 21°C. For ease of comparison, muscles are divided into 
three groups: the dorsal muscles (highlighted in red on the muscle pattern), 
the lateral muscles (highlighted in blue on the muscle pattern) and the 
ventral muscles (highlighted in yellow on the muscle pattern). The number 
of missing muscles and the proportion of embryos in which they are 
missing is given in each case. The number of muscles missing in each 
muscle group is very similar in D m ef24 mutants and embryos over­
expressing Dmesol 7A.
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both cases but, most strikingly, some muscles are disrupted in the same way with very 
particular shapes (Figure 6.1, brackets, compare I-J with K-L).
In summary, an increase in Dmeso 17A activity can phenocopy a decrease in Dmef2 
activity. There are striking similarities between the phenotypes produced by Dmesol 7A 
over-expression and those of the Dmef2 hypomorphic alleles. The same muscles or 
subsets of muscle are affected in the same way. These similarities strongly suggest that 
Dmesol 7A is involved in the main pathway of muscle differentiation, which is regulated 
by Dmef2. They also indicate that both genes play antagonistic roles, which is consistent 
with a role of inhibitor of muscle differentiation for Dmesol 7A.
6.2.2 Dmesol 7A genetically interacts with Dmef2
The results presented in the previous section suggest that Dmesol 7A and Dmef2 
might interact. In this section, I tested this possibility. I over-expressed the two genes 
together to determine whether they genetically interact. The assumption is that if 
Dmesol 7A over-expression inhibits muscle differentiation by reducing Dmef2 activity, 
an increase of Dmef2 activity in these embryos should rescue the phenotype. 
Homozygous flies for both UAS-Dmesol 7A and UAS-Dmef2 were crossed to a stock 
carrying twist/twist-GAlA at 18°C. As revealed by an antibody against muscle myosin, 
the phenotype is rescued towards wild type. The rescued embryos have many more 
correctly shaped muscles (Figure 6.3, compare A with B).
As shown in Figure 6.4 (right column), 40-45% of the embryos now have a 
phenotype close to wild-type, when only 25-30% did with Dmesol7A alone (Figure 6.4, 
compare A with D). Embryos with a moderate phenotype represent 25-30% of the cases, 
whereas in embryos over-expressing Dmeso 17A alone only 15-20% have a moderate 
phenotype (Figure 6.4, compare B with E). Finally, the proportion of embryos severely
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Figure 6.3: Dmesol7A genetically interacts with Dmef2.
Dmeso 17A and Dmef2 were over-expressed together using twist/twist-GAL4 at 
18°C to test their genetic interaction. Dmef2 rescues the Dmeso 17A over­
expression phenotype (A) towards wild-type (B).
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affected is now reduced to 25-30%, whereas it represented more than 50% of the 
embryos over-expressing Dmesol 7A alone (Figure 6.4, compare C with F). These 
results show that Dmef2 can suppress the inhibitory effect of Dmesol 7A over­
expression and therefore that the two genes genetically interact.
This interaction of Dmesol 7A with Dmef2 is most clearly revealed by measuring 
the percentage of hatching and survival (Figure 6.5). 93.5% of the embryos over­
expressing both Dmesol 7A and Dmef2 hatched, whereas 90% did with Dmesol 7A alone. 
Most importantly, nearly 38% of the larvae are now able to survive until adulthood at 
18°C, when only 18% survived with Dmesol 7A over-expressed alone. These results 
clearly show a suppression of the Dmeso 17A over-expression phenotype by Dmef2. It 
rescues the lethality and confirms that both genes genetically interact. Together with all 
my results, this implies that Dmesol 7A inhibitory effect on muscle differentiation is 
centered on Dmef2. Dmef2 might therefore be a target for Dmesol 7A action.
In addition to these results, I over-expressed Dmesol 7A-RNAi in the Dmef265 
mutant background. The idea was that the reduction of Dmesol 7A level might 
compensate the loss of Dmef2 activity. However, as shown in Figure 6.6, the over­
expression of Dmesol 7A-RNAi, driven by Dmesol 7A-GAL4 at 25°C, did not rescue the 
Dmef265 phenotype (compare A-B with C-D). This suggests that the reduction of 
Dmesol 7A level is not sufficient to balance the loss of Dmef2 activity. This result will 
be discussed further in section 6.5.1.
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Figure 6.4: Dmef2 suppresses the inhibitory effect induced by Dmesol 7A  over­
expression.
Dmeso 17A and Dmef2 were over-expressed together using twist/twist-GAL4 at 18°C to 
test their genetic interaction. (A-C) Variation of phenotype in Dmesol 7A over­
expressing embryos (categories are the same as in figure 4.2). (D-F) Dmef2 suppresses 
the inhibitory effect of Dmeso 17A over-expression. Embryos have more correctly 
shaped muscles. The proportion of embryos with weak (D) and moderate (E) phenotype 
has considerably increased, whereas the number of severely affected embryos (F) is 
reduced (compare with A, B and C respectively).
Figure 6.5: Dmef2 suppresses the lethality induced by Dmesol 7A  over-expression.
The larval hatching and survival assay was carried out as described in Figure 4.4. The 
percentage of hatching of larvae over-expressing both Dmeso 17A and Dmef2 does not 
change substantially compared to that obtained with Dmesol7A alone. However, the 
percentage of survival is substantially increased. Mean percentages +  S.D are: 
Dmeso 17A, Hatching=90% +  0.24, Survival=18% ±  0.31; Dmesol 7A+Dmef2, 
Hatching=93.5%+0.094, Survival=37.6%± 0.21.
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Figure 6.6: Dmesol7A-RNAi does not rescue the Dmef265 mutant 
phenotype.
To investigate further the link between Dmeso 17A and Dmef2, Dmeso 17A- 
RNAi was over-expressed in a Dmef265 mutant background using Dmesol 7A- 
GAL4 at 25°C. w; Dmef265/CyO,lacZ; UAS-Dmeso 17A-RNAH UAS- 
Dmesol 7 A-RNAi males were crossed with w; Dmef265/CyO,lacZ; 
Dmeso 17A-GAL4/Dmesol 7A-GAL4 virgin females. Progeny embryos were 
double stained with anti-Myosin and anti-pgalactosidase antibodies. Stage 
17 embryos lacking lacZ expression (w; Dmef265/Dmef265; Dmesol 7A- 
GAL4/Dmeso 17A-RNAi) were selected and analysed. The Dmef265 mutant 
phenotype (A-B) is not rescued by Dmeso 17A-RNAi (C-D).
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6.2.3 Dmesol7A down-regulates DMe£2 activity
The preceding sections show a close relationship between Dmesol 7A and Dmef2 
and suggest the possibility that Dmef2 might be a target for Dmesol 7A. If that is the 
case, there are two possibilities. Dmeso 17A could either affect Dmef2 expression or 
activity. I tested these two possibilities in embryos over-expressing Dmesol7A using the 
twist/twist-GAL4 driver at 25°C. To do so, I analysed the expression of Twist, Dmef2 
(RNA and protein) and p3 tubulin in these embryos. I examined stage 11 to 13 embryos 
when all three genes are expressed (Bate, 1993; Taylor et al., 1995; Buttgereit et al., 
1996).
No effect was found on the expression of Twist, the upstream regulator of Dmef2 
(Taylor et al., 1995; Cripps and Olson, 1998), nor on Dmef2 RNA (Figure 6.7, compare 
A with B and C with D). DMef2 protein expression is also comparable to wild type 
(Figure 6.7, compare E with F). These results show that Dmesol 7A over-expression 
does not affect Dmef2 expression.
However, as revealed by P3 tubulin expression, there was an effect on DMef2 
activity (Figure 6.7 G-H). p3  tubulin is a direct target of DMef2 in the somatic 
mesoderm (Damm et al., 1998), its expression therefore reflects DMef2 activity. In 
embryos over-expressing Dmeso 17A, whereas Twist and DMef2 expression are 
comparable to wild type, p3 tubulin expression is substantially reduced in somatic 
mesoderm (Figure 6.7 arrowheads, compare G with H). This result shows that 
Dmesol 7A over-expression can down-regulate DMef2 activity. Variations, probably 
due to the use of the GAL4/UAS system, are observed in the extent to which P3 tubulin 
expression is affected. Nevertheless, the embryo shown in Figure 6.7H represents more 
than 45% of the cases. In addition, p3 tubulin expression in visceral mesoderm and the 
heart precursors is normal in embryos over-expressing Dmesol7A (Figure 6.7, arrows in
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Figure 6.7: DmesoHA down-regulates DMef2 activity.
Expression o f Twist protein (A-B), Dmef2 RNA and protein (C-F) or (33-tubulin 
RNA (G-H) was assessed at stage 12 in both wild-type and embryos over­
expressing DmesoHA driven by twist/twist-GAL4 at 25°C. (A-B) Embryos were 
stained with an anti-Twist antibody. Twist expression is comparable in the wild- 
type (A) and when Dmeso 17A is over-expressed (B) (arrowheads). (C-F) Whole 
mount in situ hybridisation using a Dmef2 RNA probe (C-D) and anti-DMef2 
staining (E-F) were carried out to assess Dmef2 expression. In both cases, 
expression in Dmeso 17A -over-expressing embryos is comparable to wild-type 
(arrowheads) (compare C with D, and E with F). (G-H) Whole mount in situ 
hybridisation using a (33-tubulin RNA probe. In the wild-type (G) (33-tubulin is 
expressed in the somatic (arrowhead) and visceral (arrow) mesoderm. In embryos 
over-expressing DmesoHA (H), (33-tubulin expression is strongly reduced in the 
somatic mesoderm (arrowhead) where it is a DMef2 target, but is normal in the 
visceral mesoderm (arrow) where it is not.
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G and H point at the visceral mesoderm). Expression of (33 tubulin in these tissues is not 
regulated by DMef2 (Damm et al., 1998), and therefore provides a convenient internal 
control. This clearly suggests that the effect of DmesoHA over-expression on (33 
tubulin expression in the somatic mesoderm is specifically due to the down-regulation 
of DMef2 activity.
These results are consistent with the genetic interaction of DmesoHA with Dmef2 
and the similarities of the DmesoHA over-expression phenotype with that of the Dmef2 
hypomorphic alleles. All these together, strongly suggest that DmesoHA acts in the 
muscle differentiation pathway to down-regulate DMef2 activity.
6.3 Dmesol 7A and groucho
My analysis of the DmesoHA protein sequence revealed the presence of a WRPW 
motif at its C-terminus. As discussed in Chapter 3, this motif suggests an interaction 
with the well-known co-repressor Groucho (Gro). Gro is the key member of a family of 
transcriptional co-repressors found in flies, mice, humans, frogs and worms (Fisher and 
Caudy, 1998; Chen and Courey, 2000). In Drosophila, it is expressed ubiquitously 
(Delidakis et al., 1991; Maier et al, 1993), and it is involved in diverse embryonic 
developmental processes such as segmentation, sex determination and terminal 
patterning (Fisher and Caudy, 1998, Parkhurst, 1998, Chen and Courey, 2000). Other 
studies have shown that gro function is critical for normal wing patterning (de Celis and 
Ruiz-Gomez, 1995; Heitzler et al., 1996). In vertebrates, the homologs of Drosophila 
Gro, the transducin-like Enhancer of split (TLE) proteins, contribute to regulation of 
neuronal development, skeletogenesis, hematopoiesis and might be implicated in 
myogenesis (reviewed in Gasperowicz and Otto, 2005).
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Gro is a non-DNA binding protein and is recruited to DNA via protein-protein 
interactions with a large variety of transcriptional repressors. For example, Gro is 
required for repression by the members of the Hairy family of bHLH transcriptional 
repressors. Hairy, the main member of this family, regulates neurogenesis and 
segmentation (Rushlow et al., 1989) and recruits Gro via its C-terminal WRPW 
tetrapeptide motif (Paroush et al., 1994; Fisher et al., 1996). The WRPW motif has been 
shown to be necessary and sufficient to mediate protein-protein interaction with Gro 
(Paroush et al., 1994; Fisher et al., 1996). Once recruited to DNA, Gro can mediate 
repression by recruiting the classl histone deacetylase, HDAC1, which in Drosophila is 
encode by the rpd3 gene (Chen et al, 1999; for review see Courey and Songtao, 2001, 
Gasperowicz and Otto, 2005).
Although it does not possesses a bHLH or a DNA binding domain, DmesoHA 
could interact with Gro through its WRPW motif. I have explored the possibility of a 
link between Dmeso 17A and Gro and the strategy adopted is divided in two parts. First, 
I have tested whether the two proteins could physically interact. A GST-pull-down 
assay was used for this. Second, using the GAL4/UAS system, I have tested whether 
DmesoHA and gro genetically interact in vivo. To do so, I have over-expressed 
DmesoHA in a gro mutant background. These results are described in the following 
sections.
6.3.1 Dmesol7A physically interacts with Gro
To test whether Dmeso 17A and Gro could interact and if the WRPW motif is 
required for this interaction, I compared the ability of full length Dmeso 17A and 
Dmeso 17A-AWRPW to bind Gro in vitro. Full length and truncated forms of 
DmesoHA were expressed in bacteria as glutathione S-transferase (GST) fusions,
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Figure 6.8: Dmesol7A binds to Gro in vitro and requires its 
WRPW motif for this interaction.
Radiolabelled Gro was incubated with GST (Lane 1), GST-Dmesol7A 
(Lane 2) or GST-Dmesol7A-AWRPW (Lane 3), all bound to 
glutathione-sepharose beads. Retained Gro protein was visualised by 
SDS-PAGE and autoradiography. Whereas, full length DmesoHA can 
bind Gro (Lane 2), the absence of the WRPW motif prevents this 
interaction (Lane 3). GST alone did not retain Gro (Lane 1). A sample 
of radiolabelled Gro was loaded as a control (Lane 4).
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immobilised on glutathione sepharose beads and tested for their capacity to bind 
radiolabelled Gro protein. As shown in Figure 6.8, full length Dmesol7A can bind Gro 
(lane 2), whereas neither Dmesol7A-AWRPW (lane 3) nor the control (GST) (lane 1) 
do. To show that the protein binding to Dmeso 17A corresponds to Gro, a sample of 
radiolabelled Gro protein from the TNT reaction was loaded as a control (lane 4).
These results show that Dmeso 17A can interact with Gro, and this requires the 
WRPW motif. This suggests that Gro might be required for DmesoHA action and is 
consistent with a role for DmesoHA in the inhibition of transcription of DMef2 targets 
during muscle differentiation.
6.3.2 D m esol 7A  genetically interacts with groucho
To determine whether DmesoHA and gro genetically interact in vivo, I over­
expressed DmesoHA in a gro mutant background using the twist-GAL4 driver. This 
tests whether DmesoHA requires gro function in order to inhibit muscle differentiation. 
The phenotype induced by the over-expression of Dmesol 7A using twist-GAL4 at 25°C 
in a wild type background is shown in Figure 6.9. As described in Chapter 4 section 
4.2.1, when using twist/twist-GAL4, the over-expression of DmesoHA using twist- 
GAL4 gives a variable phenotype. Four categories of phenotype are observed, which I 
describe as moderate, intermediate, severe and extreme:
- 13.1% of the embryos have a moderate phenotype (Figure 6.9A). In these embryos, 
most muscles form correctly, with the exception of V04-6 and VA3. Occasionally, 
there are defects in other muscles.
- When the phenotype is intermediate, in 27.9% of the cases, more muscles form 
correctly (Figure 6.9B). In most of these embryos, the dorsal muscles (DO 1-5, DA1-
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Figure 6.9: Muscle phenotype variations in embryos over­
expressing Dmesol7A driven by twist-GAL4.
Dmeso 17A was over-expressed using twist-GAL4 at 25°C. A range 
of phenotype is observed: (A) moderate. Most muscles are present 
and correctly shaped. (B) Intermediate. More muscles are missing 
or misshapen. (C) Severe. The muscle pattern is considerably 
affected. (D) Extreme. No muscle is formed correctly. The 
proportion of each category is given.
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3) are affected and can be missing or misshapen. VO muscles are also misshapen 
most of the time.
- The severe phenotype is the most common (49.2% of the embryos). Some muscles 
form but only DTI, LTs, VLs and some dorsal muscles are clearly identifiable 
(Figure 6.9C).
- In the extreme phenotype category, although some myosin is expressed, no muscles 
form correctly (Figure 6.9D). This category represents 9.8% of the embryos analysed.
Thus, as described previously, the over-expression of DmesoHA inhibits muscle 
differentiation and, if gro is required for DmesoHA action, one might expect the 
absence of gro to prevent this effect and the muscle phenotype to be close to wild type.
To remove gro function, I used a combination of two gro alleles. groE48, which is a 
point mutation and a strong hypomorph (Preiss et al., 1988), and groBXn, which is a 
deficiency that removes several genes form the Enhancer of split (E(spl')) complex 
(Preiss et al., 1988). The reason for using a point mutation and a deficiency is to ensure 
that gro function only is removed.
In the absence of gro, the inhibitory effect of DmesoHA over-expression is 
prevented and the phenotype is rescued towards wild type (Figure 6.10). 24.4% of the 
embryos now have a weak phenotype which is close to wild type (Figure 6.10E). No 
such embryos were observed when DmesoHA is over-expressed in a wild-type 
background. Moreover, embryos with a moderate phenotype now represent 63.4% of 
the cases, in contrast to 13.1% in Dmeso 17A -over-expressing embryos (Figure 6.10, 
compare A with F). Finally, the intermediate phenotype category of embryos is now 
reduced to 12.2% (Figure 6.10, compare B and G) and there are no embryos with severe 
and extreme phenotype.
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Figure 6.10: Dmesol 7A genetically interacts with gro.
In order to test a genetic interaction, Dmeso 17A was over-expressed using 
twist-GAL4 at 25°C in a groE48/groBX22 mutant background, w; UAS- 
Dmesol 7 A/UAS-Dmeso 17 A; groBX22/TM3,GFP males were crossed with w; 
twist-GAL4/twist-GAL4; groE48/TM3,GFP virgin females. Progeny embryos 
were double stained with anti-Myosin and anti-GFP antibodies. Stage 17 
embryos lacking GFP expression (w; twist-GAL4/UAS-Dmesol7A; 
groE48/groBX22) were selected and analysed. (A-D) Variation of phenotype in 
DmesoHA  over-expressing embryos (categories are the same as in figure 
6.9). (E-G) The absence o f zygotic gro suppresses the inhibitory effect of 
DmesoHA. 24.4% o f the embryos now have a weak phenotype (E) and the 
proportion o f embryos with moderate phenotype (F) has considerably 
increased. Furthermore, the number o f embryos with an intermediate 
phenotype is reduced (G), and there are no severely or extremely affected 
embryos (compare with A-D).
UAS-Dmesol 7A X
tmst-GAL4
UAS-Dmesol 7A;
groE48/groBX22
X  twist-GAL4
E 24.4%
A 13.1% F 63.4%
B 27.9%A G 12.2%
C  49.2%
D 9.8%
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Unfortunately, I have not been able to apply the hatching and survival test to these 
embryos. As mentioned earlier, gro is implicated in a wide variety of developmental 
processes and although 96% of the embryos carrying the groE48/groBX22 are able to hatch, 
they all die before pupation (Delidakis et al., 1991).
Nevertheless, together my results show that DmesoHA and gro genetically and 
physically interact and that DmesoHA requires gro function to inhibit muscle 
differentiation. This, together with the fact that Dmeso 17A can down-regulate DMef2 
activity, suggest that Dmeso 17A and Gro act in the same complex to inhibit the 
transcription of DMef2-regulated genes during muscle differentiation.
6.3.3 The loss of gro function affects muscle development
Although, in mammalian cell culture, there are indications that members of the TLE 
family might be implicated in myogenesis (Sasai et al., 1992; Gao et al., 2001; reviewed 
in Gasperowicz and Otto, 2005), there is no such evidence for Gro in Drosophila and no 
muscle phenotype has been recorded for gro mutant so far. However, my results 
indicate that gro plays a role in muscle development. It was therefore necessary to 
examine the muscle pattern in gro mutant embryos.
As shown in Figure 6.11, muscle myosin staining revealed that these mutants have 
a muscle phenotype. This phenotype is variable and the embryos can be classified into 3 
categories according to the severity of the muscle defects.
The first category, which represents 29% of the embryos analysed, has a moderate 
phenotype (Figure 6.11 A). Muscles form correctly with the exception of VL1-2, V5-6 
and VA3. Occasionally, there are defects in other muscles.
The second category has an intermediate phenotype and represents 32.6% of the 
embryos analysed. In these embryos, the most dorsal muscles (DO 1-2, DA 1-2) and the
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Figure 6.11: The gro mutant muscle phenotype.
w; + /+ ; groBX22/TM3,GFP males were crossed with w; + /+ ; groE48/TM3,GFP 
virgin females. Progeny embryos were double stained with anti-Myosin and 
anti-GFP antibodies. Stage 17 embryos lacking GFP expression (w; +/+; 
groE48/groBX22) were selected and analysed. In the absence o f  zygotic gro , 
muscle development is affected and a range of phenotype is observed: (A) 
moderate. Only a few muscles are affected. (B) Intermediate. More muscles are 
missing or misshapen. (C) Extreme with no muscle formed correctly. The 
proportion o f  each category is given.
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most ventral ones (V04-6, VA1-3) are affected (Figure 6.1 IB). They are most of the 
time misshapen, but can also be missing. Defects in VL and LT muscles formation have 
also been observed.
The last category of embryos, which represents 38.4% of the embryos analysed, 
corresponds to an extreme phenotype. Myosin is expressed but no muscle forms 
correctly (Figure 6.11C).
This result shows that the absence of gro affects muscle development and therefore 
indicates that gro is required for the process. Moreover, it suggests that, in my genetic 
interaction experiment, not only is gro function required for DmesoHA action, but 
DmesoHA is also capable of compensating the loss of gro. This will be discussed 
further in section 6.5.2.
6.4 Dmesol 7A and HD AC
My preceding results show that Dmesol 7A physically and genetically interacts with 
gro and that it can down-regulate DMef2 activity. In mammalian cell culture, members 
of the Gro/TLE family, through interactions with HES1, a member of the HES 
(mammalian homologs of Drosophila Hairy and E(spl)) family, might inhibit the 
activity of MyoD, a key regulator of myogenesis (Weintraub et al., 1991, reviewed in 
Taylor,2005), and therefore inhibit myogenesis (Sasai et al., 1992; reviewed in 
Gasperowicz and Otto, 2005). However, there is no record, in vitro or in vivo, of a direct 
link between Gro/TLE and Mef2 that would regulate myogenesis. Moreover, 
DmesoHA does not possess a DNA binding domain or a Mef2 binding domain such as 
that described for the transcriptional co-regulator Cabin 1 or classll HDACs (Miska et 
al., 1999; Lu et al., 2000; Han et al., 2003; Han et al., 2005; reviewed in Yang and 
Gregoire, 2005). Therefore there may be another protein that provides a link between
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the Dmeso 17A/Gro complex and DMe£2. One possibility for such factors is members of 
classll HDACs, HDAC4 and HDAC5.
HDACs function as transcriptional repressors. They catalyse the deacetylation of 
histone and non histone proteins to create transcriptionally silent domains (Flores-Saaib 
and Courey, 2000; Thiagalingam et al., 2003). In vertebrates, classll HDACs interact 
with a wide variety of transcription factors and co-repressors (reviewed in Yang and 
Gregoire, 2005). In particular, HDAC4 and HDAC5 have been shown to directly bind 
to Mef2 and to repress its activity in cell cultures (Miska et al., 1999; Lemercier et al., 
2000; Lu et al., 2000). Binding of these HDACs to Mef2 is mediated by a conserved 18 
amino acids at their N-terminus (Miska et al., 1999; Lu et al., 2000; Han et al., 2005; 
reviewed in Yang and Gregoire, 2005). Another cell culture study showed that, once 
bound to Mef2, HDAC4 or 5 can promote its sumoylation and perhaps its 
phosphorylation, independently of their deacetylase activity. This results in the 
inhibition of Mef2 transcriptional activity (Gregoire and Yang, 2005). The activity of 
these HDACs is regulated by the phosphorylation of two serine residue by 
calcium/calmodulin-dependent protein Kinase (CaMK). When phosphorylated, these 
sites recruit the chaperone protein 14-3-3 and the complex HDAC/14-3-3 is exported 
out of the nucleus this results in the de-repression of Mef2-regulated genes (Grozinger 
et al., 2000; McKinsey et al., 2000 a and b; Wang et al., 2000). In addition to CaMK, a 
recent cell culture study revealed that HDAC5 phosphorylation and therefore activity 
can be regulated by a broad range of signalling pathways and transcriptional regulators. 
They suggest that HDAC5 (and other classll HDAC) is a point of convergence of 
diverse signalling cascades to regulate the expression of specific target genes (Chang et 
al., 2005).
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In Drosophila, there are only two classll HDACs, dHDAC4 and dHDAC6. 
dHDAC4 is involved in segmentation and is an ortholog of human HDAC4 with which 
it shares 36% amino acid identity overall and 64% in the catalytic domain (Zeremski et 
al., 2002). Most importantly, the Mef2 binding domain and the two serine residues, 
necessary for HDAC4 activity regulation, are conserved in dHDAC4 (Zeremski et al., 
2002, reviewed in Yang and Gregoire, 2005). This suggests that dHDAC4 might act 
like its vertebrate orthologs to down-regulate DMef2 activity.
Moreover, in Drosophila, Gro can bind to the classl HD AC encoded by the rpd3 
gene. Rpd3 deacetylase activity is necessary for Gro mediated repression (Chen et al, 
1999; for review see Courey and Songtao, 2001, Gasperowicz and Otto, 2005). No 
interaction between Gro/TLE proteins and classll HDACs has been reported in 
vertebrates or Drosophila. Nevertheless, the interaction of Gro with Rpd3, and the 
regulation of Mef2 activity by classll HDACs suggest that the link between the 
Dmesol 7 A/Gro complex and DMe£2 could be an HD AC. Thus, I now wanted to test 
whether Dmeso 17A interacts with HD A C.
6.4.1 The HDAQ over-expression phenotype resembles that of Dmesol7A
Besides the facts suggesting a link with DmesoHA, preliminary experiments 
performed by another group suggested that over-expressing Human-HDAC5 disrupts 
myogenesis (Olson E.N., unpublished results). I therefore used the UAS-hHDAC5 line 
available (a gift from Olson E.N.) to over-express this gene and compare the phenotype 
produced to that observed in DmesoHA over-expression. This HD AC transgene 
contains a mutation in one of the phosphorylation sites necessary for HDAC5 nuclear 
export. It is therefore considered to be a constitutively active form of HDAC (for
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Figure 6.12: HDAC5 over-expression disrupts myogenesis.
Flies homozygous for a UAS-hHDAC5 construct were crossed to Dmef2-GAL4 at 
25°C to over-express HDAC5 in the mesoderm. Stage 17 embryos were stained 
with an antibody anti-muscle Myosin. (A) Embryo over-expressing Dmesol7A 
using the same driver. (B) The effect o f HHDAC5 over-expression is similar to that 
produced by Dmesol7A.
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HDAC5 phosphorylation and nuclear export see McKinsey et al., 2000 a and b). The 
GAL4 drivers I used in this experiment were Dmef2-GAL4 and twist-GAL4 at 18°C.
The expression of muscle myosin revealed that over-expression of hHDAC5, driven 
by Dmef2-GAL4 at 25°C, results in myogenesis disruption that closely resembles the 
phenotype of Dmesol7A over-expression (Figure 6.12, compare A with B). However, 
the severity of the phenotype obtained using this driver is so extreme that the 
comparison is limited to the general aspect of the embryos. I therefore chose to use the 
twist/twist-GAL4 driver, which with Dmesol 7A gives a more moderate phenotype. 
Using this driver at 18°C, I obtained a variable phenotype with hHDAC, as was seen 
with Dmesol 7A. Figure 6.13 shows the range of phenotypes obtained.
In 25-30% of the embryos, the phenotype is moderate (Figure 6.13A). A lot of 
muscles are missing or misshapen. For example, DTI is misshapen in more than 80% of 
the embryos and D03-5, LL1, LOl and VA3 are missing in more than 70% of the cases.
In the most represented category (55-60% of the embryos), the phenotype is more 
severe (Figure 6.13B). DTI is misshapen in more than 90% of the embryos, DAI-3, 
D03-5, LL1, LOl, VA3 are missing in more than 50% of the case and ventrally 3 to 8 
muscles are often present, but they are misshapen and hard to identify.
In the most severe category (10% of the embryos), only a few misshapen fibres can 
form (Figure 6.13C).
This phenotype is comparable to that obtained in embryos over-expressing 
Dmesol 7A (Chapter 4 section 4.2.1). Figure 6.14 summarises the main similarities. 
Although the hHDAC phenotype is generally somewhat more severe than with 
Dmesol 7A, similar variations in the phenotype are observed. The two most severe 
phenotype categories (Figure 6.14 C, F and D, G) represent the same proportion of 
embryos in both cases. The moderate phenotype category is present, but in a larger
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Figure 6.13: Muscle phenotype variations in embryos over-expressing 
hHDAC5.
hHDAC5 was over-expressed using twist/twist-GAL4 at 18°C. Stage 17 embryos 
were stained with an antibody anti-muscle Myosin. A range of phenotype is 
observed: (A) Moderate. A lot o f muscles are affected affected. (B) Severe. The 
number o f muscles present and correctly shaped is considerably reduced. (C) 
Extreme. No muscles are formed correctly. The proportion o f each category is 
given, as well as details o f  the muscle pattern defects.
UAS-Dmesol 7A X  UAS-hHDAC-SA X
twist/twist-GAL4 twist/twist-GAL4
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D 05 missing
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Figure 6.14: Comparison of Dmesol 7A and hHDAC5 over-expression 
muscle phenotypes.
Dmesol 7A and hHDAC5 were over-expressed using twist/twist-GAL4 at 18°C. 
Stage 17 embryos were stained with an antibody anti-Myosin. (A-D) Variation 
o f phenotype in Dmesol 7A over-expressing embryos (categories are the same 
as in Figure 4.2). (E-G) Over-expression o f hHDAC5 produces a slightly more 
severe phenotype, but similar variations are observed. Embryos with a weak 
phenotype are absent. The proportion o f moderately affected embryos (E) is 
more important than with Dmesol 7A (compare with B). Severe (F) and 
extreme (G) phenotype categories represent the same proportion o f embryos as 
in Dmesol 7A over-expression (compare C with F and D with G). In both 
Dmesol 7A and hHDAC5 over-expressing embryos, particular muscles are 
affected in the same way. The main similarities are given in the right column.
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proportion in embryos over-expressing hHDAC (Figure 6.14, compare B and E). 
However, the weakest phenotype, is only observed in Dmesol 7i4-over-expressing 
embryos (Figure 6.14A). In addition to these comparable general muscle phenotypes, 
particular muscles are similarly affected in both Dmesol 7A and HD A C-over-expressing 
embryos. For example, the most represented category of phenotype in both cases lack 
muscles such as DAI-3, D03-5, LL1, LOl and VA3. Also, DTI and the ventral 
muscles are misshapen in most embryos (Figure 6.14, the main similarities for each 
category of phenotype are given in the right column).
The larval hatching and survival assay revealed that 70% of the embryos over­
expressing hHDAC are able to hatch, but only 6.45 % survive (Figure 6.15). Analysis of 
the larvae under polarised light showed a pattern of muscle comparable to that in the 
embryo (Figure 6.16, compare A with B). Thus, as for Dmesol 7A over-expression, 
embryos can hatch without a complete set of muscles, but in this case, the severity of 
the phenotype only allows a very small proportion to survive. Nevertheless, the 
similarities of the effects of hHDAC5 and Dmesol 7A over-expression suggest a possible 
interaction between the two genes
6.4.2 Dmesol 7A genetically interacts with HD AC
To test whether Dmesol 7A and hHDAC can interact, I over-expressed both genes 
together and also used the dominant negative form of Dmesol 7A {Dmesol 7A-AWRPW) 
to try to rescue the phenotype induced by hHDAC5 (Figure 6.17). twist/twist-GAL4 was 
used as previously and crosses were kept at 18°C.
When both Dmesol 7A and hHDAC5 are over-expressed, muscle differentiation is 
more affected than with either alone. In more than 80% of the embryos, the number of 
myosin-expressing muscles is reduced compared to each gene over-expressed alone
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Figure 6.15: hHDACS over-expression results in important larval 
lethality.
A larval hatching and survival assay was carried out as described in Figure
4.4. The percentage o f hatching of larvae over-expressing hHDAC5, 
although still high, is reduced compared to wild-type. The percentage of 
survival is dramatically reduced. Mean percentages =b S.D are: wild-type, 
Hatching=99% + 0.081, Survival=97%+0.16; hHDAC5,
Hatching=70% +  0.4, Survival=6.45%d= 0.32.
UAS-hHDAC5 
X  twist/twist- 
GAL4
Figure 6.16: hHDACS over-expressing larvae can hatch with severe muscle 
defects.
The muscle pattern o f larvae over-expressing hHDAC5 was analysed under 
polarised light. (A) Wild-type first instar larva with a normal pattern o f muscle. 
(B) hHDAC5 over-expressing larva. The muscle pattern is severely affected, as in 
Figure 6.13B, but that does not prevent hatching. The orientation is the same as in 
wild-type.
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(Figure 6.17 central column). Hardly any muscle is formed correctly. This increase in 
severity is confirmed by the larval hatching and survival assay (Figure 6.18). Only 36% 
of the embryos hatched and none of them survived.
When hHDAC5 and Dmesol7A-AWRPW are over-expressed together, the 
phenotype is rescued towards wild-type. 45-50 % of the embryos are now in the 
weakest class of phenotype, whereas only 25-30% are with HHDAC5 alone (Figure 6.17, 
compare A with G). The proportion of more severely affected embryos is now 25-30%, 
whereas it is 55-60% when only hHDAC5 is over-expressed (Figure 6.17, compare B 
and H). A dramatic phenotype is also observed in 20% of the embryos, but the effect is 
less extreme than with hHDAC5 alone (Figure 6.17, compare C with I).
This rescue is confirmed by the larval hatching and survival assay (Figure 6.18). 
85.6 % of the embryos are now able to hatch and 11.7% survived, whereas with 
hHDAC5 alone the figures are 70% and 6.45% respectively. This indicates that 
Dmesol7A-AWRPW can suppress the lethality induced by hHDAC5 and suggets that a 
diminution of Dmesol7A activity can prevent the hHDAC5 effect on muscle 
differentiation. Taken together, these results show that Dmesol7A and hHDAC5 
genetically interact and supports the hypothesis in which HD AC could link Dmesol 7 A 
and Gro to DMef2 to regulate muscle differentiation.
In addition to these results, Jun Han (a research assistant in the Taylor laboratory), 
has followed my experimental design, and tested whether Dmesol 7A-RNAi could also 
rescue the phenotype induced by the over-expression of hHDAC5. Our analysis of her 
results shows that it can (Figures 6.19 and 6.20). Embryos expressing both Dmesol 7A- 
RNAi and hHDAC5 using twist/twist-GAL4 at 18°C have more correctly shaped muscles 
compared to embryos over-expressing hHDAC5 alone (Figure 6.19, compare A with B). 
Moreover, the hatching and survival test revealed that 39% of the embryos are now able
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Figure 6.17: Dmesol 7A genetically interacts with hHDAC.
hHDAC5 was over-expressed alone (A-C) or together with either Dmesol 7A (D-F) or 
Dmesol 7A-AWRPW (G-I). twist/twist-GAL4 was used and crosses were kept at 18°C. 
Stage 17 embryos were stained with an antibody anti-muscle Myosin. (A-C) Variation 
of phenotype in hHDAC5 over-expressing embryos (categories are the same as in 
Figure 6.13). (D-F) When both hHDAC5 and Dmesol 7A are over-expressed, the 
number of muscles present is dramatically reduced. Almost no muscles form correctly. 
(G-I) Dmesol7A-AWRPW suppresses the inhibitory effect of hHDAC5. The number of 
less severely affected embryos (G) has substantially increased, whereas the proportion 
of more severely affected ones (H) is reduced (compare with A and B respectively). A 
proportion of embryos have a more severe phenotype (I), but the effect is less severe 
than that with hHDAC5 alone (C).
Figure 6.18: The lethality in hHDACS over-expressing larvae is suppressed by 
Dmesol7A-AWRPW and increased by Dmesol 7A.
The frequency of hatched and surviving larvae was scored as previously. Larvae over­
expressing both hHDACS and Dmesol7A-AWRPW have an increased hatching and 
survival. When Dmesol 7A and hHDAC5 are over-expressed together, both hatching and 
survival are reduced. The results are compared to those obtained with either Dmesol 7A 
or hHDAC5 alone. Mean percentages ±  S.D are: Dmesol7A, Hatching=90%+0.24, 
Survival=18% ±  0.31; hHDACS, Hatching=70%±0.4, Survival=6.45% +  0.32.; 
Dmesol 7A+hHDAC5, Hatching=36% ±  0.37, Survival=0%; Dmesol 7A-
AWRPW+hHDAC5, Hatching=85.6%±0.66, Survival=l 1.7%±0.41.
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to survive to adulthood when only 2% did with HDAC5 alone (Figure 6.20). The 
percentage of hatching is almost identical in both cases (Figure 6.20). These results 
clearly show that Dmesol 7A-RNAi can rescue the lethality induced by the over­
expression of hHDAC5. This is consistent with the results I obtained when both 
Dmesol7A-AWRPW and hHDAC5 are over-expressed together and confirms that 
Dmesol 7A and hHDAC5 genetically interact.
As described in section 6.4.1, the HD AC transgene used in all the above 
experiments is the human HD AC5 gene. However, we recently obtained a stock of flies 
carrying a Drosophila HDAC4 transgene (UAS-DHDAC4, a gift from Olson E.N.) and 
were able to test it in similar assays. This transgene is a truncated form of DHDAC4, 
lacking the nuclear export signal. Therefore, even if phosphorylated it should stay in the 
nucleus and thus, like the hHDAC5 transgene described above, it is considered as 
constitutively active.
Figure 6.21 shows that over-expression of DHDAC4 using twist/twist-GAL4 at 
18°C results in muscle disruption similar to that obtained with either hHDACS or 
Dmesol 7A (compare A, B and C). Following the same strategy as for the hHDACS, Jun 
Han and I have used this new transgenic line to test whether there is also a genetic 
interaction between Dmesol 7A and D HDAC4.
When both Dmesol 7A and DHDAC4 are over-expressed, the severity of the muscle 
phenotype is dramatically increased compared to when DHDAC4 is over-expressed 
alone (Figure 6.22, compare A and B). The hatching and survival test revealed that 
while 20% of the embryos hatch and 1.5% to survive with DHDAC4 alone, only 10% 
hatch when both Dmesol 7A and DHDAC4 are over-expressed and none of these 
survives (Figure 6.23).
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Figure 6.19: Dmesol 7A-RNAi suppresses the inhibitory effect of 
hHDAC5 over-expression on muscle development.
hHDAC5 and Dmesol 7A-RNAi were over-expressed together using 
twist/twist-GAL4 at 18°C. Stage 17 embryos were stained with an antibody 
anti-muscle Myosin. D m esol7A-RNAi rescues the hHDAC5 phenotype (A) 
towards wild-type (B). Embryos expressing both transgenes (B) have more 
correctly shaped muscles compared to when hHDAC5 is expressed alone (A).
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Figure 6.20: Dmesol 7A-RNAi suppresses the lethality induced by 
hHDACS over-expression.
A larval hatching and survival assay was carried out as described in Figure
4.4. The percentage of larvae hatching when both Dmeso 17A-RNAi and 
hHDAC5 are over-expressed almost does not change. However, the 
percentage of survival is substantially increased compared to that obtained 
with hHDAC5 alone. Mean percentages +  S.D are: hHDACS, 
Hatching=95%+0.31, Survival=2%±0.15.; hHDAC5+Dmeso 17A-RNAi 
Hatching=94.5%± 0.82, Survival=39% +  0.46.
H u m a n  H D  A C 5 D m e s o l  7A  D r o s o p h i la  H D  A  C 4
Figure 6.21: DHDAC4 over-expression results in muscle defects similar to 
that obtained with hHDACS and Dmesol 7A.
DHDAC4, Dmeso 17A and hHDAC5 were over-expressed using twist/twist-GAL4 
at 18°C. Stage 17 embryos were stained with an antibody anti-muscle Myosin. 
The phenotypes produced by the over-expression of hHDAC5 (A), Dmeso 17A (B) 
or DHDAC4 (C) are comparable.
UAS-DHDA C4 X  twist/twist-GAL4 UAS-DHDAC4; UAS-Dmesol7A X  twist/twist-GAL4
Figure 6.22: Dmesol7A increases the severity of the DHDAC4 over­
expression muscle phenotype.
DHDAC4 was over-expressed either alone (A) or together with Dmeso 17A (B) 
using twist/twist-GAL4 at 18°C. Stage 17 embryos were stained with an 
antibody anti-muscle Myosin. When both DHDAC4 and Dmeso 17A are over­
expressed (B), the number of muscles present is reduced and almost no 
muscles form correctly.
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Figure 6.23: Dmesol7A increases the lethality of DHDAC4 over­
expressing larvae.
The frequency of hatched and surviving larvae was scored as previously. 
When Dmeso 17A and DHDAC4 are over-expressed together, both hatching 
and survival are reduced, compared to with DHDAC4 alone. Mean 
percentages +  S.D are: DHDAC4, Hatching=20 +  0.05, Survival= 1.5 +  0.15; 
DHDAC4+Dmeso 17A, Hatching= 10.6 +  0.59, Survival=0%.
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Moreover, Dmeso 17A-RNAi and Dmesol 7A-AWRPWcan rescue towards wild-type 
the phenotype produced by the over-expression of DHDAC4 (Figure 6.24, compare A 
with B and C). This rescue is clearly demonstrated by the percentage of hatching and 
survival. 56% of the embryos over-expressing both DHDAC4 and Dmeso 17A-RNAi are 
able to hatch and 15.3% to survive, in contrast to 20% and 1.5% with DHDAC4 alone. 
When Dmesol7A-AWRPW is used, hatching and survival increases to 43% and 14% 
respectively (Figure 6.26).
These results show that Dmeso 17A can genetically interact with DHDAC4. 
Together with the results on the interactions of Dmesol 7A with gro and Dmef2, they 
support a model in which Dmeso 17 A, together with Gro and HD AC, down-regulates 
DMef2 activity.
Lastly, in order to further investigate the link between Dmesol 7A, Dmef2 and 
HD AC, we tested whether Dmef2 and DHDAC4 could genetically interact. To do so, we 
over-expressed both genes together. In embryos over-expressing both genes, more 
muscles are able to form compared to when only DHDAC4 is over-expressed (Figure 
6.25, compare A with B). Moreover, the percentage of hatching and survival showed a 
profound rescue of the lethality induced by the over-expression of DHDAC4. 94.5% of 
the embryos over-expressing Dmef2 and DHDAC4 hatched and 80% survived. This 
contrasts with only 20% hatching and 1.5% surviving when DHDAC4 is over-expressed 
alone (Figure 6.26). These results clearly show that Dmef2 can suppress the inhibitory 
effect of DHDAC4 and reinforce my model.
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Figure 6.24: Comparison of Dmesol 7A-RNAi and Dmesol 7A-AWRPW in 
suppressing the inhibitory effect of DHDAC4 over-expression on muscle 
development.
DHDAC4 was over-expressed together with either Dmeso 17A-RNAi (B) or Dmesol 7A- 
AWRPW (C). twist/twist-GAL 4 was used and crosses were kept at 18°C. Stage 17 
embryos were stained with an antibody anti-muscle Myosin. (A) Over-expression of 
DHDAC4 disrupts muscle differentiation. Dmeso 17A-RNAi (B) and Dmeso 17A- 
AWRPW(C) suppress this effect.
Figure 6.25: DHDAC4 genetically interacts with Dme/2.
DHDAC4 and Dmef2 were over-expressed together using twist/twist-GAL4 at 18°C. 
Stage 17 embryos were stained with an antibody anti-muscle Myosin. Dmef2 rescues 
the DHDAC4 phenotype (A) towards wild-type (B). Embryos expressing both 
transgenes (B) have more correctly shaped muscles compared to when DHDAC4 is 
expressed alone (A).
Figure 6.26: Comparison of Dmesol7A-RNAi, Dmesol7A-AWRPW and Dmef2 in 
suppressing the lethality induced by DHDAC4 over-expression.
The frequency of hatched and surviving larvae was scored as previously. When 
DHDAC4 is over expressed together with either Dmeso 17A-RNAi, Dmeso 17A-AWRPW 
or Dmef2, both hatching and survival are considerably increased compared to with 
DHDAC4 alone. Mean percentages ± S.D are: DHDAC4, Hatching=20 +  0.05, 
Survival=1.5±0.15; DHDA C4+Dmeso 17A -RNA i, Hatching=56±0.31,
Survival=l 5.3 ±0.43; DHDAC4+Dmesol7A-AWRPW, Hatching=43±0.83,
Survival=14±0.67; DHDAC4+Dmef2, Hatching=94.5±0.21, Survival=80±0.74.
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6.5 Discussion
6.5.1 Dmesol 7A inhibits muscle differentiation by down-regulating 
DMef2 activity
My results, presented in Chapters 4 and 5, suggested that there could be a 
relationship between Dmesol 7A and Dmef2. Whereas one can inhibit muscle 
differentiation, the other promotes it. If a link exists, the phenotype of Dmesol 7A over­
expression should closely resemble that of Dmef2 loss-of-function. I therefore compared 
the phenotype of Dmef2 hypomorphic alleles with that of embryos over-expressing 
Dmeso 17A. Not only are there striking similarities in the way in which particular 
muscles are affected, but the same variations in the severity of phenotype are observed. 
The differential effects found between the Dmef2 hypomorphic mutants can be 
attributed to different levels of DMef2 activity (Ranganayakulu et al., 1995; Gunthorpe 
et al., 1999). Moreover, it has been shown that different properties within a cell require 
different thresholds of DMef2 activity (Gunthorpe et al., 1999). The remarkable 
similarities I observed therefore strongly suggest that, in embryos over-expressing 
Dmeso 17A, the level of DMef2 activity within particular muscles is reduced to a level 
comparable to that found in Dmef2 mutants. They also suggest that different amounts of 
Dmeso 17A activity result in the reduction of DMef2 activity to different levels.
I also tested whether Dmesol 7A and Dmef2 genetically interact. My results clearly 
show that Dmef2 can suppress the lethality induced by Dmesol 7A over-expression.
Taken together, these results show that Dmesol 7A and Dmef2 genetically interact 
and that they play antagonistic roles during muscle differentiation. This is consistent 
with the possibility that Dmesol7A down-regulates Dmef2, and begins to indicate a 
mechanism by which Dmeso 17A inhibits muscle differentiation.
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In order to explore further this interaction, I tested whether Dmesol 7A-RNAi could 
rescue the phenotype of the Dmef265 hypomorphic allele. However, the phenotype 
remained unchanged. Assuming that Dmesol 7A down-regulates Dmef2, this result 
could be explained as follows. In the hypomorphic mutant, DMef2 activity is lower than 
its normal level which leads to muscle defects. When Dmesol 7A-RNAi is expressed in 
this mutant, DMef2 activity increases to a certain level. However, it may not reach the 
minimum threshold required for proper muscle differentiation. This suggests that a 
stronger loss-of-function or even a complete knock-out of Dmesol 7A may be required 
to increase Dmef2 activity to its wild-type level. However, as muscle differentiation 
starts, Dmeso 17A disappears and therefore, Dmesol?A-RNAi is ineffective. This results 
in the decrease of DMef2 activity to its original “mutant level”. Therefore, during 
muscle differentiation, the level of mutant DMef2 activity is unchanged, even if 
Dmesol 7A-RNAi is expressed. This therefore suggests that the loss-of Dmesol 7A 
function may not rescue the Dmef2 mutant phenotype.
The results discussed so far in this section indicate that there is a close relationship 
between Dmesol 7A and Dmef2 with Dmesol 7A antagonising the function of Dmefl. To 
explore how it might do this, I asked whether Dmef2 expression or activity is affected 
by Dmeso 17A. In embryos over-expressing Dmeso 17A, no effect was detected on 
Dmef2 expression. However, there was an effect on its activity as revealed by the strong 
reduction of fiS-tubulin expression in the somatic mesoderm, where it is a direct DMef2 
target (Damm et al., 1998).
Taken together, all these results show that Dmesol 7A acts in the main muscle 
differentiation pathway to down-regulate DMef2 activity.
- 136-
Chapter 6 : Genetic Interactions
6.5.2 Dmesol 7A requires groucho to inhibit muscle differentiation
In the next steps of my study, I aimed to find interactor(s) to explore the 
mechanisms by which Dmeso 17A down-regulates DMef2 activity. This first led me to 
the co-repressor Gro.
Gro proteins cannot bind DNA, but they can repress transcription trough physical 
interaction with transcription repressors such as Hairy (reviewed in Fisher and Caudy, 
1998; Parkhurst, 1998; Gasperowicz and Otto, 2005). Hairy possesses a bHLH domain 
and a WRPW motif at its C-terminus. Once bound to DNA, it can recruit Gro, and the 
WRPW motif has been shown to be necessary and sufficient for this (Paroush et al., 
1994; Fisher et al., 1996). Dmesol7A does not possess DNA binding or bHLH domains. 
Nevertheless, it possesses a WRPW motif at its C-terminus, that is required for its 
function. It was therefore still possible that Dmeso 17A interacts with Gro, maybe 
functioning as an adaptor between Gro and transcriptional repressors.
I showed that Dmeso 17A and the transcriptional co-repressor Gro interact both in 
vitro and in vivo. In a GST pull-down assay, Dmeso 17A was able to bind Gro, whereas 
Dmesol7A-AWRPW was not. This demonstrates that Dmeso 17A and Gro can 
physically interact and shows that the WRPW motif is required for this to happen. In 
vivo, the absence of gro could suppress the inhibitory effect of Dmeso 17A. This shows 
that Dmeso 17A requires gro for its function.
Taken together, these results suggest that Dmeso 17A and Gro act in the same 
complex to inhibit muscle differentiation. Gro is a transcriptional co-repressor 
(reviewed in Fisher and Caudy, 1998; Parkhurst, 1998; Gasperowicz and Otto, 2005), 
and Dmeso 17A can repress the expression of P3-tubulin by down-regulating DMef2 
activity. My results therefore suggest that the Dmesol7A/Gro complex inhibits
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transcription during muscle differentiation and that its action could be centered on 
DMef2.
Moreover, these results implicate gro in Drosophila muscle differentiation for the 
first time. In mammalian cell culture, there are indications that the mammalian 
homologs of Gro, the proteins of the transducin-like Enhancer of split (TLE) family, 
might be implicated in myogenesis. This might be through interactions with members of 
the HES (mammalian homologs of Drosophila Hairy and E(spl)) family, HES-1 and 
HES-6. HES-1 can repress the activity of the bHLH transcription factor MyoD, and thus 
repress myogenesis (Sasai et al., 1992). HES-6, on the other hand, seems to promote 
myogenesis by downregulating MyoR (Gao et al., 2001), an antagonist of MyoD (Lu et 
al., 1999). Both HES-1 and HES-6 are known to interact with TLE1, and HES-6- 
mediated transcriptional repression requires its C-terminal WRPW motif (Grbavec and 
Stifani, 1996; Gao et al., 2001; reviewed in Gasperowicz and Otto, 2005). Nevertheless, 
despite these indications, there is no clear evidence (in vitro or in vivo) of a direct role 
for TLE/gro in mammalian ox Drosophila muscle development.
My results provide in vivo evidence that gro plays a role in muscle differentiation in 
Drosophila. Study of gro and Dmesol 7A function could therefore describe a novel 
mechanism of regulation of muscle differentiation.
To further investigate the role of gro in muscle development, I tested whether 
muscle formation in gro mutants is affected. Myosin staining revealed that muscle 
development is impaired in embryos lacking zygotic gro. This provides further in vivo 
evidence that gro plays a role in normal Drosophila muscle development. Moreover, the 
fact that gro mutants have a muscle phenotype reinforces my genetic interaction result 
with Dmeso 17A. Indeed, the rescue described when Dmesol 7A is over-expressed in gro 
mutants can now be interpreted from two points of view. First, as discussed above, the
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Dmesol 7A inhibitory effect is suppressed in gro mutant demonstrating that Dmesol 7A 
requires gro for its action. Second, the gro mutant phenotype is rescued by the over­
expression of Dmesol 7A. As described in section 6.3.2, the groE48 allele I used is a point 
mutation and a hypomorph and thus the mutated protein produced may have some 
residual activity. One explanation for the rescue of the gro mutant phenotype could then 
be that the extra Dmeso 17A interacts with the mutated Gro protein and enhances its 
activity, compensating the loss of gro function. Another interpretation could be that Gro, 
in addition of interacting with it, is an upstream regulator of Dmesol 7A. In gro mutants, 
Dmesol 7A over-expression could therefore compensate the reduction of Dmeso 17A 
level.
6.5.3 D m esol7A genetically interacts with HDACs
I have shown that Dmesol 7A can interact with Dmefl and gro. However, there is 
no recorded interaction between Dmef2 and gro, and Dmeso 17A does not possess a 
DNA-binding or a DMef2-binding domain. This therefore suggests that there is another 
factor linking the Dmeso 17A/Gro complex to DMef2. A possibility for such a factor is 
HDAC. In mammalian cell cultures, classll HDACs have been shown to bind to Mef2 
and down-regulate its activity (Miska et al., 1999; Lemercier et al., 2000; Lu et al., 
2000). Moreover, Gro, in Drosophila, interacts with the classl HDAC, Rpd3 to repress 
transcription (Chen et al, 1999; for review see Courey and Songtao, 2001, Gasperowicz 
and Otto, 2005).
I therefore explored whether Dmesol7A could also interact with HDAC. In all my 
experiments, two different lines of flies carrying classll HDAC transgenes have been 
used: UAS-human HDAC5 and UAS-Drosophila HDAC4. Both gave similar results:
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The phenotype of embryos over-expressing HDAC is very similar to that obtained 
with Dmesol 7A.
The severity of this phenotype increases when both genes are over-expressed 
together.
Most importantly, the lethality of embryos over-expressing HDAC is suppressed by 
Dmesol 7A-RNAi and Dmesol 7A-AWRPW.
These results indicate that Dmesol7A and HDAC genetically interact and that they 
work together in the same pathway to disrupt myogenesis.
The role(s) of HDACs has been extensively studied in mammalian cultured cells, 
and in particular their interaction with Mef2 (Miska et al, 1999; Sparrow et al, 1999; Lu 
et al, 2000, Youn et al, 2000; reviewed in McKinsey et al, 2001; Han et al, 2005; Yang 
and Gregoire, 2005). However, relatively little is known on the specific function of 
HDACs in vivo. Only HDAC4, 5 and 9 have been studied in vivo and have been 
implicated in cellular hypertrophy (Zhang et al., 2002; Chang et al., 2004; Vega et al., 
2004). Mice lacking either HDAC5 or 9 are viable, but they have cardiac hypertrophy 
(Zhang et al., 2002; Chang et al., 2004). HDAC4 mutant mice display premature 
ossification due to chondrocyte hypertrophy (Vega et al., 2004). However, none of these 
studies implicated HDACs directly in muscle differentiation. The results I presented 
here provide in vivo evidence for how HDACs could function to inhibit myogenesis in 
Drosophila.
I also tested whether HDAC can genetically interact with Dmef2. In vertebrates, as 
mentioned previously, HDAC can bind to Mef2 and inhibit its activity (Miska et al., 
1999; Lemercier et al., 2000; Lu et al., 2000). Nevertheless, there is no such evidence in 
Drosophila. My results show that Dmef2 can suppress the lethality of embryos over­
expressing HDAC and therefore that the two genes genetically interact. Together with
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my preceding results, this supports a model in which Dmeso 17A functions, together 
with Gro and HDAC, to downregulate DMef2 activity and repress muscle gene 
expression.
HDAC, Gro and Mef2 are highly conserved proteins. This allows an immediate 
parallel to be drawn between my study of Dmesol7A in Drosophila and muscle 
differentiation in vertebrates. Although no homologues have been found for Dmesol7A 
in vertebrates, its function in a transcription-repressing complex during muscle 
differentiation might be conserved. This is further supported by the fact that both human 
and Drosophila HDACs genetically interact with Dmesol7A. The possible significance 
of this for muscle diseases will be discussed in the concluding chapter.
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It is apparent that inhibitory mechanisms are required during development to control 
when and where cells differentiate. Our knowledge of these mechanisms and the 
molecules implicated is however limited. In the particular case of muscle cell 
differentiation, some candidate negative regulators have been identified (reviewed in 
Taylor 2005; see Chapter 1, section 1.2), but their importance and in vivo mechanisms 
of action are not always clear. A more complete understanding of the molecular 
mechanisms regulating cell differentiation requires the identification and 
characterisation of restraining molecules.
The work presented in this dissertation focuses on muscle differentiation in 
Drosophila and shows that Dmesol 7A, a novel gene isolated by Dr. Taylor (Taylor, 
2000), encodes one such molecule. My approach to study Dmesol 7A has been to first 
analyse its role during muscle differentiation and then to dissect its mechanism of action.
Using the GAL4/UAS system (Brand and Perrimon, 1993; Brand et al., 1994; see 
Chapter 2 section 3.3) to achieve gain and loss-of-function of Dmesol 7A, I have shown 
that Dmesol 7A is a novel inhibitor of muscle differentiation and that its inhibitory effect 
is required for proper muscle development. I then aimed to identify candidate genes that 
could interact with Dmesol 7A to dissect how it is working. The results I obtained show 
that:
1 Dmesol 7A genetically interacts with Dmef2 and down-regulates its activity.
2 Dmesol 7A genetically and physically interacts with gro.
3 Dmesol 7A genetically interacts With HDAC.
These results taken together, allow me to draw a model for Dmeso 17A mechanism 
of action. In this model, Dmeso 17A first forms a complex with Gro. Gro is known to be 
recruited to its targets by DNA-binding factors, like Hairy (Paroush et al., 1994;
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Jimenez et al., 1997) or by adaptor molecules such as Hairless, which lacks a DNA- 
binding domain and can be recruited to DNA by Su(H) (Barolo et al., 2002). As 
Dmeso 17A appears to lack a DNA-binding domain, it is possible that it acts as an 
adaptor between Gro and a DNA-binding factor. The Dmesol7A/Gro complex then 
recruits HDAC which binds to DMef2. As mentioned in Chapter 6, section 6.4, HDACs 
are known to repress transcription by catalysing the deacetylation of histones (Flores- 
Saaib and Courey, 2000; Thiagalingam et al., 2003). However, recent studies showed 
that the activity of HDACs is not limited to histone deacetylation, but they can also 
directly modify transcription factors such as Mef2 to regulate their activity (Gregoire 
and Yang, 2005; Zhao et al., 2005). Zhao et al. showed that HDAC4 promotes the 
sumoylation of Mef2, thereby inhibiting its transcriptional activity. They also show that 
HDAC4 can directly interact with SIRT1, a classIII deacetylase, which can catalyse 
Mef2 deacetylation (Zhao et al., 2005). Therefore, in my model, it is possible that once 
recruited by the Dmeso 17A/Gro complex, HDAC regulates DMef2 activity by acting on 
both its sumoylation and acetylation state. It is also possible that histone deacetylation 
by HDAC plays a role in the regulation of DMef2 activity. At the onset of muscle 
differentiation, Dmeso 17A is down-regulated and the Dmeso 17A/Gro HDAC complex 
is destabilised. Moreover, HDAC could be phosphorylated by CaMK (or other kinases), 
and exported out of the nucleus (see Chapter 6, section 6.4). DMef2 is then activated 
and can induce the expression of muscle differentiation genes.
More work needs to be done to explore different aspects of this model. For 
example, there is a need to understand how Gro and Dmeso 17A are recruited to DNA 
and what is the role of Dmeso 17A in this complex. HDAC can directly bind to Mef2 
and inhibit its activity in cell culture. It would be interesting to know why Dmeso 17A 
and Gro are needed. Does Dmeso 17A stabilise the complex? Is it an adaptor between
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Gro and a DNA binding factor, or does Dmeso 17A also physically interact with 
HDACs to link it with Gro? One also cannot rule out the possibility that Dmeso 17A 
directly interacts with DMe£2. It would also be necessary to test whether the mechanism 
I describe for Dmeso 17A action is specific to DMe£2 or if it can also regulate other 
factors activity during muscle differentiation.
However, even though my model is not complete, it does provide information on an 
in vivo mechanism by which the activity of DMef2 can be regulated before the onset of 
muscle differentiation. My findings therefore bring a new insight in the understanding 
of the regulation of muscle progenitor differentiation. The mechanism of action of 
Dmeso 17A could provide a possible explanation for how muscle progenitors are held in 
an undifferentiated state until cues trigger their differentiation. As discussed in the 
previous Chapter, the functional conservation of DMef2, Gro and HDAC suggest that 
even though Dmeso 17A appears not to be conserved in higher organisms, its function 
could be. The mechanism I described here might therefore be conserved in the 
regulation of skeletal myogenesis in vertebrates and could be applied to explain how 
Mef2 is regulated in vivo. Moreover, one might imagine a similar mechanism for the 
regulation of MyoD or Myf5. Like Dmef2 in Drosophila, these two MRFs are key 
regulators of skeletal muscle differentiation (Weintraub et al., 1991; Braun et al., 1992; 
Rudnicki et al., 1992; Rudnicki et al., 1993; reviewed in Taylor, 2005). They are 
expressed in undifferentiated myoblasts and yet, their target genes are only activated 
later during muscle differentiation (Kopan et al., 1994; Hirsinger et al., 2001). The 
regulation of MyoD activity has been extensively studied and involves deacetylases, 
such as Sir2 (the mouse homolog of SLRT1) which is a classIII HDAC, and HDAC1 
(reviewed in Sartorelli and Caretti, 2005). My model might therefore be analogous to at
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least some part of MyoD regulation to ensure that skeletal muscle differentiation is not 
prematurely activated.
Temporal control of cell differentiation is not only important for muscle 
development but is also crucial for the development of other tissues. For example, 
during osteoblast differentiation inhibition of Runx2 activity is necessary to prevent 
premature differentiation. Runx2 is a member of the runt family of transcription factors 
(Ducy et al., 1997) and is necessary and sufficient for osteoblast differentiation (Ducy et 
al., 1997; Komori et al., 1997; Otto et al., 1997). Like Dmef2 and the MRFs during 
muscle differentiation, Runx2 is expressed long before osteoblasts start their 
differentiation (Ducy, 2000). A recent study showed that the transcriptional activity of 
Runx2 before the onset of osteoblast differentiation is directly regulated by Twist, 
which prevents Runx2 from binding DNA (Bialek et al., 2004). Interestingly, a previous 
study showed that Gro/TLE proteins can inhibit Runx2 dependent activation of the 
osteoclastin gene, which is characteristic of differentiating osteoblasts (Javed et al., 
2000). Moreover, HDAC4 has been shown to directly interact with Runx2 and inhibits 
its activity, delaying chondrocyte hypertrophy, which is necessary for osteoblast 
differentiation (Vega et al., 2005).
Thus, the regulation of Runx2 during skeletogenesis can be placed in parallel 
with that of DMef2 in myogenesis: DMef2 and Runx2 are essential positive regulators 
of differentiation, they are expressed long before the onset of differentiation in their 
respective tissues and they appear to be regulated by the same molecules, i.e. Gro and 
HDACs. Moreover, as mentioned in Chapter 6, section 6.4, HDAC activity can be 
regulated by a variety of signalling pathways (Chang et al., 2005). This suggests that 
HDACs are involved in the regulation of gene expression during the differentiation of
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various tissues. The mechanism I describe for Dmesol7A action may therefore be 
applicable to a more generalised method for cell differentiation regulation.
Finally, Understanding the genetic network governing how muscle progenitors 
differentiate is important for developing new approaches to tackling human muscle 
diseases. An interesting aspect of Dmesol 7A resides in its expression in the AMPs. This 
is for two reasons. First, it suggests that Dmesol 7A might be involved in the regulation 
of adult muscle differentiation and my preliminary results are consistent with this. As 
mentioned in chapter 1, section 1.4.4, the adult muscles in Drosophila are in many 
respects similar to vertebrates skeletal muscle. Findings on Dmesol 7A function in the 
adult muscles, together with my results in larval somatic muscles, might therefore bring 
new insights in the mechanisms regulating skeletal muscle differentiation. Second, the 
AMPs are in some respects similar to the vertebrate satellite cells. Both remain 
quiescent, undifferentiated until triggered to proliferate and differentiate. The satellite 
cells play a crucial role in the regeneration of diseased or damaged skeletal muscles 
(Morgan and Partridge, 2003). Understanding how their differentiation is regulated 
could be crucial for the development of cell-based therapies. I have shown that 
persistent Dmesol 7A expression in the thoracic AMPs can lead to defects in adult 
muscle formation, suggesting that it plays an important role in the control of the 
differentiation of these cells. Further analysis of Dmesol 7A function in the AMPs could 
therefore be highly informative and may provide new directions for the study of the 
differentiation of satellite cells.
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Appendix 1: UAS lines tested
Stock Comments Phenotype informations
UAS-Dmesol 7A (J7)
Full length Dmesol 7A 
coding sequence under 
the control of UAS 
regulatory sequences.
The stock is 
homozygous on the 2nd 
chromosome.
Disruption of somatic muscl< 
differentiation. A range of 
effect is observed. Heart and 
visceral muscle developmen 
can be affected when using 
strong GAL4 driver such as 
mef2-GAL4 (see text).
UAS-Dmesol 7A (J13)
Full length Dmesol 7A 
coding sequence under 
the control of UAS 
regulatory sequences.
The stock is 
homozygous on the 
3rdchromosome.
Phenotype very similar to thi 
of the J7 line
UAS-Dmesol 7A (J8)
Full length Dmesol 7A 
coding sequence under 
the control of UAS 
regulatory sequences.
The stock is 
homozygous on the 2nd 
chromosome.
Phenotype very similar to ths 
of the J7 line but less severe
UAS-Dmesol 7A-AWRPW (la)
Dmesol 7A coding 
sequence lacking the last 
9 base pairs under the 
control of UAS 
regulatory sequences.
The stock is 
homozygous on the 2nd 
chromosome
The dominant negative effec 
leads to aberrant muscle 
differentiation. With defects i 
shape attachment and numbe 
of the muscles (see text).
UAS-Dmesol 7A-AWRPW (lb)
Dmesol 7A coding 
sequence lacking the last 
9 base pairs under the 
control of UAS 
regulatory sequences.
The stock is 
homozygous on the 3rd 
chromosome
Phenotype very similar to the 
of the la line.
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Appendixl
Stock Comments Phenotype informations
UAS-Dmesol 7A-AWRPW (10- 
orangeC)
Dmesol 7A coding 
sequence lacking the last 
9 base pairs under the 
control of UAS 
regulatory sequences.
The stock is 
homozygous on the 2nd 
chromosome
Phenotype very similar to that 
of the la  line. Dorsal muscles 
look very dense.
UAS-Dmesol7A-RNAi (Ll.4.2)
Full length Dmesol 7A 
coding sequence cloned 
sense and antisense 
under the control of 
UAS regulatory 
sequences. The stock is 
homozygous on the 3rd 
chromosome
Reduction of Dmesol 7A level 
disrupts muscle differentiation. 
Defects are observed in muscle 
shape, size, attachment, 
number and in nuclei 
organisation.
UAS-Dmesol 7A-RNAI (L4.2)
Full length Dmesol 7A 
coding sequence cloned 
sense and antisense 
under the control of 
UAS regulatory 
sequences. The stock is 
homozygous on the 2nd 
chromosome
Phenotype very similar to that 
of the Ll.4.2 line.
UAS-Dmesol 7A-RNAi (L3.1)
Full length Dmesol7A 
coding sequence cloned 
sense and antisense 
under the control of 
UAS regulatory 
sequences. The stock is 
homozygous on the X 
chromosome
Phenotype less severe than that 
of the Ll.4.2 line although the 
same defects are observed.
